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INTRODUCTION 
The kidney is composed of nephrons, which consist of glomeruli and renal tubules (Figure 1). 
The main function of the glomeruli is the filtration of blood at a rate of approximately 125 ml 
per minute (equivalent to 180 liter per day in healthy humans). The so-called pro-urine which 
is formed by this process of glomerular filtration, consists of water that contains dissolved 
waste products and electrolytes (sodium, chloride, calcium, phosphate, magnesium, 
etcetera). The pro-urine subsequently flows through the renal tubules. These tubules can 
reabsorb water and dissolved substances into the blood, and excrete substances from the 
blood into the urine. To do this, the tubular cells contain a complex system of transport 
proteins and channels that facilitate both transcellular (through the cell) or paracellular 
(between the cells; often involving tight junction proteins) transport. These processes can be 
either passive (the transport process itself does not consume energy) or active (the transport 
directly requires consumption of ATP). Examples of transport systems in the renal tubules are 
shown in Figures 2-7. The integrated action of glomerular filtration and tubular transport is 
essential to maintain body homeostasis. 
Disorders characterized by altered tubular transport processes due to dysfunction of specific 
tubular transport proteins or channels are called renal tubular disorders, and generally 
present as disorders of electrolyte-, water- and acid-base homeostasis.
Figure 1 Global anatomy of the kidney
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Phosphate is reabsorbed at the apical membrane through the sodium-phosphate cotransporters NaPi2a and 
NaPi2c. The abundance of these sodium-phosphate cotransporters is dependent on the inhibitory effect of Na+/
H+ exchanger regulatory factor (NHERF-1). Binding of parathyroid hormone (PTH) to its receptor (PTHR) and 
fibroblast growth factor 23 (FGF23) to the Klotho-FGFR1 complex, leads to downstream signalling pathways 
that result in phosphorylation of NHERF-1. Phosphorylation of NHERF-1 stimulates endocytosis of NaPi2a 
and NaPi2c, and thereby decreases phosphate reabsorption. Basolateral extrusion of phosphate towards the 
peritubular capillaries occurs via an unknown transport mechanism.
Magnesium transport in the thick ascending limb of the loop of Henle takes place via a paracellular route 
through claudins in the tight junctions. Tight junctions which express claudin 16 and 19 are magnesium (and 
calcium) permeable, whereas claudin 10 particularly mediates paracellular sodium transport. This transport is 
mostly dependent on the lumen-positive transepithelial voltage, which in turn is dependent on the process of 
transcellular sodium reabsorption. The Na-K-2Cl cotransporter (NKCC2) mediates apical absorption of sodium, 
potassium and chloride. The apical renal outer medullary potassium channel (ROMK) mediates apical recycling 
of potassium back to the tubular lumen and generates a lumen-positive voltage. The chloride channel ClC-Kb 
mediates chloride exit through the basolateral membrane. Na-K-ATPase mediates sodium exit through the 
basolateral membrane and generates the sodium gradient for sodium reabsorption. Basolateral stimulation 
of the calcium sensing receptor (CaSR) inhibits potassium channels and NKCC2, thus inhibiting sodium 
reabsorption and decreasing paracellular magnesium transport.
Figure 2 Phosphate transport in the proximal tubule
Figure 3 Sodium and magnesium transport in the thick ascending limb of the loop of Henle
1Introduction and Outline of the Thesis   |  11
Magnesium transport in the distal convoluted tubule takes place via a transcellular route. Magnesium is 
reabsorbed at the apical membrane through the epithelial magnesium channel TRPM6 (transient receptor 
potential cation channel subfamily M member 6), which depends on the voltage gradient created by sodium 
and chloride transport created by the Na-Cl cotransporter (NCC) and the back leak of potassium via the apical 
renal outer medullary potassium channel (ROMK) and potassium voltage-gated channel subfamily A member 
1 (Kv1.1). Activity of Na-K-ATPase, which is composed of an α, β and γ subunit, stimulates NCC transport. The 
transcription factor HNF1β (hepatocyte nuclear factor 1 β) stimulates Na-K-ATPase via the γ subunit (FXYD). 
Additionally, activation of the epidermal growth factor receptor (EGFR) results in increased TRPM6 membrane 
expression and channel activity. Basolateral extrusion of magnesium towards the peritubular capillaries occurs 
via an unknown transport system, for which recently several candidates have been proposed.
Binding of arginine vasopressin (AVP, antidiuretic hormone) to vasopressin receptor type 2 (V2R) at the 
basolateral side of the principal collecting duct cells, activates adenylyl cyclase (AC). This leads to increased 
cyclic adenosine monophosphate (cAMP), causing phosphorylation and insertion of aquaporin-2 water 
channels (AQP2) into the apical membrane. Urea transporter A1 (UT-A1) and other signalling pathways involving 
cyclic guanosine monophosphate (cGMP) and adenosine monophosphate-activated protein kinase (AMPK) also 
stimulate phosphorylation and insertion of AQP2. Water can then be transported into the cell and leave the cell 
at the basolateral side via AQP3/4.
Figure 5 Water transport in the collecting duct
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Figure 4 Sodium, potassium and magnesium transport in the distal convoluted tubule
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The collecting duct consists of principal cells and different types of carbonic anhydrase containing intercalated cells. 
Principal cells play a major role in sodium and potassium transport, mainly through the action of the epithelial 
sodium channel ENaC, the renal outer medullary potassium channel (ROMK) and to a lesser extent the calcium-
activated potassium channel (BK). ENaC-mediated transport is important for the generation of a trans-epithelial 
potential. The voltage gradient generated by ENaC-mediated sodium reabsorption provides the driving force for 
chloride transport. Claudin-4 and claudin-8 form the paracellular pathway for chloride transport in the collecting 
duct, and type β intercalated cells reabsorb chloride via a transcellular route through pendrin.
Intercalated cells all express carbonic anhydrase and H+-ATPase. Type α intercalated cells contribute to acid/base 
balance by secretion of H+ and reclaiming bicarbonate via the basolateral anion exchanger 1 (AE1). H+ secretion 
mainly involves the apical H+-ATPase, an electrogenic active pump, which is driven by the voltage gradient created 
by ENaC. In case of potassium depletion, H+ can also be secreted through the apical H+-K+-ATPase. H+ secretion 
corresponds to HCO3- generation, a process governed by carbonic anhydrase (Figure 7).
Type β intercalated cells express  H+-ATPase and anion exchanger 4 (AE4) at the basolateral membrane, and pendrin 
and the Na-driven bicarbonate exchanger (NDBCE) at the apical membrane. The activity of these type β intercalated 
cells is increased during metabolic alkalosis. Next to secretion of bicarbonate and reclaiming H+ in case of alkalosis, 
type β intercalated cells also regulate transcellular chloride transport which is coupled to sodium reabsorption. 
Under normal circumstances, H+ secretion through type α intercalated cells predominates.
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Figure 6 Sodium and acid/base transport in the collecting duct
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When H+ is secreted into the lumen, it can combine with HCO3- (if present) to form H2O and CO2 in the presence of 
carbonic anhydrase IV (CAIV). Both CO2 and H2O can be freely absorbed into the cell where it can be converted into H+ 
and HCO3- again in the presence of carbon anhydrase II (CAII).
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Renal Tubular disorders
Acquired or inherited renal tubular disorders are mainly characterized by serum electrolyte 
disturbances. The most common electrolyte disorders and their causes are shown in Tables 
1-6.
Figure 7 Generation of new HCO3- in carbonic anhydrase containing cells
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Table 1a Genetic causes of (isolated) renal hypophosphatemia
Disease Underlying defect/mechanism
X-linked hypophosphatemic rickets Inactivating mutations in the gene encoding 
phosphate-regulating neutral endopeptidase 
(PHEX) are associated with increased levels of 
fibroblast growth factor 23 (FGF23), likely due 
to impaired cleavage/degradation of FGF23
Autosomal recessive hypophosphatemic 
rickets type I
Inactivating mutations in the gene encoding 
dentin matrix acidic phosphoprotein 1 (DMP1) 
are associated with increased levels of FGF23, 
likely due to impaired cleavage/degradation 
of FGF23
Autosomal recessive hypophosphatemic 
rickets type II
Inactivating mutations in the gene 
encoding ectonucleotide pyrophosphatase/
phosphodiesterase 1 (ENPP1) are associated 
with increased levels of FGF23, likely due to 
impaired cleavage/degradation of FGF23
Autosomal dominant hypophosphatemic 
rickets 
Mutations in the gene encoding FGF23, 
specifically the RXXR motif which is necessary 
for cleavage of FGF23, are associated with 
increased levels of FGF23, likely due to 
impaired cleavage/degradation of FGF23
Hypophosphatemic nephrolithiasis Mutations in the gene encoding the 
intracellular sodium-hydrogen exchanger 
regulatory factor 1 (NHERF1) cause decreased 
expression of sodium phosphate transporters 
(NaPi) at the membrane
Fanconi renotubular syndrome 2, 
idiopathic infantile hypercalcemia 2 and 
hypophosphatemic nephrolithiasis 1
Mutations in the gene encoding NaPi2a cause 
decreased phosphate reabsorption at the 
apical membrane 
Hypophosphatemic rickets with hypercalciuria 
(HHRH)
Mutations in the gene encoding NaPi2c cause 
decreased phosphate reabsorption at the 
apical membrane
Osteoglophonic dysplasia Activating mutations in the gene encoding 
FGFR1 lead to activated receptor signalling and 
thus increased phosphorylation of NHERF1 
Hypophosphatemic rickets Increased circulating α-Klotho causes 
increased phosphorylation of NHERF1 and 
thereby increased endocytosis of NaPi2a and 
NaPi2c.
Linear nevus sebaceous syndrome Most patients carry mosaic mutations in 
FGFR3, but it is unknown whether this causes 
hypophosphatemia. It has also been suggested 
that some naevi secrete FGF23
Opsismodysplasia The underlying genetic defect is unknown
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Table 1b Acquired causes of (isolated) renal hypophosphatemia
Cause Underlying defect/mechanism
Exogenic production of phosphaturic hormones 
(e.g. tumor induced osteomalacia; TIO)
Increased levels of parathyroid hormone 
(PTH) or fibroblast growth factor 23 (FGF23)Hyperparathyroidism
Kidney transplantation
Post hepatectomy
The precise underlying mechanism is 
unknown. It could be due to a combination 
of factors like increased levels of 
FGF23, cellular shift and generalized 
tubulopathy. Accordingly, in many of these 
disorders, hypophosphatemia can occur 
in combination with other electrolyte 
abnormalities
Severe sepsis / illness, inflammation
Extensive burns
Hyperaldosteronism
Hypokalemia, hypercalcemia, hypomagnesemia
Hypercortisolism
Drugs (steroïds, oral anticonception, diuretics, 
theophylline, acyclovir, imatinib)
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Table 2a Genetic causes of renal hypomagnesemia
Disease Underlying defect/mechanism
Hypomagnesemia with 
secondary hypocalcemia
Mutations in the gene encoding the epithelial magnesium 
channel TRPM6 cause decreased intestinal magnesium 
absorption and decreased magnesium transport at the apical 
membrane of the distal convoluted tubule 
Isolated renal 
hypomagnesemia
Mutations in the gene encoding pro-epidermal growth factor 
(EGF) cause a decrease in TRPM6 membrane expression and 
channel activity
Autosomal dominant 
hypomagnesemia
Mutations in the gene encoding the potassium voltage-gated 
channel subfamily A number 1 (Kv1.1) cause a defect in the back 
leak of potassium which normally drives magnesium transport 
through TRPM6
Bartter syndrome Mutations in genes encoding the Na-K-2Cl cotransporter 
(NKCC2), the chloride channels ClC-Kb and ClC-Ka, Barttin, 
the renal outer medullary potassium channel (ROMK) or the 
calcium sensing receptor (CaSR) in the loop of Henle cause a 
decrease in the transepithelial voltage gradient which normally 
drives paracellular magnesium transport. Hypomagnesemia 
occurs rather infrequently in Bartter syndrome
Gitelman syndrome Mutations in genes encoding the Na-Cl cotransporter (NCC) or 
chloride channel ClCKb in the distal convoluted tubule could 
cause a decrease in the transepithelial voltage gradient which 
normally drives magnesium transport through the transient 
receptor potential cation channel subfamily M member 6 
(TRPM6) 
Familial hypomagnesemia 
with hypercalciuria and 
nephrocalcinosis (FHNNC)
Mutations in genes encoding tight junction proteins claudin 16 
and 19 cause defective paracellular magnesium transport in the 
loop of Henle
Isolated dominant 
hypomagnesemia
Mutations in the gene encoding the γ subunit of Na-K-ATPase 
(FXYD2) are thought to cause a decrease in activation of NCC 
due to a decreased sodium gradient
Autosomal dominant 
tubulointerstitial kidney 
disease (ADTKD)- HNF1β
Mutations in the gene encoding hepatocyte nuclear factor-1-
beta (HNF1β) cause downregulation of the inwardly rectifying 
potassium channels Kir4.1/Kir5.1, γ subunit of Na-K-ATPase and 
possibly (directly) NCC
EAST/SeSAME (epilepsy, 
ataxia, sensorineural 
deafness, tubulopathy)
Mutations in the gene encoding Kir4.1 cause reduced Na-K-
ATPase activity
Renal hypomagnesemia 
6 and hypomagnesemia/
seizures/mental retardation 
(HOMGSMR)
Mutations in the gene encoding magnesium sensitive sodium 
channel (cyclin M2 protein, CNNM2) cause magnesium wasting. 
The exact underlying pathophysiology is unknown 
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Table 2b Acquired causes of renal hypomagnesemia
Cause Underlying defect/mechanism
Hypercalcemia Calcium binding to the calcium sensing receptor (CaSR) inhibits 
potassium channels and NKCC2 (Na-K-2Cl cotransporter) and 
thereby decreases paracellular magnesium transport
Volume expansion Decreased passive paracellular magnesium transport 
in the thick ascending loop of Henle due to reduced 
transcellular sodium reabsorption resulting in a decrease in 
the transepithelial voltage gradient which normally drives 
paracellular magnesium transport
Uncontrolled diabetes 
mellitus Unknown underlying mechanism
Alcohol
Loop diuretics Inhibition of NKCC2 causes a decrease in the transepithelial 
voltage gradient which normally drives paracellular magnesium 
transport
Thiazide diuretics Inhibition of NCC (Na-Cl cotransporter) causes a decrease in 
the transepithelial voltage gradient which normally drives 
magnesium transport through the transient receptor potential 
cation channel subfamily M member 6 (TRPM6)
EGFR inhibitors Inhibition of epidermal growth factor causes a decrease in 
membrane expression and channel activity of TRPM6
Aminoglycosides Aminoglycosides are thought to induce hypomagnesemia 
through activation of the calcium sensing receptor
Amphotericin B The exact underlying mechanism is unknown
Calcineurin inhibitors The exact underlying mechanism is unknown, but both TRPM6 
and epidermal growth factor receptor (EGFR) are suppressed
Cisplatin The exact underlying mechanism is unknown. Cisplatin 
causes overall tubular cell injury but also might specifically 
downregulate EGF and TRPM6
Hyperaldosteronism The exact underlying mechanism is unknown. Expansion of the 
extravascular space causes decreased sodium reabsorption 
proximal to the collecting duct and could thereby cause 
decreased magnesium reabsorption
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Table 3a Genetic causes of nephrogenic diabetes insipidus / impaired renal concentrating ability
Disease Underlying defect/mechanism
X-linked nephrogenic 
diabetes insipidus
Mutations in the gene encoding vasopressin 2 receptor (AVPR2) 
reduce or impair activation of signaling pathways which 
normally stimulate phosphorylation and insertion of aquaporin 
2 water channels in the collecting duct principal cells
Autosomal recessive or 
dominant nephrogenic 
diabetes insipidus
Mutations in the gene encoding aquaporin 2 (AQP2) cause 
decreased insertion of functional water channels in the 
membrane and thereby disturbed water transport
Autosomal dominant 
polycystic kidney disease 
Disruption of the tubular architecture and defective principal 
cell function
Autosomal dominant 
tubulointerstitial kidney 
disease
Disruption of the tubular architecture and defective principal 
cell function
Nephronophthisis The exact underlying mechanism is unknown. It is thought that 
defective renal epithelial cells show decreased expression of 
AVPR2 
Medullary sponge kidney Disruption of the tubular architecture and defective principal 
cell function
Bartter syndrome Disruption of the medullary gradient secondary to defective 
sodium reabsorption in the loop of Henle impairs water 
reabsorption in the collecting duct
HELIX syndrome Mutations in the gene encoding claudin 10 are thought to 
cause decreased paracellular sodium reabsorption in the 
thick ascending limb of the loop of Henle which disrupts the 
medullary gradient and impairs water reabsorption
Table 3b Acquired causes of nephrogenic diabetes insipidus / impaired renal concentrating ability
Disease Underlying defect/mechanism
Lithium-induced nephrogenic 
diabetes insipidus 
Lithium inhibits the translocation of cytoplasmic aquaporin 
2 to the apical membrane via inactivation of adenylyl cyclase 
signaling
Hypercalcemia Calcium-sensing receptor (CaSR) stimulation in apical 
membrane of principal cells decreases responsiveness to 
arginine vasopressin (AVP). Basolateral CaSR stimulation in 
the thick ascending loop of Henle decreases sodium-chloride 
reabsorption and thereby disrupts the medullary gradient 
Chronic hypokalemia Decreased responsiveness to AVP and decreased sodium-
chloride reabsorption in the thick ascending loop of Henle
Bilateral urinary tract 
obstruction
Increased collecting duct pressure causes damage to the tubular 
epithelium which causes downregulation of aquaporin 2
Sickle cell trait Microvascular obstruction with disappearance of the vasa 
recta, impaired countercurrent exchange and disruption of the 
medullary gradient  
Renal amyloidosis The exact underlying mechanism is unknown
Sjögren’s syndrome The exact underlying mechanism is unknown
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Table 4a Genetic causes of distal renal tubular acidosis (dRTA)
Disease Underlying defect/mechanism
Hereditary dRTA Mutations in genes encoding H+-ATPase, chloride/base 
exchanger 1 (AE1) or carbonic anhydrase II (CAII) cause defective 
urinary acidification
Osteopetrosis Mutations in the gene encoding cytosolic carbonic anhydrase II 
(CAII) that affect H+ and HCO3- generation in the cytosol cause 
defective urinary acidification
Wilson disease
The exact underlying mechanism is unknown
Ehlers-Danlos
Sickle cell trait
Carnitine deficiency
Primary hyperoxaluria type I
X-linked hypophosphatemia
Congenital adrenal 
hyperplasia
Table 4b Acquired causes of distal renal tubular acidosis (dRTA)
Disease Underlying defect/mechanism
Tubulointerstitial nephritis 
in for example autoimmune 
diseases (such as Sjögren’s 
disease) and dysproteinemias
Destruction of tubular cells and occasionally autoantibodies 
against specific transporters
Hypercalcemia Activation of the luminal calcium-sensing receptor is thought to 
induce enhanced H+-ATPase activity
Obstructive nephropathy Destruction of tubular cells
Ifosfamide The exact underlying mechanism is unknown
Amphotericin B Amphotericin B increases the permeability for protons in the 
apical membrane of the collecting duct which causes back 
diffusion of secreted protons
Ibuprofen Ibuprofen is thought to inhibit carbonic anhydrase, an enzyme 
responsible for H+ and HCO3- generation 
Chronic kidney disease  
(all causes) 
Destruction of tubular cells, decreased production of NH3
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Table 5a Genetic causes of isolated proximal renal tubular acidosis
Disease Underlying defect/mechanism
Hereditary proximal renal 
tubular acidosis
Mutations in genes encoding the sodium bicarbonate 
cotransporter 1 (kNBC1) or carbonic anhydrase II (CAII) cause 
defective acidification
Table 5b Acquired causes of isolated proximal renal tubular acidosis
Disease Underlying defect/mechanism
Carbonic anhydrase inhibitors 
(e.g. acetazolamide)
Inhibition of CAII, an enzyme responsible for H+ and HCO3- 
generation in the cytosol, causes defective acidification
Table 6a Genetic diseases associated with proximal renal tubular acidosis and Fanconi syndrome
Disease Underlying defect/mechanism
Cystinosis Mutations in the gene encoding cystinosin (CTNS) cause 
abnormal lysosomal accumulation of cystine in the proximal 
tubule resulting in proximal tubular dysfunction  
Tyrosinemia Mutations in genes involved in the phenylalanine and tyrosine 
catabolic pathway cause abnormal accumulation of tyrosine in 
the proximal tubule resulting in proximal tubular dysfunction  
Hereditary fructose 
intolerance
Mutations in the gene encoding aldolase B cause abnormal 
accumulation of fructose-1-phosphate in the proximal tubule 
resulting in proximal tubular dysfunction  
Galactosemia Mutations in genes involved in galactose degradation cause 
abnormal accumulation of galactose in the proximal tubule 
resulting in proximal tubular dysfunction  
Glycogen storage disease 
type XI (Fanconi-Bickel) 
Mutations in genes involved in glycolysis cause abnormal 
accumulation of glycogen in the proximal tubule resulting in 
proximal tubular dysfunction  
Mitochondrial disorders Proximal tubule dysfunction due to defective mitochondrial 
function 
Wilson’s disease Mutations in the gene encoding cupper transporting ATPase 
(ATP7B) cause abnormal accumulation of copper in the 
proximal tubule resulting in proximal tubular dysfunction  
Lowe’s syndrome Defective acidification of subapical endosomes due to 
mutations in the gene encoding oculocerebrorenal syndrome 
protein (OCRL1) 
Dent’s disease Defective acidification of subapical endosomes due to 
mutations in the gene encoding OCRL1 or chloride voltage-
gated channel 5 (CLCN5)
Fanconi syndrome: syndrome of proximal tubule dysfunction
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Table 6b Acquired diseases associated with proximal renal tubular acidosis and Fanconi syndrome 
Cause Underlying defect/mechanism
Drugs (e.g. anti-retroviral 
therapy, anti-cancer drugs, 
anti-convulsant therapy, 
aminoglycosides and others)
Direct toxic effect to the proximal tubules
Heavy metals
Tubulointerstitial nephritis 
and dysproteinemias
Destruction of (proximal) tubular cells
Paroxysmal nocturnal 
hemoglobinuria
Proximal tubule dysfunction due to hemosiderin deposition
Chronic kidney disease 
(all causes)
Destruction of tubular cells
Signs and symptoms
Patients with tubular disorders commonly suffer from e.g. fatigue, muscle weakness, tingling, 
muscle spasms, heart rhythm disorders, kidney stones, excessive urination, dehydration and/
or osteoporosis. Despite progress in unravelling genetic and molecular causes of these rare 
diseases, clinical care has not improved accordingly. Especially knowledge of and experience 
with validated clinical diagnostic tools and treatment strategies are sparse.
Diagnostic tools
As obvious from the above, there is no single diagnostic test to measure overall tubular 
performance. We can however investigate specific tubular functions with so-called tubular 
function tests. With these tests, we measure the response of the kidney to a specific stimulus 
(i.e. drugs that target a specific tubular transport system). Tubular function tests can therefore 
be used to pin-point a tubular defect of electrolyte and/or water transport to a specific tubular 
segment or function. Examples of tubular function tests are the thiazide test that provides 
information about sodium-chloride reabsorption in the distal convoluted tubule (typically 
used in the diagnosis of presumed Gitelman syndrome), the furosemide test that provides 
information on transcellular sodium-chloride reabsorption in the thick ascending limb 
of Henle (typically used in the diagnosis of presumed Bartter syndrome), the furosemide- 
fludrocortisone (FF) test that can be used to diagnose distal renal tubular acidosis and the 
DDAVP test which assesses urinary concentration capacity upon stimulating the collecting 
ducts with synthetic desmopressin (used in the diagnosis of a renal concentration defect 
and/or nephrogenic diabetes insipidus). 
Treatment strategies
Most patients with renal tubular disorders require lifelong treatment with drugs and/or 
electrolyte replacement therapy. The aim of treatment is to improve symptoms, quality of life 
and serum electrolyte levels. Because of the paucity of randomized controlled trials (RCT’s) 
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in these rare disorders, the optimal treatment strategy is frequently not known. Alternative 
methods are needed in order to optimize treatment in patients with rare tubular disorders in 
a personalized manner. Next to that, we need to explore new treatment options which might 
be raised by results from fundamental research.
OUTLINE OF THE THESIS
Aim of this thesis was to study diagnostic tools as well as treatment options for patients with 
rare tubular disorders with the ultimate aim to improve clinical care.
In chapter 2 we focus on patients with unexplained renal hypophosphatemia.  The 
optimal diagnostic work-up for these patients is not known while an increasing number of 
patients is being referred to our clinics. Genetic analyses, serum FGF23 assays and scans 
with radiolabelled somatostatin analogs are expensive investigations which are frequently 
performed in this patient category while the diagnostic yield is unclear. We therefore 
report the diagnostic yield of an extensive evaluation of patients with unexplained renal 
hypophosphatemia. 
Next, we study different aspects of tubular function tests. In chapter 3 we study the clinical 
use of the thiazide test. The thiazide test is an accepted diagnostic tool in the diagnosis 
of Gitelman syndrome. Earlier studies showed a blunted response to thiazide diuretics in 
patients with Gitelman syndrome and a normal response in patients with Bartter syndrome. 
As the differential diagnosis of patients presenting with hypokalemia and hypomagnesemia 
however consists of more than these two disorders, we questioned its performance in 
patients with different causes of renal magnesium wasting. The results of thiazide tests in a 
group of patients with different causes of renal magnesium wasting are reported in chapter 
3. A difficulty in the interpretation of these test results are the characteristics of these patients. 
Many of the included patients were older and/or had a compromised renal function, while 
reference values for tubular function tests are mainly based on studies with small sample 
size in young healthy volunteers. In chapter 4 we therefore evaluate reference values of four 
tubular function tests in individuals with different ages and renal function. 
In chapters 5 and 6, possible caveats of the ammonium chloride test (NH4Cl) and furosemide 
fludrocortisone test (FF test) are investigated. These tests are used to diagnose distal tubular 
acidosis (dRTA). dRTA is traditionally diagnosed by the NH4Cl test, but as it often leads to 
nausea and vomiting it has been replaced by the FF test in many centers. Patients with distal 
tubular acidosis have a defective H+ secretion in the collecting duct and are not able to acidify 
the urine in response to NH4Cl or FF. The FF test is based on the assumption that furosemide 
increases distal tubular sodium delivery and that fludrocortisone, by further stimulating 
sodium reabsorption through the epithelial sodium channel ENaC, induces H+ secretion in 
the collecting duct. Recent reports however show a high percentage of discrepant results 
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between the NH4Cl test and the FF test. Lowering of the urine pH after NH4Cl but not after FF 
could be due to a false positive FF test (due to incomplete proximal HCO3- reabsorption or 
inadequate distal sodium delivery in response to furosemide) or due to a false negative NH4Cl 
test (due to the presence of an ENaC-independent pathway of urine acidification which is 
triggered by an acid load). Lowering of the urine pH after FF but not in response to NH4Cl 
could be due to a false negative FF test (due to the presence of a furosemide induced ENaC-
independent pathway of urine acidification) or false positive NH4Cl test (due to inadequate 
gastro-intestinal absorption of NH4Cl). An ENaC-independent pathway of urine acidification, 
via NHE3 in the loop of Henle, was recently demonstrated in animals. If such a mechanism 
is present in human as well, this could explain discrepant results between the NH4Cl test 
and the FF test. To investigate the presence of such an ENaC-independent pathway of urine 
acidification, we perform the NH4Cl test and FF test under blockade of ENaC in chapter 5 
and chapter 6. 
In the last two chapters, we focus on the treatment of patients with rare tubular disorders. 
The optimal treatment of patients with rare tubular disorders is often not known, 
mostly due to lack of (large) RCT’s. An interesting alternative method to RCT’s are single-
subject trial designs, such as the N-of-1 trial. An N-of-1 trial is a prospectively planned 
trial within an individual patient to compare the effectiveness of two or more treatments. 
Despite its direct implications for the individual patient, it has been sparsely used in medical 
research and clinical practice. An example in which N-of-1 trials could be helpful, is the 
treatment of individual patients with renal magnesium wasting. These patients mostly 
require lifelong treatment with high doses of magnesium salts while there is a lack of RCT’s 
comparing different magnesium salts. We therefore use the N-of-1 trial methodology in 
chapter 7 to compare different magnesium salts in the treatment of patients with renal 
magnesium wasting. 
In chapter 8 we investigate new treatment options for patients with nephrogenic diabetes 
insipidus. Nephrogenic diabetes insipidus is a disorder characterized by resistance of the 
kidney collecting duct to the action of anti-diuretic hormone (ADH), resulting in a decreased 
capacity to concentrate urine. Current treatment options are only partially capable to lower 
urine production. Recent reports in animals suggested that sildenafil, metformin, and 
simvastatin might ADH-independently improve urine concentrating ability. The rationale for 
using these drugs is based on intracellular effects downstream to the vasopressin receptor. 
We therefore test the effect of these drugs on ADH-independent urine concentrating capacity 
in healthy volunteers in chapter 8.
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ABSTRACT
Background
Isolated renal hypophosphatemia may be inherited or acquired. An increasing number of 
patients with unexplained renal hypophosphatemia is being referred to our clinics, but the 
optimal diagnostic work-up is not known. Therefore, the aim of this study was to assess the 
diagnostic yield in these patients.  
Methods
We retrospectively evaluated all patients who were referred because of unexplained isolated 
renal hypophosphatemia to two academic tertiary referral centers in The Netherlands in the 
period of 2013-2017.
Results
We evaluated 17 patients. In five female patients renal hypophosphatemia could be 
attributed to the use of oral contraceptives. The other 12 patients had a median age of 48 
years (10 males). There were no other signs of tubulopathy and none of the patients used 
drugs known to be associated with hypophosphatemia. FGF23 levels were above normal 
(> 125 RU/ml) in 2/12 patients. Genetic testing, performed in all patients, did not identify 
a mutation in genes known to be associated with renal phosphate wasting. A scan with a 
radiolabeled somatostatin analogue was performed in 8 patients. In one patient, with an 
FGF23 level of 110 RU/ml, an increased uptake of the somatostatin analog was observed due 
to tumor-induced osteomalacia (TIO). 
Conclusions
Oral contraceptive use is an important but under-recognized cause of renal 
hypophosphatemia. The cause of isolated renal hypophosphatemia remained unexplained in 
the majority of other patients despite extensive and expensive additional investigations. The 
pre-test probability for tumor-induced osteomalacia or inherited renal hypophosphatemia 
in a patient with aspecific complaints and a normal FGF23 level is low. Further research is 
needed to investigate which patients should be screened for TIO. At present we suggest to 
perform somatostatin scans only in patients with severe complaints, elevated FGF23 levels, 
or progressive disease. 
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BACKGROUND
Phosphate is freely filtered by the glomerulus and 80-90% is reabsorbed at the brush border 
membrane of the proximal tubule, through apical sodium-dependent phosphate transporters 
(primarily NaPi2a and NaPi2c). The principal regulators of this transcellular phosphate 
reabsorption are dietary phosphate, PTH, 1,25 dihydroxy vitamin D3 (1,25OHD3) and fibroblast 
growth factor 23 (FGF23). A defect in one of these transporters or perturbation in one of the 
regulating factors can result in increased renal phosphate loss. Various inherited phosphate 
wasting disorders have been identified, including X-linked autosomal hypophosphatemia 
(XLH; due to a mutation in PHEX), autosomal dominant hypophosphatemic rickets (ADHR; 
due to impaired cleavage of FGF23 caused by a mutation in FGF23), autosomal recessive 
hypophosphatemic rickets (ARHR; due to a mutation in DMP1) and Fanconi renotubular 
syndrome-2 (dysfunction of NaPi2a due to homozygous mutations in SLC34A1) [1]. Some 
of these inherited disorders, such as ADHR, can become apparent after childhood, which 
can make the differentiation with acquired disorders difficult. The most common causes 
of acquired isolated renal hypophosphatemia are drugs (for example acetazolamide, 
bisphosphonates, diuretics, glucocorticosteroids, imatinib, acyclovir, aminoglycosides, 
tenofovir and valproic acid), hyperparathyroidism and tumor-induced osteomalacia (TIO) [2]. 
TIO is a rare disorder in which there is renal phosphate wasting due to tumors that secrete 
phosphaturic factors (most commonly FGF23) [3,4,5]. 
The cause of hypophosphatemia is often identified during the initial diagnostic evaluation of 
patients presenting with (renal) hypophosphatemia. Yet, an increasing number of patients is 
being referred to our clinics because of unexplained chronic renal hypophosphatemia. The 
optimal diagnostic work-up of these patients is not known. We report the diagnostic yield of 
extensive evaluation in these patients. 
METHODS
We retrospectively evaluated all patients who were referred because of unexplained chronic 
renal hypophosphatemia, which was confirmed on several occasions, to two university 
hospitals in The Netherlands in the period of  2013-2017. In these patients, well-known causes 
of acquired renal hypophosphatemia had been previously excluded. Renal hypophosphatemia 
was defined as a serum phosphate below 0.70 mmol/l and an inappropriately high renal 
phosphate excretion. Fractional excretion of phosphate was calculated as (urine phosphate 
*serum creatinine)/(serum phosphate *urine creatinine). TmP/GFR was calculated by 
the method of Bijvoet [6]. All measurements were performed during low serum phosphate 
levels. The reference value for serum phosphate in our centers is 0.80-1.40 mmol/l (variation 
coefficient of 3.7%). In most patients a fasting serum phosphate was measured at 8.00 
am because it is known that serum phosphate shows a circadian rhythm with the lowest 
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value between 8.00–11.00 am [7,8]. To exclude that the hypophosphatemia was due to this 
circadian rhythm, we determined serum phosphate in 100 fasting anonymous samples of 
patients visiting the outpatient clinic with an eGFR > 60 ml/min/1.73 m2, withdrawn between 
8.00-10.00 am. The mean serum phosphate level was 1.06 mmol/l (SD 0.17, range 0.67-1.42 
mmol/l), indicating that the hypophosphatemia in our patients was not the result of the early 
morning blood sampling. 
General (proximal) tubular dysfunction was assessed by measuring glucose, pH, urate and 
α1-microglobulin in urine. Glucose, calcium, potassium, creatinine (enzymatic method) and 
phosphate were measured on a Cobas c6000 (Roche, Switzerland) or c18000 (Abbott, USA) 
analyzer. The α1-microglobulin concentration in urine was measured on a BNII nephelometer 
(Siemens, Germany) and urinary pH was measured with a PHM220 potentiometer (Hach 
Lange Nederland, the Netherlands). Genetic testing for mutations in genes that are known to 
be associated with renal phosphate wasting (DMP1, FGF23, FGFR1, GALNT3, PHEX, SLC34A1, 
SLC34A3, SLC9A3R1) was done by Sanger sequencing and MPLA on genomic DNA derived 
from peripheral blood cells. Vitamin D was measured by LC-MSMS. Intact PTH (second 
generation) was measured by an ECLIA on a modular E170 analyzer (Roche, Switzerland). 
FGF23 was measured by an ELISA of Immutopics measuring both intact FGF23 and C-terminal 
fragments, San Clemente, CA, USA. Somatostatin scans were performed per protocol in all 
patients with an elevated FGF23 level. In addition, somatostatin scans were performed in 
some patients with a normal FGF23 level at the discretion of the treating physician. These 
scans use somatostatin analogs (pentetreotide, TOC , TATE or NOC), which are labelled with 
tracer molecules (111Indium, 68Gallium or 99 Technetium) and sometimes a chelator molecule 
(DOTA). The somatostatin scans that were used in our clinics are the 68Ga-DOTA-TOC PET/CT 
scan and the 111Indium-pentetreotide SPECT/CT scan.
RESULTS
Seventeen patients with unexplained chronic renal hypophosphatemia were evaluated. 
The median age was 42 years old, 10 patients were male and there were no other signs of 
tubulopathy in any of these patients. 
Five female patients used oral contraceptives, containing estrogens, at the time of referral. 
Their demographical and clinical characteristics are shown in Table 1.
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Table 1 Patient characteristics
Oral contraceptive 
induced 
hypophosphatemia
(N=5)
Unexplained renal 
hypophosphatemia
(N=12)
Reference 
value
Age (years) 34 (28-53) 48 (24-64)
Gender (M/F) 0/5 10/2 
Serum phosphate 
(mmol/l) 
0.62 (0.33-0.65) 0.59 (0.36-0.77) 0.80-1.40
TmP/GFR (mmol/l) 0.58 (0.30-0.68) 0.50 (0.38-0.55) 0.80-1.40
FePi (%) 11 (4-13) 18 (5-35) <5
Serum creatinine 
(µmol/l)
74 (62-77) 87 (53-142) 60-110
eGFR (ml/min/1.73m2) * 95 (80-118) 95 (45-122) >90
Serum calcium (mmol/l) 2.27 (2.20-2.33) 2.39 (2.27-2.59) 2.20-2.65
Serum potassium 
(mmol/l)
3.9 (3.7-4.4) 3.9 (3.5-4.5) 3.5-4.7
Serum magnesium 
(mmol/l)
0.80 (0.79-0.91) 0.82 (0.78-0.95) 0.70-1.10
PTH (pmol/l) 5.3 (4.7-6.6) 5.2 (3.2-8.7) 1.0-6.5
25OHD(nmol/l) 106 (57-148) 72 (40-135) >50
1,25OHD3 (pmol/l) 169 (129-246) 140 (78-322) 50-150
cFGF23 (RU/ml) 66 (48-124) 89 (53-202) <125
24h urinary calcium 
excretion (mmol)
3 (2.2-4.8) 5.5 (0.6-11.0) <5.0
Values are given as median (range)
FePi = fractional excretion of phosphate
*eGFR was calculated by CKD-EPI formula
After discontinuing the oral contraceptives, renal hypophosphatemia resolved in all patients 
with normalisation of serum phosphate levels (Figure 1). TmP/GFR was measured in three 
patients before and after stopping the oral contraceptives and increased from 0.58 mmol/l 
(range 0.30-0.62) to 0.92 mmol/l (range 0.78-0.95).  
A re-challenge with the oral contraceptive was performed in one patient after which renal 
hypophosphatemia re-emerged. Characteristics of the other 12 patients are shown in 
Table 1. PTH was above normal (8.7 pmol/l) in only one patient. This patient did not have 
vitamin D deficiency and calcium excretion was normal (5 mmol/day). One patient had 
a 25-hydroxyvitamin D (25OHD) level below 50 nmol/l together with a slightly elevated 
1,25OHD3 level of 206 pmol/l. 1,25OHD3 was above normal in another four patients and 
FGF23 was above 125 RU/ml in two patients.
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Figure 1 Course of serum phosphate levels before and after stopping oral contraceptives in 5 
women
Genetic testing, which was performed in all remaining patients, did not show any mutations 
in genes known to be associated with renal phosphate wasting. 
The two patients with an FGF23 level above 125 RU/ml both underwent an 111Indium-
pentetreotide SPECT/CT scan. These scans did not show increased somatostatin uptake 
that would have been suggestive of TIO. Three additional patients, with normal FGF23 
levels, underwent an 111Indium-pentetreotide SPECT/CT scan and three additional patients 
a 68Ga-DOTA-TOC PET/CT scan, at the discretion of the treating physician. One of these 
six scans, a 68Ga-DOTA-TOC PET/CT, showed increased uptake in the right lateral femur 
suggestive of TIO. This patient had a normal serum FGF23 level of 110 RU/ml but progressive 
hypophosphatemia which required increasing doses of phosphate replacement. In this 
patient the tumor in the femur was resected (histology showed an enchondroma) after which 
renal hypophosphatemia resolved.
Yield of Diagnostic Tests in Unexplained Renal Hypophosphatemia   |  31
2
DISCUSSION
Our study shows that in female patients presenting with previously unexplained renal 
hypophosphatemia, estrogen-induced hypophosphatemia due to oral contraceptive use 
appears to be frequent. In 5 out of 7 female patients the hypophosphatemia could be 
attributed to the use of oral contraceptives. This is a relatively unknown and often overlooked 
cause of renal phosphate loss. No previous study reported hypophosphatemia as the 
result of oral contraceptive use, but a decrease in serum phosphate has been described 
in response to estrogen replacement therapy in postmenopausal women [9,1011,12]. This 
decrease in serum phosphate was accompanied by a decrease in TmP/GFR, confirming renal 
phosphate wasting [11,12]. The estrogen content of the replacement therapy that was used in 
these postmenopausal women was higher than the estrogen content in oral contraceptives 
in our patients (50 µg to 62.5 µg compared to 30 µg). Treatment with even higher doses of 
diethylstilbestrol diphosphate in male patients with metastatic prostate cancer also resulted 
in lowering of serum phosphate in 16 out of 18 patients [13]. Urinary parameters were measured 
in 3 of these patients, and were compatible with increased renal phosphate loss. Thus, the 
pathophysiological mechanism of the renal phosphate loss with oral contraceptive use is 
most likely related to the estrogen content. Indeed, estrogen treatment in ovariectomized 
rats and mice results in renal hypophosphatemia. In these animals both NaPi2a and NaPi2c 
in the proximal tubule were shown to be downregulated [14,15,16].
In 11/12 of the remaining patients the underlying cause of renal hypophosphatemia remains 
unknown, despite extensive diagnostic evaluation. Although genetic testing did not reveal a 
mutation, this does not rule out genetic causes as we might still have missed mutations of 
which the significance is not yet understood. 
One patient was diagnosed with TIO. This diagnosis was made after this patient underwent 
a somatostatin scan, despite a normal serum level of FGF23, because he suffered from 
progressive hypophosphatemia. 
Although most reported patients with TIO have clearly elevated serum FGF23 levels, fourteen 
TIO patients with normal FGF23 levels have been described in literature previously [17-25]. In 
these patients another phosphaturic hormone could be involved or FGF23 levels could have 
been misinterpreted due to the use of incorrect reference values and/or FGF23 assays.
Intact FGF23 (iFGF23) is degraded by proteolytic cleavage into inactive N- and C-terminal 
fragments [25]. Since iFGF23 is rapidly degraded ex-vivo, special sampling procedures are 
required with the use of protease inhibitors [27]. In routine clinical practice in our country, a 
commercially available assay is used that measures both intact FGF23 and the C-terminal 
fragments. Therefore, we cannot exclude that some patients might have had increased iFGF23 
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values in the presence of normal cFGF23 values. Furthermore, reference values are based on 
studies in healthy volunteers. Ideally, FGF23 values in our patients with hypophosphatemia 
should be compared to FGF23 values in persons with FGF23-independent hypophosphatemia. 
Although iFGF23 is decreased in such patients [17,28,29], validated reference values of FGF23 
adjusted for severe phosphate deficit do not exist.  
We could have missed TIO’s because a somatostatin scan was not performed in all 
patients and because of low sensitivity of the scanning technique. Scans with radiolabeled 
somatostatin analogs are being used for the diagnosis of TIO as these tumors are of 
mesenchymal origin and frequently express somatostatin receptors (mostly SSTR 2 and 5) 
[22,30,31,32]. The scans differ in affinity for SSTR’s and spatial resolution. PET-based imaging has 
better spatial resolution and signal-to-noise ratios as compared to SPECT-based imaging. 
The somatostatin analogues also differ in their affinity for various somatostatin receptor 
subtypes. DOTA-conjugated peptides have 4-8 higher affinity to SSTR 2 than ¹¹¹Indium-
pentetreotide [22,31]. DOTANOC has affinity for a wide range of receptors like SSTR 1, 2, 3 and 5, 
while DOTATATE and DOTATOC bind more avidly to SSTR 2 [34,35]. The exact percentage of SSTR 
positive tumors in TIO is not known, neither is the exact sensitivity of the different scanning 
techniques for diagnosing TIO. 
Since tumors causing TIO typically are slow growing neoplasms that are benign in 
behaviour, a defensive diagnostic approach seems justified. We therefore do not advocate 
to immediately perform a somatostatin scan in all patients with unexplained chronic renal 
hypophosphatemia. We suggest to perform somatostatin scans only in patients with severe 
complaints including bone pain and fractures, elevated FGF23 levels, progressive disease 
and/or increasing FGF23 levels.
Another striking finding is the male predominance of the group of patients with an unexplained 
renal hypophosphatemia. This raises the question whether endogenous testosterone, in 
analogy to exogenous estrogen, plays a role in the phosphate loss. Supporting this theory 
is the negative correlation between serum testosterone and serum phosphate in men in the 
general population [36]. Data about the effect of testosterone therapy on serum phosphate 
is conflicting [37,38] but testosterone depletion (states) seems to induce an increase in serum 
phosphate due to increased tubular phosphate reabsorption [39,40,41]. We did not test whether 
serum testosterone levels were elevated in our patients. 
A main limitation of our paper is the retrospective study design, in which the analyses 
were performed to the discretion of the treating physician. Another limitation is the lack of 
other proximal tubular function markers such as aminoaciduria, which could be helpful to 
differentiate isolated renal hypophosphatemia from a more general proximal tubular defect 
as seen in Fanconi syndrome.
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CONCLUSION
In conclusion, oral contraceptive use is an important but under-recognized cause of isolated 
chronic renal hypophosphatemia. The cause of chronic renal hypophosphatemia remained 
unexplained in the majority of other patients despite extensive and expensive additional 
investigations. The pre-test probability for TIO or inherited renal hypophosphatemia in 
a patient with aspecific complaints and a normal FGF23 level is low. Further research is 
needed to investigate which patients should be screened for TIO with measurements of 
both cFGF23 and iFGF23 and DOTA-conjugated PET/CT scans. At present we suggest to 
perform somatostatin scans only in patients with severe complaints including bone pain 
and fractures, elevated FGF23 levels, progressive disease and/or increasing FGF23 levels. This 
strategy seems justified in view of the benign course of TIO.
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ABSTRACT
Background
Magnesium and potassium wasting disorders can result from excessive urinary loss of these 
cations due to mutations in genes encoding specific tubular transporters or ion channels. 
In Gitelman syndrome (GS) for example, a defective sodium-chloride cotransporter 
(NCC) leads to hypokalemia and hypomagnesemia. In Bartter syndrome (BS), a defective 
sodium-potassium-chloride cotransporter (NKCC2) leads to a salt loosing nephropathy 
with hypokalemia and hypomagnesemia as well. A challenge with thiazide diuretics, which 
assesses the functional presence of NCC, is used to differentiate GS from BS. However, the 
performance of the thiazide test in renal magnesium wasting disorders other than GS and BS 
has not been studied. 
Methods
Eleven unrelated patients with renal magnesium wasting presenting at our nephrology 
department between 2010-2014 in whom a thiazide test was performed were included. 
Genetic testing of SLC12A3, CLCNKB, KCNJ1, FXYD2 and/or HNF1B was performed by Sanger 
sequencing and Multiplex Ligation Probe Assay (MLPA) subsequently. 
Results
In three patients a mutation in SLC12A3 (GS) was identified, in one patient a mutation in 
CLCNKB  and KCNJ1 (BS), in one patient a mutation in FXYD2 and in five patients a heterozygous 
deletion of HNF1B. In one patient a molecular cause was not identified. The three patients 
with GS showed a blunted response to thiazide diuretics, whereas the BS patient showed a 
normal response, the single patient with a FXYD2 mutation showed a blunted response and 
the five patients with HNF1B deletions showed different responses ranging from normal to 
blunted. 
Conclusions
A blunted response to thiazide diuretics is not pathognomic for GS and can also be found 
in other renal magnesium wasting disorders, such as patients with mutations in FXYD2 or 
HNF1B. In contrast to what has been assumed until now, these mutations do not cause 
isolated distal tubular magnesium wasting but also seem to affect NCC function. Although 
not specific for diagnostic purposes, performing a thiazide test in patients with tubulopathies 
may improve patient phenotyping and increase our understanding of the interrelationship 
between transcription factors, transporters and ion-channels.
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INTRODUCTION
Electrolyte disorders such as hypomagnesemia and hypokalemia can result from excessive 
urinary losses of these cations. In most cases this is caused by acquired tubular disorders 
due to drug toxicity or tubulointerstitial disease. In rare cases, the disorder is caused by loss-
of-function mutations in genes encoding for specific tubular transporters or ion channels. 
An example of such a disorder is Gitelman syndrome (GS). GS is clinically characterized by 
hypokalemia, metabolic alkalosis, hypomagnesemia and hypocalciuria, primarily caused 
by impaired sodium chloride reabsorption in the distal convoluted tubule [1]. Pathogenic 
mutations in the gene SLC12A3 underlying GS result in a defective sodium-chloride co-
transporter (NCC) in the distal tubule. Alternatively, mutations in the CLCNKB gene encoding 
the ClC-Kb chloride channel, present in both the loop of Henle and the distal tubule, are 
thought to lead to secondary dysfunction of NCC-mediated sodium chloride transport [2]. 
Patients can therefore present phenotypically as GS as well. Because thiazide diuretics exert 
their effects by blocking the same NCC in the distal tubule, a challenge with thiazide diuretics 
historically has been used to investigate the functional presence of NCC as a diagnostic test 
in patients thought to have GS [3]. Patients with GS show a blunted natriuretic and chloruretic 
response to thiazide diuretics. The two main studies confirming this concept are those of 
Colussi and Nozu [2,4]. Colussi et al. performed thiazide tests in 41 patients with genetically 
proven GS, seven patients with the phenotypically similar salt-losing nephropathy Bartter 
syndrome (BS), and 12 healthy controls [4]. Nozu et al. performed thiazide – and furosemide 
tests in 16 patients with GS and BS [2]. These studies demonstrated good differentiation 
between patients with GS with either SLC12A3 or CLCNKB mutations, versus patients with BS 
based on proven mutations in the sodium-potassium-chloride cotransporter NKCC2 or the 
potassium channel ROMK. It was therefore concluded that an abnormal thiazide test pointed 
to a defect in the distal tubule and thus accurately predicted GS [4]. 
The differential diagnosis of renal magnesium wasting disorders however is broader than 
GS and BS. Most magnesium reabsorption takes place paracellularly through claudins in the 
proximal tubule (10-30%) and thick ascending limb of Henle’s loop (40-70%). This transport 
is driven by a favourable concentration gradient of magnesium and/or a lumen-positive 
electrochemical gradient, which is dependent on sodium reabsorption in the proximal 
tubule and thick ascending limb of Henle’s loop [5]. Approximately 5-10% of the filtered 
magnesium load is reabsorbed in the distal tubule where fine-tuning occurs through an 
active transcellular reabsorption process [5]. While not all key players in this process have 
been identified, the transient receptor potential channel melastatin 6 (TRPM6), endothelial 
growth factor (EGF), NCC, ClC-Kb, hepatocyte nuclear factor 1β (HNF1β), the γ subunit of Na-
K-ATPase (FXYD2) and the potassium channels Kv1.1 and Kir4.1 appear to play a role [6]. A 
defect in one of these proteins can result in renal magnesium wasting. The clinical value and 
performance of the thiazide test in these renal magnesium wasting disorders is not known. 
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In the past years, we performed thiazide tests to screen for the diagnosis GS in 11 patients 
presenting with renal magnesium wasting. Genetic testing to identify the underlying 
molecular cause was performed thereafter. Most case series in literature evaluated the value 
of thiazide tests in a selected group of patients with genetically confirmed GS or BS. The 
performance and, therefore, clinical value of the thiazide test in undiagnosed patients with 
renal magnesium wasting, including disorders other than GS and BS, is not known. Therefore, 
we performed a diagnostic test study in patients with renal magnesium wasting, using 
thiazide responsiveness as the index test and genetic analysis as the reference standard. 
Based on these results, we discuss the value of tubular function tests in phenotyping patients 
and its contribution in understanding the interrelationship between transcription factors, 
transporters and ion channels.
METHODS
Patients and healthy volunteers
All 11 unrelated patients in whom a thiazide test was performed because of renal magnesium 
wasting and a clinical suspicion of GS between 2010 and 2014 were included. All patients 
were seen at the department of Nephrology at the Radboud university medical center in 
Nijmegen, the Netherlands. To confirm normal values as published by Colussi et al. [4], thiazide 
tests were also done in eight healthy volunteers. This was approved by the medical ethics 
committee of the Radboud university medical center Nijmegen and the healthy volunteers 
gave their informed consent.
 
Thiazide test
The thiazide test was performed according to the protocol described by Colussi [4]. A washout 
period of seven days for therapy that could interfere with the test (i.e. diuretics, NSAID’s) was 
required, but potassium and magnesium salts were allowed. Patients visited the clinic in the 
morning after an overnight fast. They were instructed to drink 10 ml/kg tap water (t=0). At t=30 
minutes and t=90 minutes, patients were asked to void, but urine was discarded. At t=120 
minutes and t=150 minutes urine samples were taken. At t=150 minutes blood samples were 
taken and subsequently 50 mg hydrochlorothiazide was administered orally. Urine samples 
were taken every 30 minutes until t=330 minutes. Another blood sample was drawn at t=270 
minutes. As reference and cut-off values in healthy controls, the data derived from the paper 
from Colussi was used (maximal fractional chloride excretion (FeCl) of 5.73 ± 1.58% and a 
mean maximal change (∆) FeCl of 3.58 ± 1.00%; the lowest maximal ∆ FeCl in normal subjects 
was 2.3%, which was advocated and now generally used as cut-off value for an abnormal test 
result). We performed thiazide tests in eight healthy volunteers. The maximal FeCl was 4.31 
± 0.87% with a mean maximal ∆ FeCl 3.12 ± 0.48%. The lowest maximal ∆ FeCl was 2.35%, 
similar to that described by Colussi [4].
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Laboratory test/values
Fractional excretions (Fe) were calculated by the following formula: (urine concentration 
solute * serum concentration creatinine)/(serum concentration solute * urine concentration 
creatinine) *100. For the fractional excretion of magnesium (FeMg), the following formula 
was used: (urine concentration magnesium * serum concentration creatinine)/(serum 
concentration magnesium * 0.7 * urine concentration creatinine) *100. The plasma 
magnesium concentration was multiplied by 0.7 as 70% of circulating magnesium is 
not bound to albumin and thus freely filtered across the glomerulus. In the presence of 
hypomagnesemia, a FeMg <2.7% would be an appropriate reaction [7].
Molecular diagnostics
Genetic testing for mutations in the known GS-causing genes SLC12A3 (NCC) and CLCKNB 
(ClC-Kb), as well as additional genes like KCNJ1 (ROMK), FXYD2 and HNF1B, was done by 
Sanger sequencing and Multiplex Ligation Probe Assay (MLPA) on genomic DNA derived from 
peripheral blood cells. 
RESULTS
Four male and seven female patients with renal magnesium wasting were included. Their 
characteristics at time of presentation to our clinic are depicted in Table 1. Most patients 
were already using magnesium and/or potassium salts at the time of referral.
In all eleven patients thiazide tests and DNA mutation analyses were performed. These results 
are shown in Table 1 and Figure 1. Three patients had a mutation in SLC12A3 (classical GS), 
one patient had a mutation in CLCNKB and KCNJ1 (BS), one patient had a mutation in FXYD2 
and five patients had a deletion of one HNF1B gene. One patient did not show a mutation in 
SLC12A3, KCNJ1, FXYD2 nor HNF1B.
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Figure 1 Thiazide test results in healthy controls and patients with renal magnesium wasting 
disorders: maximal ∆ FeCl values
Grey area represents the range of ∆FeCl values in normal subjects as reported by Colussi et al [4]
GS: Gitelman syndrome due to a mutation in SLC12A3 
BS: Bartter syndrome due to compound heterozygous mutations in CLCNKB and KCNJ1
The three patients with a SLC12A3 mutation showed a blunted response to hydrochlorothiazide 
administration (Figure 1). The single patient with heterozygous mutations in CLCNKB and KCNJ1 
showed a normal to increased response to hydrochlorothiazide. The five patients with HNF1B 
mutations showed responses ranging from normal to completely unresponsive. The  single  patient 
with a FXYD2 mutation also showed a clearly blunted response. There was no clear association 
between actual serum magnesium levels and chloruretic response to hydrochlorothiazide.
DISCUSSION
The main finding of our study is that a blunted response to thiazide diuretics is not specific 
for GS caused by a mutation in SLC12A3. We show that the response to thiazide diuretics 
can also be blunted in patients with a GS-like phenotype (including magnesiuria and 
hypocalciuria), with other underlying genetic causes of renal magnesium wasting, like a 
mutation in HNF1B or FXYD2 genes. This could indicate that NCC dysfunction is also affected 
in these patients. This is remarkable since mutations in FXYD2 are thought to cause isolated 
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renal hypomagnesemia and mutations in HNF1B cause a multi-system phenotype which 
frequently consists of renal cysts, diabetes and renal dysfunction, but its tubulopathy is 
characterized by an isolated magnesium reabsorption defect as well [8,9]. The underlying 
mechanism of a presumed NCC dysfunction in these diseases is unresolved. It could be due 
to the magnesiuria itself, but both we and others show that e.g. patients with BS suffering 
from magnesiuria exhibit a normal response to thiazide diuretics. 
An interaction between tubular transporters or a tubular development defect seems more 
likely. 
A mechanism linking mutations in FXYD2 to NCC function could be that the membrane 
potential, which is the driving force for sodium reabsorption, is affected in case of a defect of 
FXYD2. FXYD2a is expressed in Henle’s loop and the proximal tubule and FXYD2b is expressed in 
the distal tubule and collecting duct. FXYD2 encodes the γ subunit of basolateral Na-K-ATPase, 
which is important for the maintenance of Na-K-ATPase transport capacity [10-13]. Decreased 
Na-K-ATPase capacity, and thus basolateral membrane potential in the distal tubule, hinders 
the reabsorption of magnesium and sodium through the apically located TRPM6 and NCC, 
respectively [14-16] (Figure 2). 
Figure 2 Distal convoluted tubule and transporters involved in magnesium transport
NCC: sodium-chloride cotransporter
TRPM6: transient receptor potential channel melastatin 6
ClC-Kb: chloride channel kidney B
HNF1β: hepatocyte nuclear factor 1β
EGF: endothelial growth factor.
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HNF1β is a transcription factor located along all segments of the nephron where it regulates 
the transcription of FXYD2 [15]. Thus, it could be that mutations in HNF1B affect sodium 
reabsorption through NCC by decreasing Na-K-ATPase activity as well, as a consequence of 
reduced FXYD2 expression. Alternatively, HNF1β could directly affect NCC expression. However, 
as HNF1β is a transcription factor affecting the expression of several renal and extra-renal 
expressed genes, other HNF1B targets could also be involved. It is also possible that HNF1B 
mutations may similarly affect function of NKCC2 by decreasing Na-K-ATPase activity in Henle’s 
loop. Performing a furosemide test in patients with HNF1B mutations could help to underscore 
this hypothesis as furosemide exerts its effect through inhibition of NKCC2.
An important future question to investigate is whether dysfunction of NCC is specific for 
mutations in genes that are known to affect Na-K-ATPase activity in the DCT. Alternatively, do 
defects in distal tubular transporters leading to hypomagnesemia, like TRPM6 and EGF, also 
affect NCC independent of Na-K-ATPase activity. To our knowledge, there are no literature data 
on thiazide responsiveness in patients with hypomagnesemia with secondary hypocalcemia 
(caused by TRPM6 mutations) or isolated hypomagnesemia due to EGF mutations.
Another mechanistic pathway could be that mutations in genes like HNF1B  or FXYD2 cause 
a more general developmental defect leading to structural alterations in the distal tubule, 
including NCC-expression or –function. Such a phenomenon has been described in NCC-
deficient mice, in which the loss of NCC has led to major and structural remodelling of the 
distal tubule [17].
This study also has important limitations. We have studied a small number of selected patients 
and the normal/reference values of the thiazide test are validated against only a few healthy 
volunteers with which we aimed to confirm that the thiazide test in our hands performs as 
described in the paper from Colussi et al. In particular the patients with HNF1B mutations or 
deletions suffer from various degrees of renal insufficiency, which might theoretically affect 
thiazide responsiveness. However, there was no correlation between renal function and FeCl 
in the HNF1β patients (data not shown). More specific reference values for different ages and 
renal function strata might be needed to interpret the results more properly. Another limitation 
is the lack of proper clinical baseline data, as most patients were already on treatment with 
magnesium and potassium salts at presentation to our clinic. 
CONCLUSION
The present case series shows that thiazide tests cannot be used unequivocally to diagnose 
GS due to SLC12A3 (or CLCNKB) mutations in patients with renal magnesium wasting. Our 
data demonstrate that mutations suggested to cause isolated distal tubular magnesium 
wasting like a mutation in HNF1B or FXYD2 genes, could also affect NCC function and 
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thereby lead to a blunted response to thiazide challenge. However, thiazide testing or rather 
clinical renal tubular function tests in general, still will be a valuable tool in phenotyping 
patients and clinical research. Such detailed clinical phenotyping will ultimately increase 
our understanding of the underlying pathophysiological processes and the interrelationship 
between transcription factors, transporters and ion channels in the renal tubule. 
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Reference Values of Renal Tubular Function Tests Are 
Dependent On Age And Kidney Function
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ABSTRACT
Background
Electrolyte disorders due to tubular disorders are rare, and knowledge about validated clinical 
diagnostic tools such as tubular function tests is sparse. Reference values for tubular function 
tests are based on studies with small sample size in young healthy volunteers. Patients with 
tubular disorders however frequently are older and can have a compromised renal function. 
We therefore evaluated four tubular function tests in individuals with different ages and renal 
function.
Methods
We performed furosemide, thiazide, furosemide-fludrocortisone and desmopressin tests in 
healthy individuals aged 18 to 50 years, healthy individuals aged more than 50 years and 
individuals with compromised renal function. For each tubular function test we included 10 
individuals per group. 
Results
The responses in young healthy individuals were in line with previously reported values in 
literature. The maximal increase in fractional chloride excretion after furosemide was below 
the lower limit of young healthy individuals in 5/10 older subjects and in 2/10 patients with 
compromised renal function. The maximal increase in fractional chloride excretion after 
thiazide was below the lower limit of young healthy individuals in 6/10 older subjects and 
in 7/10 patients with compromised renal function. Median maximal urine osmolality after 
desmopressin was 1002 mOsmol/kg in young healthy individuals, 820 mOsmol/kg in older 
subjects and 624 mOsmol/kg in patients with compromised renal function.
Conclusions
Reference values for tubular function tests obtained in young healthy adults cannot simply 
be extrapolated to older patients or patients with compromised renal function. Larger 
validation studies are needed to define true reference values in these patient categories.
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INTRODUCTION
Electrolyte disorders can be the consequence of acquired or inherited renal tubular defects 
that cause malfunctioning of channels and transporters that are critically involved in the 
(re)absorption or secretion of electrolytes. These tubular disorders are rare, and knowledge 
about as well as experience with validated clinical diagnostic tools such as tubular function 
tests is sparse. Tubular function tests are valuable because they can help to elucidate the 
underlying defect(s) and can direct more specific diagnostic tests and therapy. Reference 
values for tubular function tests are mainly based on studies with small sample size in young 
healthy volunteers [1-4]. Patients with tubular disorders however are frequently older and/or 
have a compromised renal function. It is important to know whether we can use the available 
reference values when using tubular function tests in such patients.  
The aim of this study was to evaluate four different tubular function tests in our institution in 
young healthy individuals, older individuals and patients with compromised renal function 
(CRF). We performed the furosemide test that provides information on transcellular sodium-
chloride reabsorption in the thick ascending limb of Henle (typically used in the diagnosis 
of presumed Bartter syndrome), the thiazide test that reflects activity of sodium-chloride 
reabsorption in the distal convoluted tubule (typically used in the diagnosis of presumed 
Gitelman syndrome), the furosemide fludrocortisone (FF) test that can be used to diagnose 
distal renal tubular acidosis and the DDAVP test which assesses urinary concentration upon 
stimulating the collecting ducts with synthetic desmopressin (DDAVP) used in the diagnosis 
of a renal concentration defect and/or nephrogenic diabetes insipidus.
MATERIALS AND METHODS
Study population
We performed four different tubular function tests in three groups of volunteers: healthy 
individuals aged 18 to 50 years, healthy individuals over 50 years old and patients with CRF. 
CRF was defined as an eGFR of less than 90 ml/min/1.73m2 based on the CKD-EPI formula. 
For each tubular function test, we included 10 individuals per group. Exclusion criteria were 
pregnancy, severe heart failure, disorders of sodium or potassium balance, kidney disease 
primarily involving the kidney tubule such as tubulointerstitial nephritis or suggested by an 
urinary alpha-1-microglobulin level of  ≥ 40 mg/10 mmol creatinine. After informed consent, 
each volunteer participated in one or more tubular function tests. The tests were performed 
in the Radboud university medical center by a group of trained nurses. If participating in 
more than one test, the tests were performed at least 7 days apart. This study was approved 
by the medical ethics committee of the Radboud university medical center in Nijmegen, the 
Netherlands, and all participants gave written informed consent. 
54  |  Chapter 4
Duplicate urine and serum samples of all tests were stored in a freezer at -80ºC. 
To investigate whether there were differences between the use of an oral fluid load or an 
intravenous fluid load during the furosemide test and thiazide test, both tests were performed 
in duplicate in five young healthy volunteers: once with an oral fluid load as described below 
and once using NaCl 0.45% at 250 ml/h during the test. No statistically significant differences 
between oral and intravenous fluid loads were noted with respect to furosemide and thiazide 
test results (data not shown). We therefore choose to perform furosemide and thiazide tests 
with an oral fluid load.
The protocols of the tubular function tests are based on previous reports in literature [1-4].
Furosemide test
In the 7 days preceding the test, subjects were not allowed to take diuretics or non-steroidal 
anti-inflammatory drugs (NSAID’s). In the 3 days preceding the test, subjects were not 
allowed to take angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor 
blockers (ARB). On the morning of the test, subjects were allowed to have a small breakfast 
without coffee. During the test, participants were allowed to eat one sandwich. They visited 
the clinic at 8:00h. At that time (T=0), body weight and blood pressure were measured and 
a urine sample was taken. Thereafter they were instructed to drink 10 ml/kg of body weight 
water in 15 minutes time. After 45, 90 and 120 minutes, a urine sample was collected. After 
150 minutes (T=150), blood and urine samples were collected and one dose of furosemide 
was given orally. If the eGFR was >60 ml/min/1,73 m2, 40 mg of furosemide was given. If the 
eGFR was between 30 and 60 ml/min/1.73m2, 60 mg furosemide was given, and if the eGFR 
was below 30 ml/min/1.73m2, 80 mg of furosemide was given. From this moment on, the 
subject was instructed to drink 250 ml of water per hour until the end of the test. Urine was 
collected every 30 minutes until T=330 minutes and at T=270 an additional blood sample 
was collected. At the end of the test (T=330), body weight and blood pressure were measured 
again.
Thiazide test
In the 7 days preceding the test, subjects were not allowed to take diuretics or NSAID’s. In 
the 3 days preceding the test, subjects were not allowed to take ACEi or ARB. On the morning 
of the test, subjects were allowed to have a small breakfast without coffee. During the test, 
participants were allowed to eat one sandwich. They visited the clinic at 8:00h. At that time 
(T=0), body weight and blood pressure were measured and a urine sample was taken. 
Thereafter they were instructed to drink 10 ml/kg of body weight water in 15 minutes time. 
After 45, 90 and 120 minutes, a urine sample was collected. After 150 minutes (T=150), blood 
and urine samples were collected and 50 mg of hydrochlorothiazide was given orally. From 
this moment on, the subject was instructed to drink 250 ml of water per hour until the end of 
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the test. Urine was collected every 30 minutes until T=510 minutes and at T=270 and T=510, 
an additional blood sample was collected. At the end of the test (T=510), body weight and 
blood pressure were measured again.
Furosemide Fludrocortisone test (FF test)
In the 7 days preceding the test, subjects were not allowed to take diuretics, NSAID’s or sodium 
bicarbonate. On the morning of the test, the subjects were allowed to have a small breakfast 
without coffee. Subjects visited the clinic at 8:00h in the morning. At that time, body weight 
and blood pressure were measured, blood was withdrawn, a urine sample was taken and 
40 mg of furosemide and 1 mg of fludrocortisone were given orally. If the eGFR was between 
30 and 60 ml/min/1.73m2, a gift of 60 mg furosemide was given. If the eGFR was below 30 
ml/min/1.73m2, a gift of 80 mg of furosemide was given. Thereafter, urine samples were 
collected every hour during four hours. After 120 minutes (T=120) and 240 minutes (T=240) 
an additional blood sample was withdrawn. At the end of the test (T=240), body weight and 
blood pressure were measured again.
DDAVP test
In the 7 days preceding the test, subjects were not allowed to take diuretics or NSAID’s. In 
the 24 hours preceding the test, the subjects were not allowed to smoke cigarettes or drink 
alcohol or coffee. From 22:00h on the evening before the test, they were not allowed to drink 
anymore, and during the test they were not allowed to drink or eat. The subjects visited 
the clinic at 8:00h in the morning. At that time (T=0) body weight and blood pressure were 
measured, blood was withdrawn, a urine sample was taken and 4 µg of desmopressin was 
given subcutaneously. Thereafter, urine was collected every hour during 6 hours. At T=180 
and T=360 an additional blood sample was withdrawn. At the end of the test (T=360), body 
weight and blood pressure were measured again.
Calculations and assays
Urinary chloride was measured using an ion selective electrode for the cobas system (Roche 
Diagnostics). If the urine chloride concentration was reported as <20 mmol/l, calculations 
were done with 20 mmol/l. Fractional chloride excretion (FeCl) was calculated using the 
formula ((urine chloride * serum creatinine) / (urine creatinine * serum chloride)) *100. 
Urinary concentration of hydrochlorothiazide was measured by liquid chromatography-
mass spectrometry (LCMS). Urine pH was measured using a pH meter (PHM220, Hach, Tiel, 
the Netherlands).
Statistics
Baseline characteristics are reported as median values with interquartile ranges. For statistical 
analyses, results in the experimental groups (either the elderly or the patients with CRF) were 
compared with results in the young healthy controls. Differences were analysed with the 
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Mann Whitney U test. Differences between groups for categorical values were analysed by 
the chi square test. A result was considered statistically significant if the p value was <0.03 
according to the Bonferroni correction.
RESULTS
We performed 129 tubular function tests in 53 individuals. No serious adverse events 
occurred. Test results are shown in Figures 1-4 and Tables 1-4. Urine chloride was below the 
level of detection of 20 mmol/l in 24/570 samples of the furosemide and thiazide tests.
Table 1 Furosemide test results
Young healthy 
individuals (N=10)
Older healthy 
individuals (N=10)
CRF patients
(N=10)
Age (years) 22 (21-26) 67 (62-73) * 69 (55-73) *
Gender (M/F) 2/8 8/2 * 7/3 
Body weight – start (kg) 65 (62-70) 82 (72-96) * 90 (78-109) *
Body weight – end (kg) 63 (60-69) 81 (71-95) * 90 (77-109) *
Systolic BP – start (mmHg) 124 (115-137) 131 (120-146) 166 (156-172) *
Systolic BP – end (mmHg) 124 (115-137) 129 (126-145) * 159 (149-165) *
Diastolic BP – start (mmHg) 72 (66-78) 75 (71-79) 85 (78-89) *
Diastolic BP – end (mmHg) 69 (67-80) 75 (70-81) 82 (75-92) *
Pulse – start (bpm) 70 (64-85) 67 (59-71) 75 (63-82)
Pulse – end (bpm) 63 (59-78) 65 (57-70) 65 (59-78)
Serum creatinine – start (µmol/l) 65 (59-79) 77 (72-85) * 118 (102-151) *
Serum potassium – start (mmol/l) 4.2 (4.1-4.3) 4.3 (4.1-4.5) 4.5 (4.4-4.7) *
Serum sodium – start (mmol/l) 141 (140-141) 141 (139-142) 138 (137-140)
Baseline FeCl (%) 0.99 (0.78-1.76) 1.23 (0.88-1.56) 1.61 (1.08-1.96)
Maximal FeCl (%) 17.8 (15.9-21.5) 12.1 (9.8-16.4) * 15.5 (12.9-18.6)
Maximal ∆FeCl (%) 16.4 (14.9-19.9) 11.0 (8.3-15.1) * 14.0 (11.6-16.8)
Time max FeCl (minutes) 225 (210-240) 240 (240-278) 240 (240-308)
Median values with interquartile ranges
M= male
F= female
BP = blood pressure 
FeCl: fractional chloride excretion (%)
∆FeCl = maximal change in FeCl compared to baseline FeCl
* P<0.03 compared to young healthy individuals
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Table 2 Thiazide test results
Young healthy 
individuals (N=10)
Older healthy 
individuals (N=10)
CRF patients
(N=10)
Age (years) 21 (21-24) 67 (62-69) * 65 (55-72) *
Gender (M/F) 3/7 8/2 * 7/3 
Body weight – start (kg) 65 (56-70) 83 (74-94) * 82 (77-109) *
Body weight – end (kg) 64 (56-69) 82 (74-94) * 82 (77-109) *
Systolic BP – start (mmHg) 130 (122-136) 138 (130-158) 154 (137-182) *
Systolic BP – end (mmHg) 125 (115-141) 135 (128-149) 177 (146-180) *
Diastolic BP – start (mmHg) 70 (67-84) 80 (79-88) * 78 (68-89)
Diastolic BP – end (mmHg) 76 (69-81) 80 (77-89) * 84 (77-87) *
Pulse – start (bpm) 79 (64-86) 73 (61-86) 68 (63-74)
Pulse – end (bpm) 62 (45-72) 64 (58-72) 57 (52-66)
Serum creatinine – start (µmol/l) 68 (58-75) 77 (70-86) * 124 (112-142) *
Serum potassium – start (mmol/l) 4.2 (3.9-4.2) 4.2 (4.1-4.4) 4.6 (4.3-4.9) *
Serum sodium – start (mmol/l) 140 (138-141) 141 (139-142) 139 (138-142)
Baseline FeCl (%) 1.08 (0.891.40) 1.02 (0.75-1.20) 1.61 (1.30-2.52) *
Maximal FeCl (%) 4.3 (3.7-5.0) 3.4 (3.0-3.9) * 3.8 (2.5-5.0)
Maximal ∆FeCl (%) 2.9 (2.6-3.9) 2.3 (2.0-2.8) * 2.1 (0.9-2.6) *
Time max FeCl (minutes) 300 (270-300) 285 (240-390) 420 (270-510)
Median values with interquartile ranges
M= male
F= female
BP = blood pressure 
FeCl: fractional chloride excretion (%)
∆FeCl = maximal change in FeCl compared to baseline FeCl
* P<0.03 compared to young healthy individuals
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Table 3 Furosemide Fludrocortisone test results
Young healthy 
individuals (N=10)
Older healthy 
individuals (N=10)
CRF patients
(N=10)
Age (years) 21 (21-24) 68 (74-89) * 62 (52-72) *
Gender (M/F) 4/6 8/2 6/4
Body weight – start (kg) 66 (61-71) 80 (74-89) * 87 (78-107) *
Body weight – end (kg) 64 (59-69) 79 (72-88) * 85 (77-106) *
Systolic BP – start (mmHg) 127 (119-135) 142 (127-148) * 147 (143-178) *
Systolic BP – end (mmHg) 117 (108-126) 131 (122-156) 147 (137-169) *
Diastolic BP – start (mmHg) 71 (64-82) 74 (69-87) 78 (69-86)
Diastolic BP – end (mmHg) 69 (61-74) 77 (73-87) * 74 (70-86)
Pulse – start (bpm) 80 (64-95) 75 (65-88) 63 (61-69) 
Pulse – end (bpm) 68 (55-83) 67 (59-75) 60 (53-62)
Serum creatinine (µmol/l) T0 72 (63-84) 75 (72-81) 129 (112-160) *
Urine pH T0 5.6 (5.4-5.8) 5.5 (5.4-5.9) 5.6 (5.3-6.1)
Urine pH T60 5.8 (5.4-6.4) 5.8 (5.0-6.4) 5.8 (5.1-6.5)
Urine pH T120 5.6 (5.2-6.6) 5.3 (4.7-6.2) 5.3 (5.0-6.2)
Urine pH T180 5.2 (4.6-6.0) 5.0 (4.5-6.0) 4.8 (4.6-5.7)
Urine pH T240 4.9 (4.7-5.1) 4.7 (4.4-4.9) 4.7 (4.5-5.2)
Lowest urine pH 4.8 (4.5-5.1) 4.7 (4.3-4.8) 4.7 (4.4-5.2)
Time lowest urine pH (minutes) 180 (180-240) 240 (180-240) 240 (225-240)
Median values with interquartile ranges
M= male
F= female
BP = blood pressure
T0= time 0 etc
* P<0.03 compared to young healthy individuals
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Table 4 DDAVP test results
Young healthy 
individuals (N=10)
Older healthy 
individuals (N=10)
CRF patients
(N=10)
Age (years) 21 (20-23) 66 (58-68) * 68 (53-73) *
Gender (M/F) 7/2 7/3 6/3
Body weight – start (kg) 65 (61-71) 81 (68-100) * 82 (77-111) *
Body weight – end (kg) 64 (61-70) 80 (68-99) * 81 (110) *
Systolic BP – start (mmHg) 132 (120-134) 134 (120-160) 163 (148-179) *
Systolic BP – end (mmHg) 123 (105-133) 138 (118-160) 157 (140-168) *
Diastolic BP – start (mmHg) 74 (65-84) 81 (75-93) 80 (75-86)
Diastolic BP – end (mmHg) 65 (60-77) 82 (70-90) * 76 (73-83) *
Pulse – start (bpm) 79 (69-93) 76 (62-89) 67 (60-78)
Pulse – end (bpm) 64 (52-76) 69 (55-72) 60 (55-67)
Serum creatinine T0 (µmol/l) 72 (61-81) 80 (67-83) 132 (105-160) *
Serum sodium T0 (mmol/l) 141 (139-141) 141 (140-144) 140 (139-143)
Serum sodium T360 (mmol/l) 141 (140-142) 141 (140-142) 142 (140-144)
Urine osmol start (mOsmol/kg) 898 (775-980) 694 (498-743) * 510 (396-590) *
Max urine osmol (mOsmol/kg) 1002 (869-1074) 820 (799-934) 624 (477-814) *
Time max urine osmol (minutes) 330 (300-360) 330 (240-360) 360 (240-360)
Median values with interquartile ranges
M= male
F= female
BP = blood pressure 
* P<0.03 compared to young healthy individuals 
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Figure 1 Furosemide test
Maximal increase of fractional excretion of chloride (∆FeCl ) after administration of furosemide in young healthy 
individuals (young), older healthy individuals (old), and patients with compromised renal function (eGFR 60-89 ml/
min/1.73 m2 □,  eGFR 45-60 ml/min/1.73 m2 ▼, eGFR 30-44 ml/min/1.73 m2  ○ and eGFR 15-29 ml/min/1.73 m2 ▲).
Figure 2 Thiazide test
Maximal increase of fractional excretion of chloride (∆FeCl ) after administration of hydrochlorothiazide in young 
healthy individuals (young), older healthy indivduals (old), and patients with compromised renal function (eGFR 60-
89 ml/min/1.73 m2  □,  eGFR 45-60 ml/min/1.73 m2 ▼, eGFR 30-44 ml/min/1.73 m2  ○ and eGFR 15-29 ml/min/1.73 m2 ▲).
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Figure 3 Furosemide Fludrocortisone (FF) test
Urine pH after administration of furosemide and fludrocortisone in young healthy individuals (young), older 
healthy individuals (old), and patients with compromised renal function (eGFR 60-89 ml/min/1.73 m2 □, 
eGFR 45-60 ml/min/1.73 m2 ▼, eGFR 30-44 ml/min/1.73 m2  ○ and eGFR 15-29 ml/min/1.73 m2 ▲).
Figure 4 DDAVP test
Maximal urine osmolality after administration of desmopressin in young healthy volunteers (young), older 
healthy volunteers (old), and patients with compromised renal function (eGFR 60-89 ml/min/1.73 m2 □, 
eGFR 45-60 ml/min/1.73 m2 ▼, eGFR 30-44 ml/min/1.73 m2  ○ and eGFR 15-29 ml/min/1.73 m2 ▲).
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Young healthy individuals
Clinical characteristics of young healthy individuals are given for each separate test in 
Tables 1-4. Overall, there were more female than male participants. Median age was 21 years 
(IQR 21-24). Test results were in line with earlier reports. The median maximal increase in 
FeCl (∆FeCl) was 16.4% (range 10.3-26.3) after furosemide and 2.9% (range 2.5-5.1) after 
hydrochlorothiazide (Figures 1 and 2, Tables 1 and 2). In all subjects urine pH was below 
5.3 in the FF test (Figure 3, Table 3). Median maximal urine osmolality after DDAVP  was 1002 
mOsmol/kg (range 782-1129) (Figure 4, Table 4). 
Older healthy individuals
Clinical characteristics per test are given in the supplementary Tables 1-4. Overall, there were 
more male than female participants. Median age was 67 years (IQR 63-68). The decrease in 
urine pH after FF  was similar to young healthy individuals (p=0.35). Older individuals showed 
an attenuated response to furosemide, thiazide and DDAVP compared to young healthy 
individuals (p <0.05). In five subjects ∆FeCl remained below the lower end of the range of 
young healthy individuals (10.3%) after furosemide and in six subjects ∆FeCl remained below 
the lower end of the range of young healthy individuals (2.5%) after hydrochlorothiazide 
(Figure 1 and 2, Table 1 and 2). Median maximal urine osmolality after DDAVP was 820 
mOsmol/kg (range 674-1044) (Figure 4). All but one of the older subjects lowered their urine 
pH below 5.3 during the FF test (Figure 3, Table 3). 
Patients with CRF
Clinical characteristics per test are given in supplementary Tables 1-4. Overall, there were 
more male than female participants with CRF. Median age was 68 years (IQR 57-72), median 
eGFR 49 ml/min/1.73m2 (IQR 33-61) and median urinary alpha-1-microglobulin excretion 
15 mg/10 mmol creatinine (IQR 7-28). The underlying kidney disease was considered to be 
renovascular in 9 patients, secondary focal segmental glomerulosclerosis in 3 patients and 
primarily of urologic origin in 2 patients. Eleven patients with CRF used an ACEi or ARB and four 
patients with CRF were on chronic diuretic therapy (which were stopped per the particular test 
protocol). Patients with CRF showed a wide variation with respect to response to furosemide 
and thiazide (Figures 1 and 2). Overall the increase in FeCl after hydrochlorothiazide in CRF 
patients was lower compared to healthy individuals (p<0.01). In contrast, the increase of FeCl 
after furosemide was not lower in CRF patients compared to healthy individuals (p=0.12). In 
two subjects ∆FeCl remained below the lower end of the range of young healthy individuals 
(10.3%) after furosemide and in seven subjects ∆FeCl remained below the lower end of the 
range of young healthy individuals (2.5%) after hydrochlorothiazide. The peak of FeCl after 
hydrochlorothiazide occurred later in patients with CRF, although the difference was not 
statistically significant. In view of the wide range in ∆FeCl in response to hydrochlorothiazide, 
we determined hydrochlorothiazide concentrations using LCMS in urine samples collected at 
the time of maximal ∆FeCl. Urine hydrochlorothiazide excretion varied between patients and 
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was not explained by variations in eGFR (data not shown). However, we observed a significant 
correlation between hydrochlorothiazide excretion and chloride excretion (Figure 5).
Figure 5 Correlation between hydrochlorothiazide excretion and chloride excretion in patients with 
compromised renal function (closed circles) and healthy volunteers (open squares)
In all but one CRF patient, urine pH fell below 5.3 during the FF test. Lowest urine pH did not 
significantly differ between CRF patients and healthy individuals (p=0.97). Patients with CRF 
showed an attenuated response to DDAVP compared to healthy individuals (p<0.01), with a 
median maximal urine osmolality after DDAVP of 624 mOsmol/kg (range 397-866) (Figure 4).
DISCUSSION
Tubular function tests can be used to pin-point a tubular defect of electrolyte transport to 
a specific tubular segment or function, after which other tests might detect the underlying 
cause, e.g. genetic testing in presumed genetic renal tubular disorders. While the latter 
diagnostic technique seems to be taking over the role of tubular function testing in some 
disorders, we should realize that genetic testing is not readily available in large parts of the 
world and that tubular function testing can also be very instrumental and informative in 
disorders without (known) genetic basis. In this study we tested whether reference values 
for tubular function tests obtained in young healthy individuals can be extrapolated to older 
individuals and patients with compromised renal function. 
The response to FF was similar to young healthy individuals in nearly all older individuals 
and patients with CRF. This is in line with earlier reports that showed that patients with CRF 
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are still capable of lowering their urine pH [5,6]. This may partly be explained by the reduced 
ammonium generation in patients with CRF, which limits the buffer capacity. Interestingly, 
one of the patients in both the older and CRF groups did not acidify their urine within 4 hours. 
However, this could still be due to the 4 hour follow-up being too short in these particular 
patients and we therefore cannot exclude that these patients are still be able to (normally) 
acidify their urine. The responses to furosemide, hydrochlorothiazide and DDAVP however 
differed between young healthy individuals, older individuals and patients with CRF. If one 
would apply the often quoted reference values for the furosemide and thiazide test to elderly 
and patients with CRF, about 50% of subjects would have an abnormal test result. Colussi et 
al. previously showed that an increase of ∆FeCl in response to hydrochlorothiazide of less 
than 2.3% diagnoses Gitelman syndrome with a sensitivity of 93% and specificity of 100% [1]. 
Using this cut-off value, none of the healthy young adults but five out of ten older individuals 
and six out of ten patients with CRF, would have a false-negative test result compatible with 
this diagnosis. CRF patients furthermore showed a remarkable wide variation in response. 
We hypothesised that this variation could be due to differences in tubular secretion. 
Therefore, we measured urine hydrochlorothiazide concentrations in all patients with CRF 
and in five healthy volunteers at the time of maximal FeCl during the thiazide test. Patients 
with CRF had a lower median thiazide excretion than young healthy individuals (33 µg/min 
vs 65 µg/min, p=0.01). There was a correlation between hydrochlorothiazide excretion and 
chloride excretion (Figure 5, R2 = 0.48, p<0.01). The urine hydrochlorothiazide concentration 
did not correlate with eGFR. This indicates that the often lower and variable response 
to hydrochlorothiazide in patients with CRF is possibly explained by a variable tubular 
secretion of hydrochlorothiazide. Hydrochlorothiazide and furosemide are excreted from 
the blood into the proximal tubular lumen via organic anion transporters (OAT), mainly 
OAT1. OAT1 is inhibited by uremic toxins which could explain the reduced tubular excretion 
in CRF [7]. The individual variation within the group of patients with CRF in OAT-mediated 
transport can additionally be explained by polymorphisms of OAT expression, the underlying 
kidney disease, co-medication and competition with other anions [8]. An important 
difference between the furosemide and thiazide test we performed, is the adjustment of 
furosemide dose for eGFR. This could have led to relatively better urinary availability of 
furosemide compared to hydrochlorothiazide in participants with CRF, and thereby to less 
difference in response to furosemide than hydrochlorothiazide compared to the healthy 
young adults. Additional studies are needed to investigate whether tubular secretion of 
hydrochlorothiazide and furosemide are disturbed in elderly as well and to see if chloride 
excretion factored for hydrochlorothiazide or furosemide excretion is a more informative 
parameter. Another explanation for the variation in response encountered in CRF patients 
could be a difference in NCC expression. NCC expression could vary due to the underlying 
disease, plasma potassium and aldosterone levels and could be affected by previous drug 
use, albeit all possible confounding drugs were stopped beforehand [9]. 
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In response to DDVAP, older individuals and patients with CRF had a lower maximal urine 
osmolality than young healthy individuals. The age dependent decrease in maximal urine 
concentrating ability is in line with the results of Tryding et al [10]. These authors performed 
DDAVP tests in 212 healthy adults aged 20 to 80 years. Peak urine osmolality declined with age 
ranging from 982 ± 214 mOsm/kg at 20 years to 823 ± 278 mOsm/kg at 80 years. 
While our study shows that results of renal tubular function tests are dependent on age 
and kidney function, the main limitation of this study is the low number of participants 
which precludes true definition of reference values for older individuals and patients with 
compromised renal function. Besides this, it would have been informative to obtain standard 
urinary concentrations of furosemide and hydrochlorothiazide to give insight into the 
underlying mechanisms explaining the differences in test results between individual patients 
and groups. Another limitation is the urinary chloride concentration that was below the 
level of detection in a small amount of individuals in both baseline samples. We performed 
calculations using a urine chloride concentration of 20 mmol/l in these patients, but this 
could have led to incorrect higher baseline FeCl values and thereby lower ∆FeCl values in 
these individuals. However, when we excluded these individuals, the overall conclusion did 
not change. Another limitation concerns the heterogeneity of CRF patients as these patients 
have different underlying kidney diseases and (chronic) medication use. Chronic diuretic use 
could have influenced the natriuretic response according to the braking phenomenon, which 
is postdiuresis sodium avidity after diuretic use, despite that these drugs were stopped 7 
days prior to the test [11]. This bias cannot fully explain the results as only one patient with 
chronic thiazide use underwent a thiazide test (and did not show a reduced response) and 
only two patients with chronic furosemide use underwent a furosemide test of which one 
showed a reduced response. 
CONCLUSION
In conclusion, reference values for tubular function tests obtained in young healthy adults 
cannot be readily extrapolated to older subjects or patients with compromised renal function, 
except for the FF test. Larger  studies with measurement of urine drug concentrations would 
be necessary to determine correct and clinically relevant reference values in these subject 
categories. For now, we should take the results of this validation study into account when 
interpreting results from patients of older age or with compromised renal function.
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Use of the Furosemide Fludrocortisone Test to Clinically 
Assess Distal Tubular Acidification
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ABSTRACT
Background
The furosemide fludrocortisone test (FF test) is advocated as a test to diagnose (incomplete) 
distal renal tubular acidosis (dRTA). The FF test is based on the assumption that furosemide 
increases distal tubular sodium delivery and that fludrocortisone, by further stimulating 
sodium reabsorption through the epithelial sodium channel ENaC, which subsequently 
drives H+ secretion through adenosine triphosphatase proton pumps (H+-ATPase and H+/
K+-ATPase) in the collecting duct. This classical assumption has been questioned by recent 
animal studies. Furosemide itself can acidify the urine by stimulating the Na+/H+ exchanger 
NHE3 in mice. If such a mechanism is present in humans as well, the FF test could erroneously 
suggest normal urinary acidification in patients with dRTA. This would limit the use of the FF 
test as a diagnostic test for patients with dRTA. We therefore investigated whether furosemide 
can induce ENaC-independent urine acidification in man.
Study design
An intervention study in which ten healthy volunteers underwent two FF tests on separate 
days, either with or without pre-treatment with the ENaC blocker amiloride (20 mg orally), 
two hours prior to the start of the test.
Results
In the absence of amiloride, urine pH was reduced to values ≤ 5.3 after FF in all volunteers. In 
the presence of amiloride, there was an attenuated decrease of urine pH. Still, two subjects 
had a pH <5.3 at the end of the test. Urine sodium and potassium excretion indicated that 
at that time, blockade of ENaC was incomplete. In contrast, during the time period in which 
ENaC was optimally blocked, no increase in H+ excretion was observed compared to the 
same time period in the standard FF test.
Conclusion
These data demonstrate that furosemide does not cause ENaC-independent urine 
acidification in man. Our data support the applicability of the FF test for diagnosing dRTA.
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INTRODUCTION
Urine acidification is the net effect of the reabsorption of HCO3-, the secretion of H+ and the 
presence of buffers. In distal renal tubular acidosis (dRTA) there is a defect in H+ secretion in 
the collecting duct. dRTA is traditionally diagnosed by an oral ammonium chloride (NH4Cl) 
loading test. Patients with dRTA are unable to adequately acidify the urine in case of an acid 
load with NH4Cl [1]. However, the oral NH4Cl test often leads to nausea and vomiting, resulting 
in early termination and inconclusive test results. Therefore, the furosemide fludrocortisone 
test (FF test) was developed [2]. This test has replaced the oral NH4Cl test in many centers. 
The FF test is based on the assumption that furosemide increases distal tubular sodium 
delivery and fludrocortisone further enhances sodium reabsorption through the epithelial 
sodium channel ENaC and, subsequently, increases H+ secretion through H+-ATPase/H+-
K+-ATPase in the collecting duct. Administration of FF therefore induces urine acidification 
in normal subjects but not in patients with a defect in distal H+ secretion as in dRTA. This 
classical assumption has been questioned by recent animal studies. Bruijn et al studied the 
effects of furosemide in mice with deletion of both ENaC and H+-ATPase and observed that 
urine acidification still occurred [3]. These studies indicated that furosemide may influence 
urine acidification via an alternative pathway involving stimulation of the Na+/H+ exchanger 
(NHE3) in the thick ascending loop of Henle (TAL). It is unknown if such a mechanism occurs 
in humans as well. Understanding if such an ENaC-independent acidification mechanism is 
also present in human is critical for the correct interpretation of the FF test. If furosemide also 
has a significant effect on NHE3 in the TAL in man, FF administration could still induce urinary 
acidification in patients with dRTA (i.e. a false negative test result). This would limit the use of 
the FF test in clinical practice. A recent report indeed noted discrepant results between the 
NH4Cl test and the FF test in a group of patients with Sjögren’s syndrome [4]. Administration of 
NH4CL did not lower urine pH in 17 patients. In six of these, urine pH did decrease to values 
<5.3 after FF. These discrepant findings could be explained by reduced uptake of NH4Cl, or 
the presence of an ENaC-independent furosemide-induced pathway of urine acidification. 
Therefore it is important to ascertain whether an alternative ENaC-independent mechanism 
of furosemide-induced urine acidification is present in man as well. We investigated this by 
performing FF tests in healthy volunteers during ENaC blockade with amiloride. 
METHODS
Study population
We performed a study in 10 healthy volunteers, aged >18 year and not using any medication. 
After informed consent, each healthy volunteer underwent two FF tests, one without and one 
with 20 mg of the ENaC blocker amiloride administered 2 hours before performing the test. 
These two tests were performed on different occasions, at least 7 days apart. The tests were 
performed in the Radboud university medical center by a group of trained nurses. This study 
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was approved by the medical ethics committee of the Radboud university medical center 
Nijmegen. 
FF test with or without amiloride
The healthy volunteers visited the clinic at 8:00h in the morning. At that time, subjects were 
weighed, blood was withdrawn, a urine sample was taken and 40 mg of furosemide and 1 
mg of fludrocortisone were given orally (T=0). Thereafter, every hour urine samples were 
collected during four hours. After two hours an additional blood sample was withdrawn. In 
case of the FF test with amiloride, 20 mg of amiloride was given orally at 8:00h. Two hours 
later the FF test was performed as described above. 
Calculations
Urine free hydrogen (H+) excretion was calculated from the urine pH. The concentration of free 
hydrogen is 10–pH. The concentration was corrected for the volume of urine to approximate 
H+ excretion rate. The urine osmol gap was calculated by the formula: urine osmolality – 
(2*(sodium + potassium) + urea + glucose)).
Statistics 
Baseline characteristics are reported as median values with interquartile ranges. 
RESULTS
We included ten healthy volunteers (5 male, 5 female) with a median age of 29 years (IQR 
21-64) and a median serum creatinine level of 73 µmol/l (63-82). A summary of baseline 
characteristics is shown in Table 1. 
In the absence of amiloride, furosemide in combination with fludrocortisone led to a 
decrease of urine pH ≤ 5.3 in all ten subjects as expected. After pre-treatment with amiloride, 
furosemide still led to a moderate decrease in urine pH, with two subjects reaching a urine 
pH ≤ 5.3. The H+ excretion is maximal at T=180 (Figure 1). During the time period of maximal 
effect of amiloride and thus optimal blockade of ENaC, between T=0 and T=60, no increase in 
H+ excretion was observed compared to the same time period in the standard FF test (Figure 
2, p=0.01). From T=120 onward, the sodium/potassium ratio starts to decline and at T=180 
urine volume and urine sodium excretion were already decreasing, while urine potassium 
excretion was increasing (Figure 1), indicating return of ENaC activity.
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Table 1 Clinical characteristics and test results
FF test FF test after amiloride
eGFR (ml/min/1.73m2) 94 (87-107) 94 (87-107)
Weight start (kg) 70 (64-86) 68 (63-85)
Weight end (kg) 68 (63-85) 66 (61-83)
Systolic blood pressure start (mmHg) 128 (121-136) 124 (115-136)
Systolic blood pressure end (mmHg) 124 (116-131) 120 (115-123)
Diastolic blood pressure start (mmHg) 69 (66-83) 72 (68-81)
Diastolic blood pressure end (mmHg) 73 (69-95) 77 (69-81)
Pulse start (beats/min) 85 (67-95) 80 (72-93)
Pulse end (beats/min) 72 (59-81) 68 (64-78)
Urine pH before amiloride 5.5 (5.2-6.0)
Urine pH before FF 5.5 (5.2-5.8) 8.0 (7.9-8.3)
Lowest urine pH 4.7 (4.2-4.8) 6.1 (5.3-6.9)
Number of subjects with a urine pH ≤5.3 10/10 2/10
Time of lowest urine pH (minutes after FF) 180 (180-240) 180 (180-240)
Values are given as median (IQR)
eGFR was calculated using CKD-EPI formula
Figure 1 Urine volume in ml (left axis,○) potassium excretion in mmol/min *100 (right axis, ▲), 
hydrogen excretion in nmol/min (right axis, *) and sodium excretion in mmol/min *10 (right axis,▼) 
in furosemide fludrocortisone test with amiloride.
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Figure 2. Median urine H+ excretion after administration of furosemide and fludrocortisone  
without (●) and ith amiloride (○)
DISCUSSION
In this study we tested the presence of an ENaC-independent pathway of urine acidification 
in healthy volunteers by performing an FF test under 20 mg of amiloride, to ascertain whether 
such a pathway could interfere with the interpretation of the FF test. We observed a urine pH 
≤ 5.3 in two subjects during the FF test after 20 mg of amiloride. At first sight this might seem 
compatible with ENaC-independent urine acidification, at least in these two subjects.
However, the interpretation of urine pH as primary outcome measure is difficult as it is also 
dependent on volume excretion. For this reason we calculated free H+ excretion. While H+ 
excretion still showed an increase during the FF test under amiloride, a closer look at the 
data shows that the dose and time of amiloride administration was insufficient to fully block 
ENaC throughout the test. This is reflected by the change in urine sodium and potassium 
excretion during the test. At T=180, urine volume and urine sodium excretion were already 
decreasing, which should have lowered potassium excretion via the flow-dependent BK 
potassium channel. Urine potassium excretion however increased. The decreased sodium 
to potassium ratio reflects that recovering ENaC activity is the driving force behind distal 
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potassium excretion via the renal outer medullary potassium channel (ROMK). Thus, the 
increase of free H+ excretion could be attributed to recovering ENaC activity during the latter 
part of the test. Therefore, we evaluated urine pH and calculated urine free H+ excretion in 
the period of maximal ENaC blockade (i.e. 0-120 minutes after FF administration). In this 
period, no change in H+ excretion occurred, whereas in the absence of amiloride, H+ excretion 
progressively increased (Figure 2). This makes the existence of an ENaC-independent 
pathway very unlikely. 
The main limitation of our study is the inability to block ENaC fully during the whole duration 
of the FF test, and the fact that we rely on indirect measurements for ENaC activity. In 
addition, it would have been informative to measure urine ammonia, titratable acid and 
bicarbonate excretion to calculate net acid excretion. We did calculate the urine osmol gap, a 
representative measure for NH4+ excretion. Under treatment with amiloride, the urine osmol 
gap decreased close to zero. This is consistent with a reduction of NH4+ excretion. As the NH3/
NH4+ system is the most important buffer system, this finding further supports the lack of an 
increase of H+ excretion during the FF test under amiloride.
CONCLUSION
Altogether, these results show that under optimal ENaC blockade there is no FF-induced 
increase of H+ excretion. This would exclude the existence of a clinically relevant ENaC-
independent pathway of furosemide-induced urine acidification in humans that would 
interfere with the interpretation of the FF test. Therefore, these data support the applicability 
of the FF test in the diagnostic work-up of dRTA.
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Urine Acidification after Ammonium Chloride
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ABSTRACT
Background
Distal renal tubular acidosis can be diagnosed with an ammonium chloride test (NH4Cl 
test) or a furosemide fludrocortisone test (FF test). The FF test is based on the assumption 
that furosemide and fludrocortisone enhance sodium reabsorption through ENaC, which 
increases H+ secretion through H+-ATPase in the collecting duct. Recent reports showed 
discrepant results between these two tests; about 30% of patients with suspected distal 
renal tubular acidosis showed a normal decrease in urine pH after NH4Cl, but not after FF. 
An explanation could be the existence of an alternative (ENaC-independent) mechanism of 
urine acidification in response to NH4Cl. We therefore investigated whether NH4Cl can induce 
ENaC-independent urine acidification in man.
Study design
An intervention study in which ten healthy volunteers underwent two NH4Cl tests on separate 
days, either with or without co-treatment with the ENaC blocker amiloride.
Results
In the absence of amiloride, NH4Cl led to a decrease of urine pH ≤ 5.3 in nine out of ten 
subjects. In the presence of amiloride, H+ excretion did not increase after NH4Cl and urine pH 
remained > 5.3.
Conclusion
These data demonstrate that ammonium chloride does not cause ENaC-independent urine 
acidification in man. Further research is needed to investigate the cause of the discrepant 
results between the NH4Cl and FF test. 
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INTRODUCTION
Urine acidification is the net effect of the reabsorption of HCO3-, the secretion of H+ and the 
presence of buffers. The majority of HCO3- is reabsorbed in the proximal tubule. In the absence 
of intraluminal HCO3- at distal tubular sites, secretion of H+ will cause lowering of urine pH. 
The alpha-intercalated cells in the collecting duct are mainly responsible for H+ secretion, 
mediated by H+-ATPase (an electrogenic pump, mainly driven by sodium transport through 
the epithelial sodium channel ENaC) and H+-K+-ATPase (an electroneutral pump, mainly 
active in case of potassium depletion). A defect in H+ secretion in the collecting duct causes 
distal renal tubular acidosis (dRTA). Incomplete forms of distal renal tubular acidosis can be 
diagnosed by either an ammonium chloride (NH4Cl) test or a furosemide fludrocortisone (FF) 
test. The acid load in the NH4Cl test induces mild systemic acidosis and thereby stimulates 
(distal) H+ secretion. The FF test is based on the assumption that furosemide increases distal 
tubular sodium delivery and fludrocortisone further enhances sodium reabsorption through 
ENaC. This sodium reabsorption through ENaC increases H+ secretion through H+-ATPase in 
the collecting duct. Patients with dRTA do not adequately lower their urine pH in response to 
these two acidification tests [1-3]. 
Recent reports however showed discrepant results between the NH4Cl test and the FF 
test in a significant number of patients with suspected dRTA [4-7]. In many patients urine 
pH was lowered to a value < 5.4 after NH4Cl, but not after FF. This could be the result of 
an inadequate natriuretic response to furosemide due to enhanced proximal sodium 
reabsorption or impaired distal delivery of furosemide. Alternatively, the NH4Cl test and the 
FF test may evaluate different pathways of H+ secretion. We previously demonstrated that 
the response to FF is ENaC-dependent [8]. In the mouse, ENaC-independent H+ secretion 
has been shown. Thus, a decrease in urine pH after NH4Cl but not FF might occur if ENaC-
independent acidification exists in humans, which is triggered by an acid load. If such an 
ENaC-independent mechanism is present, (partial) defects of ENaC will not result in the 
typical dRTA phenotype with a disturbed response to acid loading due to this alternative 
pathway of urine acidification. To investigate whether such an ENaC-independent pathway 
is present, we tested urine acidification in response to NH4Cl under blockade of ENaC in 
healthy volunteers.
METHODS
Study population
We performed a study in 10 healthy volunteers, aged >18 year and not using any medication. 
After informed consent, each healthy volunteer underwent two NH4Cl tests, one without and 
one with the ENaC blocker amiloride. These two tests were performed on different occasions, 
at least 7 days apart. The tests were performed in the Radboud university medical center by 
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a group of trained nurses. This study was approved by the medical ethics committee of the 
Radboud university medical center Nijmegen. All volunteers gave written informed consent. 
NH4Cl test with or without amiloride
The healthy volunteers visited the clinic at 8:00h in the morning. At that time, subjects were 
weighed, blood pressure was measured and blood was withdrawn. After 30 minutes (T=30), 
a urine sample was taken and 100 mg/kg ammonium chloride (as capsules of 500 mg) was 
given. The ammonium chloride was given slowly (over one hour) to reduce nausea and 
prevent vomiting. Every hour thereafter urine samples were collected during 6 hours. At the 
end of the test, at T=420, an additional urine and blood sample were taken. In case of the 
NH4Cl test with amiloride, three doses of amiloride were given to ensure ENaC blockade 
during the entire test. The first dose of 20 mg of amiloride was given orally together with the 
ammonium chloride (at T=30), a second dose of 10 mg was given at T=150 and the third dose 
of 10 mg was given at T=270. 
Calculations and assays
Glucose, calcium, phosphate, sodium, potassium and creatinine (enzymatic method) were 
measured on a Cobas c6000 (Roche, Switzerland) or c18000 (Abbott, USA) analyzer. Urine pH 
was measured using a pH meter (PHM220, Hach, Tiel, the Netherlands).
Urine free hydrogen (H+) excretion was calculated from the urine pH [concentration free hydrogen 
equals 10–pH ] and corrected for the volume of urine to approximate H+ excretion rate.
Urine osmolality reflects the sum of charged and uncharged molecules, the latter being 
represented by urea and glucose. Calculation of the urine osmol gap (which is the difference 
between measured urine osmolality and calculated urine osmolality based on measured 
osmoles in the urine), reflects the amount of unmeasured molecules, which mainly consists 
of ammonium. The urine osmol gap can therefore be used as an estimate of urine ammonium 
excretion. The urine osmol gap was calculated as follows: urine osmolality – (2*(sodium + 
potassium) + urea + glucose)). 
Statistics 
Baseline characteristics are reported as median values with interquartile ranges. 
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Table 1 Clinical characteristics and test results
NH4Cl test without 
amiloride (n=10)
NH4Cl test with 
amiloride (n=10)
Weight start (kg) 71 (62-77) 71 (63-77)
Weight end (kg) 70 (62-77) 71 (62-76)
Systolic blood pressure start (mmHg) 129 (117-135) 122 (119-133)
Systolic blood pressure end (mmHg) 120 (112-129) 120 (115-123)
Diastolic blood pressure start (mmHg) 64 (56-68) 67 (59-75)
Diastolic blood pressure end (mmHg) 62 (58-70) 69 (58-73)
Serum HCO3- start (mmol/l) 25.2 (23.8-27.6) 25.2 (22.8-27.1)
Serum HCO3- end (mmol/l) 23.8 (21.7-24.9) 23.9 (21.8-24.5)
Urine pH before NH4Cl 5.96 (5.45-6.65) 5.96 (5.42-6.77)
Urine osmol gap before NH4Cl 43 (2-95) 36 (-9-52)
Urine osmol gap after NH4Cl 34 (17-56) 0 (-10-3)
Lowest urine pH 4.95 (4.81-5.05) 6.26 (5.84-6.58)
Number of subjects with a urine pH ≤5.3 9/10 0/10
Values are given as median (IQR)
Urine osmol gap calculation: urine osmolality – (2*(sodium + potassium) + urea + glucose))
In nine out of ten subjects, NH4Cl led to a decrease of urine pH ≤ 5.3 (Figure 1). The single 
subject that did not adequately lower her urine pH, spontaneously drank a lot of water 
during the NH4Cl test. This led to a mean urine production of 454 ml/hour and thus dilution 
of urinary H+, and therefore urine pH did not drop to the level that would be expected in a 
healthy volunteer. However, there was a significant increase in net free H+ excretion from 0.4 
nmol/min to 28.2 nmol/min, which is not different from the response in the other subjects. 
Thus, all healthy volunteers actually showed a significant increase in H+ excretion in response 
to NH4Cl.
RESULTS
We included ten healthy volunteers (4 male) with a median age of 22 years (IQR 21-23) and 
a median serum creatinine level of 81 µmol/l (75-86). The median dose of NH4Cl was 7250 
mg (IQR 6375-7625). The NH4Cl dose was the same within subjects for the test with and 
without amiloride. NH4Cl caused nausea but did not result in vomiting. A summary of clinical 
characteristics and test results is shown in Table 1.
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Figure 1 Urine pH during NH4Cl test without amiloride
Figure 2 Median urine Na/K-ratio during NH4Cl without ( ●) and with amiloride (○)
Under ENaC blockade, none of the subjects showed a decrease in urine pH after NH4Cl 
(Figure 3).
Under amiloride, ENaC activity started to recover at the end of the test (from T=390) as the 
urine Na/K-ratio starts to decrease (Figure 2).
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Figure 3 Urine pH during NH4Cl test with amiloride
Figure 4 Median urine H+ excretion during NH4Cl without (●) and with amiloride (○)
The lack of a decrease in urine pH with concomitant ENaC blockade was not explained by 
dilution: we observed no net increase of H+ excretion after administration of NH4Cl under 
amiloride (Figure 4).
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DISCUSSION
In this study we tested the presence of an ENaC-independent pathway of urine acidification 
in response to NH4Cl by performing NH4Cl tests under amiloride. Such a pathway could 
erroneously suggest normal urinary acidification in patients with dRTA that is due to a defect 
of ENaC or ENaC-dependent acidification.
In nine out of ten healthy volunteers, NH4Cl led to a decrease of urine pH ≤ 5.3. The lack of 
a decrease in urine pH in one of the subjects was due to urine dilution and not because of 
inadequate H+ excretion. Therefore we conclude that all healthy volunteers showed adequate 
H+ excretion in response to NH4Cl.
In contrast, we did not observe urine acidification when the NH4Cl test was done under 
amiloride. There was no decrease in urine pH, nor an increase in net H+ excretion. Our data 
indicate that there is no ENaC-independent pathway of urine acidification in response to 
NH4Cl. In a previous study we showed that urine acidification after FF is also strictly ENaC- 
dependent [8]. Therefore, the data do not provide an explanation for the discrepant results 
between both tests.  
A possible explanation for a disturbed FF test in the absence of dRTA could be inadequate 
distal sodium delivery in response to furosemide (if for example the dose of furosemide or 
tubular secretion of furosemide is inadequate). Unfortunately, previous studies did not report 
urine sodium and chloride excretions of these patients, nor urinary furosemide excretion. 
Another explanation could be incomplete proximal HCO3- reabsorption during the FF test, 
due to inhibition of carbonic anhydrase and NHE3. Normally however, the HCO3- threshold 
increases in response to furosemide and furosemide-induced volume contraction causes an 
increase in HCO3- reabsorption.
As previously mentioned, a single subject in our study inadvertently drank a lot of water and 
was able to dilute her urine to such an extent that she did not reach urinary pH ≤ 5.3, and 
strictly had an abnormal test result in the presence of a normal increase in net H+ excretion. 
This at least leaves open the possibility that similar unexpected behaviour of patients can 
theoretically have affected test results in the studies that report discrepancies between FF 
and NH4Cl tests. In any case, it teaches us that results of tubular function tests such as the 
NH4Cl test should be critically evaluated, and one should not rely solely on the performance 
of the primary outcome measure, in this case urinary pH. 
The main limitation of our study is the inclusion of only healthy volunteers. In addition, it 
would have been informative to measure urine ammonia, titratable acid and bicarbonate 
excretion to calculate net acid excretion in addition to net free H+ excretion. We did calculate 
the urine osmol gap to estimate NH4+ excretion (Figure 5). During amiloride, the urine osmol 
Urine Acidification after Ammonium Chloride   |  87
6
gap decreased to values close to zero. This is compatible with the expected decrease in NH4+ 
excretion when H+ excretion is blocked.
Figure 5 Urine osmol gap during NH4Cl without (●) and with amiloride (○)
Another limitation is the use of amiloride, since it is not a specific ENaC blocker and also 
inhibits ammonia excretion and NHE3 [9]. A reduction of NH3 buffer would have led to lower 
pH values. Blockade of NHE3 by amiloride on the other hand could have masked an ENaC- 
independent effect of NH4Cl on urine acidification. In mice, urine acidification indeed takes 
place through NHE3 in the thick ascending limb of Henle [10]. Amiloride however is far less 
potent in blocking NHE3 than in blocking ENaC. After a single dose of 20 mg amiloride, the 
urine concentration at the distal tubule is 3-20 uM. The IC50 value for blocking NHE3 is at 
least >50 uM which is in contrast to an IC50 of 0.1 uM for blocking ENaC. It is thus not likely 
that our dose of amiloride resulted in a significant blockade of NHE3. In addition, NHE3 has 
never been detected in the human thick ascending limb. 
CONCLUSION
In conclusion, our data suggest that NH4Cl does not cause ENaC-independent urine 
acidification in man. Further research is needed to unravel the cause of the frequently 
encountered discrepant results between the NH4Cl and FF test. Until this has been clarified, 
we advise to perform a confirmatory NH4Cl test in patients who do not show an adequate 
decrease in urinary pH in response to furosemide fludrocortisone.
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The Use of N-of-1 Trials to Individualize Treatment in 
Patients with Renal Magnesium Wasting
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ABSTRACT  
Background
Patients with tubular disorders which cause chronic renal magnesium wasting and 
hypomagnesemia are rare. These patients require lifelong supplementation treatment 
with magnesium salts. Because of the paucity of randomized controlled trials in these rare 
disorders, the optimal treatment is not known. In this study we used the N-of-1 methodology 
to compare different magnesium salts in the treatment of patients with therapy-resistant 
renal magnesium wasting.
Methods
We performed randomized, double-blinded multi-crossover trials within individual patients 
which compared magnesium-gluconate, magnesium-aspartate and magnesium-lactate 
in four-week treatment blocks during a total of 36 weeks. Main outcome parameters 
were patient reported outcome measures. At two weeks intervals, patients completed a 
personalized questionnaire and a general quality-of-life questionnaire. In addition, laboratory 
investigations were performed.
Results
Thus far, we evaluated four patients with therapy-resistant renal hypomagnesemia. Based 
on patient reported outcome measures, the N-of-1 trials were able to identify a superior 
treatment in three out of four patients. The three different magnesium salts did not result 
in significantly different serum magnesium levels, nor did serum magnesium correlate well 
with patient reported outcome measures. The magnesium salt that was superior for the 
individual patient was not the same for all patients.
Conclusions
N-of-1 trials help to determine the best treatment strategy for the individual patient in an 
evidence-based fashion. They are particular useful to asses treatment effects in stable and 
chronic diseases in relation to patient reported outcome measures. We urge nephrologists to 
consider the use of N-of-1 trials to directly impact on individual decision making.
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INTRODUCTION
Patients with chronic renal magnesium wasting often suffer from various complaints 
such as generalized fatigue, neuromuscular symptoms such as muscle weakness and 
cramps, neuropsychiatric signs ranging from confusion to parkinsonism, or arthralgias. 
Furthermore, hypomagnesemia can cause other clinically relevant electrolyte disturbances 
such as hypokalemia and hypocalcemia. Most patients require lifelong treatment with 
high doses of magnesium salts. The aim of treatment is to improve symptoms, quality of 
life and serum electrolyte levels. Sufficient magnesium replenishment however is difficult. 
Complaints and serum magnesium levels are not always clearly related. Moreover, it is 
often difficult to administer sufficient magnesium because high doses of magnesium salts 
are not well tolerated as they induce diarrhoea and gastrointestinal complaints. Another 
difficulty is that magnesium salts, at least theoretically, highly differ in bio-availability. 
Local availability of specific magnesium salts can be limited, which is further hampered 
by the fact that prescription options are often determined by the willingness of health 
insurances to reimburse. In clinical practice it is not clear which magnesium salt one should 
prescribe, as there is a lack of randomized controlled trials (RCT’s) comparing these 
compounds in patients [1,2]. 
While the double blind RCT is nowadays the standard scientific strategy for determining 
efficacy of therapy, it still has caveats. Selected groups of patients are included whereby 
observed treatment effects may not apply to the individual patient, and for rare diseases the 
number of patients is mostly too small to perform an RCT. A very interesting alternative in 
these situations is the single-subject trial design of which the N-of-1 trial is the most common 
example. The N-of-1 trial is a prospectively planned trial conducted within an individual 
patient to compare the effectiveness of two or more treatments for a specific patient. The 
N-of-1 trial mostly consists of multiple randomized crossover periods and is often blinded 
and placebo controlled. It was first developed and used in psychology research in 1984, 
and two years later Guyatt et al. described the use of N-of-1 trials in medical research [3]. 
Due to its multiple cross-over design, N-of-1 trials are particularly appropriate for stable 
and chronic conditions in which treatment effects are quick in both onset and termination. 
Despite its attractive methodology with direct clinical implications for the individual patient, 
N-of-1 trials are still sparsely used in medical research. To our knowledge, only three 
N-of-1 trials have been described within nephrology [4,5,6]. N-of-1 trials however have the 
potential for application in a broad range of kidney disorders, as many kidney diseases are 
rare and/or chronic in nature. Moreover, in chronic kidney disorders focus should not only 
be on “hard” end points, but also on patient reported outcome measures that have a major 
impact on quality of life. 
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In this paper we describe the results of N-of-1 trials in which we compared the efficacy of 
different magnesium salts in the treatment of patients with clinical symptoms attributed to 
renal magnesium wasting.
MATERIALS AND METHODS 
Design
We used a randomized, double-blinded multi-crossover study design with a total duration 
of 36 weeks. Each individual N-of-1 trial consisted of three treatment blocks. A treatment 
block comprised three treatment periods of four weeks with three different magnesium 
salts: magnesium-lactate, magnesium-gluconate and magnesium-aspartate. Within each 
treatment block, the order in which the magnesium salts were offered was randomized by 
the hospital pharmacy. The magnesium salts were encapsulated so that both patient and 
doctor were blinded for the therapy that was given. The capsules were of size 00. The maximal 
amount of magnesium fitting the capsules was used. This maximal amount was different 
for the respective magnesium salts. The magnesium content of the capsules was 1.5 mmol 
elemental magnesium for magnesium-lactate, 0.8 mmol for magnesium-gluconate and 1.7 
mmol for magnesium-aspartate. We chose not to make the magnesium content uniform 
per capsule, because we wanted to give the patients magnesium capsules that could be 
prescribed after the trial. Furthermore, normalizing to the amount of elemental magnesium 
would still not correct for differences in absorption and/or bio-availability. The need of a 
higher number of magnesium capsules could influence the choice for a certain magnesium 
salt. We therefore let the patients titrate the dose themselves. The first treatment period 
started with 3 capsules thrice daily. Patients were instructed to increase the dose with an 
additional 3 capsules divided over the day each 3 days if symptoms persisted. The maximal 
dose of magnesium capsules at the end of a period was therefore 36 capsules a day. If for 
all three magnesium salts the maximal dose of capsules was used in the first block, a fixed 
maximal dose of 36 capsules was used in the next periods for the rest of the trial. The trials 
were performed at the Radboud university medical center in Nijmegen, the Netherlands. This 
study was approved by the medical ethics committee Arnhem-Nijmegen, the Netherlands. All 
participants gave their informed consent.
Outcome measures
At baseline and at weekly intervals, patients were asked to complete two questionnaires with 
patient reported outcome measures (PROMs). First, we used a personalized questionnaire 
that had been created collaboratively with the individual patient. This questionnaire 
consisted of 6-8 questions concerning the PROMs (mostly symptoms) that the individual 
patient judged most important. The scores of the PROMS questions range from 0-10, with 
higher scores indicating more severe symptoms. Because of the personalized nature of such 
questionnaires, validation was not possible. Second, the Short-Form 36-Item Health Status 
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Survey (SF-36, Dutch version) was used as a general quality-of-life measure. The SF36 is a 
generic questionnaire to establish self-reported health status of patients. The questionnaire 
consists of the following domains: physical function, role functioning physical, social 
functioning, body pain, mental health, vitality, general-health perception and change in 
health. The scores range from 0-100%, with higher scores indicating less severe symptoms. 
Additionally, these scales are incorporated into two summary measures: a Physical 
Component Summary (PCS) and a Mental Component Summary (MCS). At baseline and at 
two weeks intervals, laboratory investigations were performed with determination of serum 
magnesium, potassium and creatinine. During the study patients were instructed to report 
side effects that they attributed to the intervention. 
Analysis
We analysed the differences in treatment effects between different magnesium salts with 
a Bayesian model. In Bayesian analysis, parameters in a model do not have an exact fixed 
value but follow a distribution. When performing a Bayesian analysis, observations (data) are 
used to update a prior belief (prior distribution) of a specific parameter into a posterior belief 
(posterior distribution). So Bayesian analysis allows us to incorporate prior information into 
the analysis, in a mathematical way. In case there is no information at all, a so called non-
informative prior is chosen for the parameter under study. The posterior distribution is then 
completely determined by the data. In our Bayesian models, it is assumed that outcome 
variables for a given magnesium salt, measured on different days, follow a normal distribution 
with a given mean and variance. The score of the outcome variable on a specific day can be 
seen as a drawing from this distribution. The mean for each magnesium salt may be different, 
the variance is considered to be the same. Our model hereby estimates four parameters: the 
three means for three different magnesium salts and a variance. For all parameters we used 
a non-informative prior. For the three means of the score, the prior chosen was a normal 
distribution with a mean of 0 and a standard deviation of 100. For the standard deviation, the 
prior was a uniform distribution between 0.01 and 100. No starting values for the parameters 
were chosen. So the WinBUGS program generated the initial values itself. Convergence was 
assessed studying the iteration plots. We ran 2 chains and saved 2000 samples per chain 
from 100000 iterations. 
Because the last measurement of each treatment period was considered to be the most 
important (cross-over effect is lowest at that time), we doubled its weight by counting it 
twice. We did not control for time trend or serial correlation.
Markov chain Monte Carlo (MCMC) simulations were used to compute posterior probabilities 
of the treatment ranks. Rank 1 means the best treatment option in terms of benefit of the 
magnesium salt. 
All Bayesian analyses were performed in WinBUGS 1.4. (© WinBUGS 1996-2003: Imperial 
College and Medical Research Council, UK), using MCMC techniques. The WinBUGS program 
96  |  Chapter 7
was run from R version 3.2.4 (© 2016 The R Foundation for Statistical Computing) using the 
packages R2WinBUGS and coda.
RESULTS
We included four patients with renal magnesium wasting. All four patients had genetically 
confirmed diseases responsible for the magnesium wasting. Two patients had a mutation 
in SLC12A3 encoding the sodium-chloride cotransporter (Gitelman syndrome), one patient 
had a mutation in the transcription factor gene HNF1B (ADTKD-HNF1β) and one patient 
had a mutation in FXYD2 encoding the γ subunit of Na-K-ATPase (autosomal dominant 
hypomagnesemia). Two patients were using magnesium-gluconate and two patients were 
using magnesium-hydroxide before participating in the N-of-1 trial. The median age was 49 
years (range 35-62) and two patients were male. All four patients used the maximal dose of 36 
capsules a day of each magnesium salt at the end of period 1. Patients therefore used a fixed 
dose of 36 capsules for the rest of the trial.
Median outcome measures at the end of the blocks per patient are shown in Tables 1-4.
Table 1 Outcome measures at the end of treatment periods of patient 1
Mg-gluconate Mg-aspartate Mg-lactate
Personalized questionnaire 
Muscle pain 8 (7-8) 4 (4-6) 6 (6-6)
Fatigue 8 (8-8) 7 (6-8) 7 (7-8)
Overall complaints GS 8 (8-8) 6 (5-6) 7 (7-9)
Side effects 8 (8-8) 6 (5-6) 7 (7-7)
SF36 component scores
Physical component score 19 (15-20) 32 (27-34) 25 (15-27)
Mental component score 49 (49-52) 51 (50-52) 20 (43-51)
Stool frequency (total number) 47 (44-53) 51 (47-51) 48 (37-71)
Serum magnesium (mmol/l) 0.60 (0.57-0.60) 0.60 (0.55-0.60) 0.66 (0.62-0.70)
Serum potassium (mmol/l) 3.2 (3.1-3.3) 3.4 (3.4-3.6) 3.4 (3.1-3.6)
Data are given as median values (minimum-maximum).
Each magnesium supplement was given during three treatment periods.
Personalized questionnaire: score ranges from 0-10 with higher scores indicating more severe symptoms.
SF36 questionnaire: score ranges from 0-100 with higher scores indicating less severe symptoms.
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Table 2 Outcome measures at the end of treatment periods of patient 2
Mg-gluconate Mg-aspartate Mg-lactate
Personalized questionnaire
Muscle pain 8 (6-8) 6 (4-7) 2 (1-2)
Fatigue 8 (6-8) 6 (3-7) 3 (3-3)
Overall complaints GS 2 (2-6) 2 (2-2) 2 (1-2)
Side effects 2 (2-4) 3 (2-4) 2 (1-2)
SF36 component scores
Physical component score 19 (15-33) 28 (24-32) 36 (31-36)
Mental component score 42 (35-52) 42 (34-44) 49  (46-49)
Stool frequency (total number) 46 (42-54) 42 (32-56) 37 (32-42)
Serum magnesium (mmol/l) 0.65 (0.61-0.70) 0.70 (0.70-0.71) 0.69 (0.66-0.69)
Serum potassium (mmol/l) 3.5 (3.4-3.7) 3.5 (3.4-3.9) 3.5 (3.2-3.5)
Data are given as median values (minimum-maximum).
Each magnesium supplement was given during three treatment periods.
Personalized questionnaire: score ranges from 0-10 with higher scores indicating more severe symptoms
SF36 questionnaire: score ranges from 0-100 with higher scores indicating less severe symptoms.
Table 3 Outcome measures at the end of treatment periods of patient 3
Mg-gluconate Mg-aspartate Mg-lactate
Personalized questionnaire
Muscle pain 7 (0-7) 5 (0-57 3 (0-6)
Fatigue 10 (7-10) 5 (4-10) 10 (8-10)
Arthralgia 10 (9-10) 3 (0-8) 10 (10-10)
Overall complaints GS 0 (0-7) 0 (0-0) 0 (0-10)
Side effects 7 (0-10) 0 (0-0) 0 (0-10)
SF36 component scores
Physical component score 20 (17-22) 45 (23-54) 24 (21-26)
Mental component score 47 (38-64) 58 (42-59) 45 (40-46)
Stool frequency (total number) 75 (68-75) 58 (48-69) 65 (58-74)
Serum magnesium (mmol/l) 0.56 (0.50-0.60) 0.55 (0.51-0.60) 0.68 (0.60-0.70)
Serum potassium (mmol/l) 4.0 (3.6-4.0) 3.8 (3.8-3.9) 3.7 (3.6-3.8)
Data are given as median values (minimum-maximum).
Each magnesium supplement was given during three treatment periods.
Personalized questionnaire: score ranges from 0-10 with higher scores indicating more severe symptoms
SF36 questionnaire: score ranges from 0-100 with higher scores indicating less severe symptoms.
98  |  Chapter 7
Table 4 Outcome measures at the end of treatment periods of patient 4
Mg-gluconate Mg-aspartate Mg-lactate
PROMS questionnaire
Muscle pain 9 (8-9) 9 (9-9) 9 (7-9)
Fatigue 9 (8-10) 10 (9-10) 10 (8-10)
Muscle cramps 8 (8-9) 9 (9-10) 9 (8-10)
Arthralgia 9 (8-9) 9 (9-10) 10 (8-10)
Mood disturbances 9 (8-10) 10 (10-10) 10 (8-10)
SF36 component scores
Physical component score    28 (28-33) 28 (27-31) 29 (27-31)
Mental component score 21 (17-21) 15 (14-16) 16 (13-38)
Stool frequency (total number) 75 (74-90) 82 (74-88) 84 (50-104)
Serum magnesium (mmol/l) 0.45 (0.45-0.47) 0.53 (0.40-0.54) 0.54 (0.40-0.59)
Serum potassium (mmol/l) 3.7 (3.7-4.1) 3.7 (3.6-3.8) 3.7 (3.6-3.8)
Data are given as median values (minimum-maximum).
Each magnesium supplement was given during three treatment periods.
Personalized questionnaire: score ranges from 0-10 with higher scores indicating more severe symptoms
SF36 questionnaire: score ranges from 0-100 with higher scores indicating less severe symptoms.
Results from Bayesian analyses are shown in appendix Tables S1-S16 and Figures S1-S34. 
Patient 1 had the highest serum magnesium levels with magnesium-lactate, but experienced 
the least symptoms and the best overall quality of life while on magnesium-aspartate. 
Patient 2 did not show differences in serum magnesium levels, but experienced the least 
symptoms and highest quality of life while on magnesium-lactate. Patient 3 had the highest 
serum magnesium levels with magnesium-lactate but experienced the least symptoms 
while on magnesium-aspartate. Patient 4 did not show a difference in serum magnesium nor 
symptoms between the different magnesium salts.  
DISCUSSION
In this report we describe the results of four N-of-1 trials in which three different magnesium 
salt are compared within individual patients with renal hypomagnesemia. Results were 
analysed by a Bayesian model, and the N-of-1 trial method was able to successfully identify 
the optimum magnesium salt in an evidence-based fashion in three out of four patients, 
although the interventions did not result in complete correction of serum magnesium. 
Notably, the effects of the magnesium salts differed within and between patients. In one 
patient symptoms were evidently less while on magnesium lactate, two patients experienced 
the least symptoms while on magnesium aspartate and in one patient no differences 
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between the magnesium salts were observed. Our findings point to the relevance of this 
strategy toward improved personalized medicine. 
An interesting observation from our data is that serum magnesium levels did not correlate 
well with self-reported symptoms or quality of life. This is most clearly illustrated in patient 
1. On the basis of the presumption that signs and symptoms in these patients are indeed 
the result of the magnesium wasting, this finding may imply that serum magnesium is not 
a good representative of body magnesium content or intracellular magnesium levels. This 
might not be surprising as only <1% of total body magnesium is present in the serum [10,11]. In 
patients with chronic magnesium wasting, replacement therapy could therefore first result in 
replenishment of intracellular stores before increasing serum magnesium levels [12]. In every 
day practice however we tend to use serum magnesium as the main parameter to guide our 
magnesium supplementation therapy in patients with renal hypomagnesemia, a strategy 
which is advocated by the most recent KDIGO consensus and controversies report for the 
diagnosis and treatment of patients with Gitelman syndrome [13]. 
Another advantage of performing N-of-1 trials in patients with rare diseases is that the results 
of a series of N-of-1-trials could be combined across individuals to estimate population 
level effects. This can be done by using summary data meta-analysis (in which each N-of-
1 trial is considered as a separate trial) or linear mixed models using maximum likelihood 
(in which N-of-1 trials may be viewed as independent or correlated repeated measures). 
Both approaches support incorporation of prior information through Bayesian hierarchical 
models [14-16]. 
The main limitation of our N-of-1 trial was the different elemental magnesium content of 
the prescribed capsules. Patients were allowed to increase the dose themselves, but as 
they reached the maximum number of (tolerable) capsules, the maximum dose of ingested 
magnesium differed between the magnesium salts. A solution for the different magnesium 
contents per capsule could be the use of magnesium salts in a liquid form, with a standard 
amount of magnesium per ml. A more general limitation of N-of-1 trials are the costs for 
blinding the medication and the time and effort they require. 
CONCLUSION
In conclusion, N-of-1 trials are an elegant method to determine the best therapeutic option(s) 
for individual patients. Especially in rare diseases where large RCTs are generally lacking, or in 
patients who would not fulfil the inclusion criteria of previously performed trials, this method 
can be of great value for clinical practice. 
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APPENDIX
Table S1 Posterior densities of the mean with 95% credible intervals (patient 1)
Mg-gluconate Mg-aspartate Mg-lactate
PROMS questionnaire 
Muscle pain 6.71 (6.14 - 7.26) 5.95 (5.40 – 6.52) 6.61 (6.06 – 7.18)
Fatigue 7.65 (7.34 – 7.96) 7.44 (7.16 – 7.73) 7.33 (7.06 – 7.64)
Overall complaints 7.29 (6.87-7.72) 6.72 (6.31-7.13) 7.11 (6.70-7.52)
Side effects 7.29 (6.87-7.72) 6.72 (6.31-7.13) 7.11 (6.70-7.52)
SF36 questionnaire
Physical component score  23.16 (20.34 - 25.96) 26.51 (23.71 - 29.21) 22.51 (19.71 - 25.26)
Mental component score 49.93 (47.95 - 51.95) 48.06 (46.05 - 50.02) 49.28 (47.32 - 51.16)
Serum magnesium 0.55 (0.51-0.58) 0.60 (0.56-0.63) 0.66 (0.62-0.69)
Serum potassium 3.22 (3.07-3.37) 3.37 (3.22-3.53) 3.39 (3.23-3.54)
Table S2 Probabilities of a real difference in mean scores (patient 1)
P(Mean Aspartate <  
Mean Gluconate)
P(Mean Lactate <  
Mean Aspartate)
P(Mean Lactate <  
Mean Gluconate)
PROMS questionnaire 
Muscle pain 97.3 5.2 50.6
Fatigue 83.4 70.1 93.4
Overall complaints 97.1 8.9 73.1
Side effects 97.1 8.9 73.1
SF36 questionnaire
Physical component score  5.1 97.9 62.9.
Mental component score 90.2 19.3 68.9
Serum magnesium 2.8 1.1 0.0
Serum potassium 7.7 45.2 5.9
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Table S3 Posterior probabilities of the treatment ranks (patient 1)
Mg-gluconate Mg-aspartate Mg-lactate
Ranks 1 2 3 1 2 3 1 2 3
PROMS questionnaire 
Muscle pain 2.7 38.3 58.9 93.0 6.2 0.7 4.2 55.4 40.3
Fatigue 3.5 16.5 79.9 28.1 56.4 15.4 68.3 26.9 4.7
Overall complaints 2.1 25.6 72.3 89.5 9.2 1.3 8.4 65.2 26.4
Side effects 2.1 25.6 72.3 89.5 9.2 1.3 8.4 65.2 26.4
SF36 questionnaire
Physical component score 4.3 60.1 35.6 94.0 5.3 0.6 1.7 34.6 63.8
Mental component score 63.8 29.0 7.2 5.1 19.9 74.9 31.1 51.1 17.8
Serum magnesium 0.0 2.8 97.2 44.3 48.9 6.8 53.8 41.3 4.9
Serum potassium 1.9 9.8 88.3 44.3 48.9 6.8 53.8 41.3 4.9
Rank 1 is the best treatment option in terms of symptoms (i.e. less severe symptoms)
Table S4 Posterior densities of the standard deviation with 95% credible intervals (patient 1), 
which are the same for all medication groups (model assumption)
Mg-salt
PROMS questionnaire 
Muscle pain 1.20 (0.99 – 1.48)
Fatigue 0.62 (0.51 – 0.77)
Overall complaints 0.88 (0.73-1.07)
Side effects 0.88 (0.73-1.07)
SF36 questionnaire
Physical component score    5.85 (4.79 -7.19)
Mental component score 4.15 (3.50 - 5.21)
Serum magnesium 0.06 (0.04-0.07)
Serum potassium 0.23 (0.17-0.31)
104  |  Chapter 7
Table S5 Posterior densities of the mean with 95% credible intervals (patient 2)
Mg-gluconate Mg-aspartate Mg-lactate
PROMS questionnaire  
Muscle pain 6.22 (5.18 – 7.30) 5.16 (4.10 – 6.21) 4.21 (3.03 – 5.34)
Fatigue 6.55 (5.68 – 7.47) 5.50 (4.63 – 6.35) 4.55 (3.59 – 5.52)
Overall complaints 3.66 (2.87-4.47) 2.22 (1.42-3.00) 1.94 (1.08-2.80)
Side effects 2.72 (2.28-3.16) 2.67 (2.22-3.11) 1.87 (1.38-2.35)
SF36 questionnaire
Physical component score 25.66 (22.37 – 28.86) 27.80 (24.42 – 31.05) 30.82 (27.21 – 34.43)
Mental component score 40.57 (37.29 – 43.81) 41.50 (38.10 – 44.70) 48.23 (44.50 – 51.95)
Serum magnesium 0.68 (0.65-0.71) 0.68 (0.65-0.71) 0.69 (0.66-0.72)
Serum potassium 3.62 (3.44-3.82) 3.658 (3.64-3.72) 3.64 (3.43-3.82)
Table S6 Probabilities of a real difference in mean scores (patient 2)
P(Mean Aspartate <  
Mean Gluconate)
P(Mean Lactate <  
Mean Aspartate)
P(Mean Lactate <  
Mean Gluconate)
PROMS questionnaire 
Muscle pain 92.2 88.9 99.5
Fatigue 95.4 99.8 92.4
Overall complaints 99.3 69.1 99.8
Side effects 56.7 99.1 99.4
SF36 questionnaire
Physical component score  17.9 10.5 1.8
Mental component score 35.0 0.1 0.3
Serum magnesium 44.4 22.4 26.4
Serum potassium 39.4 55.9 44.9
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Table S7 Posterior probabilities of the treatment ranks (patients 2)
Mg-gluconate Mg-aspartate Mg-lactate
Ranks 1 2 3 1 2 3 1 2 3
PROMS questionnaire 
Muscle pain 0.4 7.9 91.7 10.7 81.4 7.9 88.9 10.7 0.4
Fatigue 0.2 4.9 94.9 7.8 87.3 4.9 91.1 7.8 0.1
Overall complaints 0.0 0.9 99.1 30.9 68.4 0.7 69.1 30.7 0.2
Side effects 0.5 42.8 56.7 0.8 55.9 43.2 98.6 1.3 0.1
SF36 questionnaire
Physical component score 0.9 17.0 82.0 10.3 72.7 17.0 88.8 10.3 0.9
Mental component score 0.1 34.9 65.0 0.5 64.6 34.9 99.4 0.6 0.0
Serum magnesium 16.1 34.6 49.3 19.9 42.2 37.9 64.0 23.2 12.8
Serum potassium 25.5 33.3 41.2 41.6 33.3 25.1 32.9 33.4 33.7
Rank 1 is the best treatment option in terms of symptoms (i.e. less severe symptoms)
Table S8 Posterior densities of the standard deviation with 95% credible intervals (patient 2), 
which are the same for all medication groups (model assumption)
Mg-salt
PROMS questionnaire 
Muscle pain 2.25 (1.84 – 2.76)
Fatigue 1.92 (1.57 – 2.38)
Overall complaints 1.70 (1.39-2.10)
Side effects 0.95 (0.77-1.18)
SF36 questionnaire
Physical component score    6.78 (5.56 – 8.33)
Mental component score 7.12 (5.86 – 8.74)
Serum magnesium 0.04 (0.03-0.06)
Serum potassium 0.28 (0.21-0.38)
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Table S9 Posterior densities of the mean with 95% credible intervals (patient 3)
Mg-gluconate Mg-aspartate Mg-lactate
PROMS questionnaire  
Muscle pain 4,09 (2.45 – 5.66) 3.78 (2.20 – 5.29) 4.74 (3.22 – 6.31)
Fatigue 8.48 (7.48 – 9.47) 7.50 (6.53 – 8.46) 9.37 (8.42 – 10.34)
Arthralgia 8.52 (7.02 -10.02) 5.60 (4.08 – 7.01) 9.50 (8.01 – 11.04)
Overall complaints 3.24 (1.36-5.12) 0.55 (0.00-2.38) 3.16 (1.33-5.02)
Side effects 5.71 (3.54-7.89) 1.68 (0.00-3.81) 4.17 (2.06-6.30)
SF36 questionnaire
Physical component score 28.05 (22.86 – 33.27) 34.85 (29.66 – 39.93) 25.37 (20.35 – 30.62)
Mental component score 47.45 (42.92 – 51.84) 50.45 (45.97 – 54.70) 47.41 (43.07 – 51.69)
Serum magnesium 0.53 (0.48-0.57) 0.56 (0.52-0.61) 0.60 (0.55-0.64)
Serum potassium 3.87 (3.74-3.99) 3.77 (3.65-3.89) 3.81 (3.69-3.93)
Table S10 Probabilities of a real difference in mean scores (patient 3)
P(Mean Aspartate <  
Mean Gluconate)
P(Mean Lactate <  
Mean Aspartate)
P(Mean Lactate <  
Mean Gluconate)
PROMS questionnaire 
Muscle pain 61.4 18.9 28.1
Fatigue 90.9 0.3 10.1
Arthralgia 99.8 0.0 18.5
Overall complaints 97.8 2.5 52.2
Side effects 99.4 5.3 84.8
SF36 questionnaire
Physical component score  3.7 99.4 76.7
Mental component score 17.1 84.0 51.4
Serum magnesium 13.2 15.6 2.0
Serum potassium 87.0 30.1 74.3
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Table S11 Posterior probabilities of the treatment ranks (patients 3)
Mg-gluconate Mg-aspartate Mg-lactate
Ranks 1 2 3 1 2 3 1 2 3
PROMS questionnaire 
Muscle pain 32.9 41.9 25.2 56.4 31.3 12.4 10.7 26.9 62.5
Fatigue 8.2 82.3 9.5 91.6 8.2 0.2 0.2 9.5 90.3
Arthralgia 0.4 82.4 17.2 99.5 0.4 0.0 0.2 17.1 82.7
Overall complaints 1.9 46.0 52.0 95.8 3.7 0.5 2.3 50.2 47.5
Side effects 0.3 14.9 84.7 94.5 5.3 0.2 5.1 79.7 15.1
SF36 questionnaire
Physical component score 3.5 72.9 23.6 96.1 3.7 0.2 0.4 23.3 76.3
Mental component score 14.1 40.5 45.4 73.3 19.9 6.8 12.6 39.6 47.8
Serum magnesium 0.9 13.3 85.8 15.4 71.6 13.0 83.7 15.1 1.2
Serum potassium 68.7 23.8 7.4 8.3 26.5 65.2 23.0 49.7 27.3
Rank 1 is the best treatment option in terms of symptoms (i.e. less severe symptoms)
Table S12 Posterior densities of the standard deviation with 95% credible intervals (patient 3), 
which are the same for all medication groups (model assumption)
Mg-salt
PROMS questionnaire 
Muscle pain 3.31 (2.73 – 4.04)
Fatigue 2.09 (1.73 – 2.57)
Arthralgia 3.11 (2.56 – 3.83)
Overall complaints 3.92 (3.22-4.82)
Side effects 4.52 (3.73-5.53)
SF36 questionnaire
Physical component score    10.97 (9.06 – 13.42)
Mental component score 9.40 (7.77 – 11.43)
Serum magnesium 0.07 (0.05-0.09)
Serum potassium 0.18 (0.14-0.25)
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Table S13 Posterior densities of the mean with 95% credible intervals (patient 4)
Mg-gluconate Mg-aspartate Mg-lactate
PROMS questionnaire  
Muscle pain 8.56 (8.18 – 8.93) 8.88 (8.48 – 9.28) 8.16 (7.76 – 8.55)
Fatigue 8.44 (8.06 – 8.81) 9.01 (8.63 – 9.39) 8.50 (8.14 – 8.87)
Muscle cramps 8.45 (8.08 – 8.81) 9.00 (8.63 – 9.37) 8.50 (8.13 – 8.88)
Arthralgia 8.77 (8.48 – 9.09) 9.17 (8.86 – 9.49) 9.22 (8.92 – 9.53)
Mood disturbances 9.06 (8.61 – 9.49) 9.61 (9.18 – 10.04) 9.22 (8.80 – 9.64)
SF36 questionnaire
Physical component score 29.39 (28.36 – 30.42) 28.39 (27.39 – 29.38) 29.58 (28.54 – 30.63)
Mental component score 18.60 (14.38 – 22.55) 20.33 (16.43 – 24.20) 21.50 (17.42 – 25.45)
Serum magnesium 0.46 (0.43-0.51) 0.48 (0.44-0.53) 0.49 (0.45-0.54)
Serum potassium 3.87 (3.72-4.02) 3.73 (3.59-3.88) 3.89 (3.74-4.04)
Table S14 Probabilities of a real difference in mean scores (patient 4)
P(Mean Aspartate <  
Mean Gluconate)
P(Mean Lactate <  
Mean Aspartate)
P(Mean Lactate <  
Mean Gluconate)
PROMS questionnaire 
Muscle pain 11.3 99.5 92.5
Fatigue 8.6 87.1 41.3
Muscle cramps 2.0 96.5 41.4
Arthralgia 3.8 40.4 2.3
Mood disturbances 3.5 89.8 29.6
SF36 questionnaire
Physical component score  91.4 5.6 40.2
Mental component score 26.7 33.8 15.6
Serum magnesium 20.1 45.2 17.0
Serum potassium 90.6 6.9 42.3
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Table S15 Posterior probabilities of the treatment ranks (patient 4)
Mg-gluconate Mg-aspartate Mg-lactate
Ranks 1 2 3 1 2 3 1 2 3
PROMS questionnaire 
Muscle pain 8.3 79.8 11.8 0.04 11.6 87.9 91.2 8.5 0.02
Fatigue 57.3 36.3 6.4 3.3 14.1 82.5 39.4 49.5 11.1
Muscle cramps 58.2 40.1 1.7 0.5 4.2 95.3 41.4 55.7 2.9
Arthralgia 94.5 4.9 0.5 3.5 56.8 39.6 1.9 38.2 59.8
Mood disturbances 70.1 27.2 1.6 1.6 11.1 87.4 28.3 61.7 9.9
SF36 questionnaire
Physical component score 39.8 52.4 7.8 2.1 10.4 87.4 58.1 37.1 4.7
Mental component score 9.0 25.4 65.6 30.1 45.9 23.9 60.8 28.8 10.4
Serum magnesium 7.8 21.5 70.7 41.5 42.2 16.4 50.8 36.3 12.9
Serum potassium 41.1 50.8 8.2 2.2 11.8 86.0 56.8 37.4 5.9
Rank 1 is the best treatment option in terms of symptoms (i.e. less severe symptoms)
Table S16 Posterior densities of the standard deviation with 95% credible intervals (patient 4), 
which are the same for all medication groups (model assumption)
Mg-salt
PROMS questionnaire 
Muscle pain 0.84 (0.70-1.03)
Fatigue 0.73 (0.60-0.89)
Muscle cramps 0.80 (0.66-0.98)
Arthralgia 0.65 (0.54-0.80)
Mood disturbances 0.93 (0.77-1.14)
SF36 questionnaire
Physical component score    2.22 (1.83-2.69)
Mental component score 8.64 (7.11-10.56)
Serum magnesium 0.06 (0.05-0.09)
Serum potassium 0.22 (0.17-0.30)
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Figure S1 Probability density plots of muscle pain scores (patient 1) 
Figure S2 Probability density plots of fatigue (patient 1)
This figure shows posterior probability distributions of the muscle pain scores per magnesium salt. The peak of 
the density curve indicates the location of the most probable mean score. For example, the most probable mean 
score for muscle pain equals 5.95 for magnesium-aspartate. Most probable mean scores for magnesium-lactate 
and magnesium-gluconate equal 6.61 and 6.71, respectively.
N-of-1 trials in Renal Magnesium Wasting  |  111
7
Figure S3 Probability density plots of overall complaints (patient 1)
Figure S4 Probability plots of side effects (patient 1)
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Figure S5 Probability density plots of SF36 physical component score (patient 1)
Figure S6 Probability density plots of SF36 mental component score (patient 1)
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Figure S7 Probability density plots of serum potassium (patient  1)
Figure S8 Probability density plots of serum magnesium (patient  1)
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Figure S9 Probability density plots of muscle pain (patient 2)
Figure S10 Probability density plots of fatigue (patient 2)
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Figure S11 Probability density plots of overall complaints (patient 2)
Figure S12 Probability density plots of side effects (patient 2)
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Figure S13 Probability density plots of SF36 physical component score (patient 2)
Figure S14 Probability density plots of fatigue (patient 2)
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Figure S15 Probability density plots of serum potassium (patient 2)
Figure S16 Probability density plots of serum magnesium (patient 2)
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Figure S17 Probability density plots of muscle pain (patient 3)
Figure S18 Probability density plots of fatigue (patient 3)
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Figure S19 Probability density plots of arthralgia (patient 3)
Figure S20 Probability density plots of overall complaints (patient 3)
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Figure S21 Probability density plot of side effects (patient 3)
Figure S22 Probability density plots of SF36 physical component score (patient 3)
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Figure S23 Probability density plots of SF36 mental component score (patient 3)
Figure S24 Probability density plots of serum potassium (patient 3)
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Figure S25 Probability density plots of serum magnesium (patient 3)
Figure S26 Probability density plots of muscle pain (patient 4)
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Figure S27 Probability density plots of muscle cramps (patient 4)
Figure S28 Probability density plots of fatigue (patient 4)
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Figure S29 Probability density plots of arthralgia (patient 4)
Figure S30 Probability density plots of mood disturbances (patient 4)
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Figure S31 Probability density plots of SF36 physical component score (patient 4)
Figure S32 Probability density plots of SF36 mental component score (patient 4)
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Figure S33 Probability density plots of serum potassium (patient 4)
Figure S34 Probability density plots of serum magnesium (patient 4)
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ABSTRACT
Background
Nephrogenic diabetes insipidus (NDI) is a rare disorder characterised by resistance to the 
action of anti-diuretic hormone (ADH), resulting in a decrease in the capacity of the kidney to 
concentrate the urine. NDI can be inherited or acquired due to e.g. chronic lithium therapy. 
Current treatment options are limited to attempts to lower urine output by a low-solute 
diet and the use of diuretics or anti-inflammatory drugs. These measures are only partially 
effective. Recent reports suggested that sildenafil, metformin, and simvastatin might 
improve ADH-independent urine concentration. If confirmed, this would provide interesting 
additional therapeutic options for patients with NDI. We therefore tested the effect of these 
drugs on ADH-independent urine concentrating capacity in healthy volunteers.
Methods
Intervention study in which 36 healthy volunteers received sildenafil 20 mg thrice daily, 
metformin 500 mg thrice daily or simvastatin 40 mg once daily during 1 week. At baseline 
and at the end of treatment a water loading test was performed. 
Results
No significant increase in lowest urine osmolality was seen after the use of metformin or 
sildenafil (p=0.66 and p=0.09 respectively). Lowest urine osmolality increased modestly but 
significantly after the use of simvastatin (70 mOsm/kg to 85 mOsm/kg, p=0.05). 
Conclusions
Our data suggest that only simvastatin has an effect on urine osmolality in healthy volunteers. 
Validation studies are needed and, most importantly, these drugs should be tested in patients 
with NDI.
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INTRODUCTION
Nephrogenic diabetes insipidus (NDI) is a rare disorder characterized by resistance of the 
kidney collecting duct to the action of anti-diuretic hormone (ADH), resulting in a decrease in 
the capacity of the kidney to concentrate urine. Water reabsorption in the collecting duct is 
initiated by ADH that binds to its receptor (type 2 vasopressin receptor, V2R) in the collecting 
duct principal cells (Figure 1). Activation of the V2R activates an intracellular signalling 
cascade in which stimulation of adenylyl cyclase (AC) leads to the production of cyclic 
adenosine monophosphate (cAMP), which in turn stimulates the insertion of aquaporin-2 
water channels (AQP2) into the apical membrane through which water can enter the cell. 
Hereditary NDI is caused by mutations in the AVPR2 gene (encoding for the V2R) in the vast 
majority of patients, leading to X-linked NDI. Alternatively, mutations in the AQP2 gene 
(encoding aquaporin-2) can cause either autosomal dominant or recessive NDI, or it can 
occur in the context of hereditary tubulointerstitial kidney diseases. The most common 
cause of acquired NDI is chronic lithium therapy. The inability to concentrate urine results in 
high urine volumes, which can be as high as 15 liters per day in patients with hereditary NDI. 
This can lead to several secondary problems, such as hypernatremia and rapid dehydration 
when water intake is restricted. In addition, chronic vesico-ureteral reflux leading to chronic 
kidney injury can occur due to chronically high bladder volumes. Current treatment consists 
of countering the polyuria by drinking large amounts of water and attempts to lower urine 
output by a low-salt and low-protein diet, the use of non-steroidal anti-inflammatory drugs 
and the use of diuretics that increase proximal sodium and water reabsorption and/or 
prevent lithium influx into principal cells [1-4]. These measures however are only partly able 
to correct the polyuria. NDI is therefore a chronic disease seriously affecting quality of life. 
Recent reports have suggested novel therapeutic options by repurposing already available 
and FDA approved drugs that could, theoretically, be more effective than the current standard 
of care [5]. The rationale for using these drugs in the context of NDI is based on the fact that 
they would be able to beneficially target the intracellular signalling cascade downstream to 
the V2R in the collecting tubule cell and thereby potentially rescue, at least in part, urine 
concentrating ability (Figure 1).
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Figure 1 Overview of potential therapeutic targeting of the intracellular mechanisms involved in 
transcellular water reabsorption in the collecting duct
Upon vasopressin (AVP) binding to its receptor (V2R) at the basolateral side of the principal collecting duct
cells, an intracellular signalling cascade is activated that ultimately results in phosphorylation and
subsequent insertion of aquaporin-2 water channels (AQP2) in the apical membrane. Sildenafil is
hypothesized to target this cascade by increasing cyclic guanosine monophosphate (cGMP), Metformin by
increasing adenosine monophosphate-activated protein kinase (AMPK) and Simvastatin through inhibiting
the recycling of AQP2 and thereby a net increase of AQP2 channels inserted in the membrane. UT-A1, urea
transporter A1; AC, adenylyl cyclase; V2R, vasopressin receptor type 2; AVP, arginine vasopressin.
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The first drug for which a potential positive effect on urine concentration was suggested is 
sildenafil, currently registered for use in erectile dysfunction and pulmonary hypertension. 
Sildenafil increases cyclic guanosine monophosphate (cGMP) which, like cAMP, is thought 
to be able to induce phosphorylation of AQP2 and thereby promote insertion of AQP2 
water channels into the apical membrane (Figure 1). Sildenafil indeed increased the apical 
accumulation of AQP2 in rats with central diabetes insipidus [6,7]. Assadi et al. described a child 
with a mutation in V2R who showed a lower urine volume and higher urine osmolality after 10 
days treatment with sildenafil compared to conventional treatment with hydrochlorothiazide, 
amiloride and indomethacin [8]. The second potential drug is metformin, currently registered 
for use in diabetes mellitus. Metformin activates adenosine monophosphate kinase (AMPK), 
which increases phosphorylation and accumulation of AQP2 (Figure 1). Metformin resulted in 
an increase of urine osmolality in V2R knockout mice and tolvaptan treated rats [9,10]. The third 
potential drug is simvastatin, a cholesterol-lowering drug of the HMG-CoA-reductase inhibitor 
class of drugs. With respect to NDI, simvastatin is thought to enhance the expression of AQP2 
through down regulation of Rho GTPases and the inhibition of AQP2 endocytosis (Figure 1) 
[11]. In line with this finding it was shown that hypercholesterolemic patients upon initiation of 
simvastatin show an increase in urinary AQP2 and an increase in urine osmolality [12]. 
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These three drugs are thus hypothesized to have an ADH-independent effect on AQP2 and 
water transport in the collecting duct, where statins are mainly thought to promote AQP2 
trafficking to the membrane and sildenafil and metformin would induce phosphorylation 
of AQP2. These drugs could thereby serve as new treatment options in patients with NDI, 
particularly by bypassing the defective V2R receptor signalling in patients with AVPR2 
mutations. In this study, we performed physiological experiments determining whether these 
drugs affect ADH-independent urine concentration in healthy man, which would strengthen 
their therapeutic potential in patients with NDI.
METHODS
Study population
We performed a study in 36 healthy volunteers, aged >18 year and not using any medication. 
After informed consent, each healthy volunteer received either sildenafil (20 mg thrice 
daily), metformin (500 mg thrice daily) or simvastatin (40 mg once daily) during one week. 
In total, 12 healthy volunteers per study medication were included. A water loading test 
was performed to evaluate ADH-independent urine concentration/dilution. This study had 
a cross-over design, i.e. each patient was studied after one week on and off therapy with at 
random selection of the order of the study periods. 
The tests were performed in the Radboud university medical center by a group of trained 
nurses. This study was approved by the medical ethics committee of the Radboud university 
medical center Nijmegen, and all participants provided written informed consent. 
Water loading test
In the 24 hours preceding the test, the subjects were not allowed to smoke cigarettes or drink 
alcohol or coffee. On the morning of the test, subjects were allowed to have a small breakfast 
without coffee or tea. They were instructed to drink two glasses of water before going to bed 
and to drink an extra glass of water at breakfast.  
The healthy volunteers then visited the clinic at 8:00h in the morning. At that time (T=0), 
subjects were weighed, blood pressure was measured and a urine sample was taken. Next 
they were requested to lie down for one hour. At T=60 (minutes) a urine and blood sample 
were taken and the subject was instructed to drink 20 ml/kg of body weight in 15 minutes. 
Thereafter, every hour urine samples were collected during four hours. At T=300, an additional 
blood sample was withdrawn and body weight and blood pressure were measured again. 
During the test, participants were not allowed to eat, to drink coffee or tea and they were not 
allowed to smoke cigarettes. Except for going to the toilet, the subjects were seated and not 
allowed to walk around.
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Statistics 
Baseline characteristics are reported as median values with interquartile ranges. Medians 
between the baseline test and the test after medication were compared using a Wilcoxon 
matched pairs test. Spearman correlation coefficients were used to perform univariate 
analyses. Statistical significance was defined as a two-sided p-value of <0.05. Statistical 
analyses were performed using SPSS.  
Power calculation
We considered an increase in lowest osmolality of more than 20 mOsm/kg clinically relevant. 
A power calculation with a two sided paired T test with a power of 0.80, an alpha of 0.05 
results in a number of 12 subjects per drug. 
RESULTS
Test results of the subjects on sildenafil are shown in Table 1 and Figure 2. Eight out of twelve 
subjects were male. Median age was 27 years (IQR 22-34). Urine osmolality at start of the water 
loading test was lower on the test day after sildenafil compared to the test day without sildenafil, 
but this difference was not significant. Lowest urine osmolality was not significantly higher after 
the use of sildenafil (+6 mOsm/kg, +9%, p=0.09). Frequent side effects were noted during the 
treatment period. Six subjects experienced headache, 4 subjects blushing, 1 subject diarrhea, 1 
subject palpitations, 1 subject dizziness and 4 subjects did not experience side effects.
Table 1 Test characteristics in the sildenafil group
Without sildenafil With sildenafil P value
Body weight (kg) - start 73 (63-90) 73 (64-89) 0.18
Body weight (kg) - end 72 (63-90) 72 (64-92) 0.05
Systolic BP - start 123 (120-134) 122 (112-132) 0.05
Systolic BP - end 124 (115-129) 128 (111-132) 0.42
Diastolic BP - start 73 (64-77) 66 (61-73) 0.37
Diastolic BP - end 70 (66-80) 72 (59-76) 0.19
Pulse - start 75 (61-91) 82 (70-91) 0.21
Pulse - end 61 (53-66) 62 (57-70) 0.25
Serum creatinine – start (µmol/l) 79 (63-89) 73 (68-88) 0.17
Urine osmol baseline (mOsm/kg) 441 (262-618) 226 (105-540) 0.18
Lowest urine osmol (mOsm/kg) 70 (61-83) 76 (70-89) 0.09
Sodium excretion (mmol in 300 minutes) 44 (36-52) 55 (50-64) 0.06
Potassium excretion (mmol in 300 minutes) 19 (15-25) 25 (21-32) 0.02
Urea excretion (mmol in 300 minutes) 95 (74-125) 100 (90-125) 0.43
Median values with IQR
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Figure 2 Effect of sildenafil on urine osmolality after a water loading test in healthy subjects
Test results of the subjects on metformin are shown in Table 2 and Figure 3. Five out of twelve 
subjects were male. Median age was 20 years (IQR 19-25). Urine osmolality at start of the 
water loading test was lower on the test day after metformin compared to the test day without 
metformin, but this difference was not significant. Lowest urine osmolality was not different 
after the use of metformin (-7 mOsm/kg, -10%, p=0.66). Two subjects did not experience any 
side effect, five subjects had diarrhoea and eight subjects experienced nausea when using 
metformin.
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Table 2 Test characteristics in the metformin group
Without 
metformin 
With metformin P value
Body weight (kg) - start 69 (58-78) 69 (59-77) 0.27
Body weight (kg) - end 68 (58-77) 68 (58-77) 0.08
Systolic BP - start 117 (111-128) 115 (110-124) 0.39
Systolic BP - end 126 (111-140) 116 (107-128) 0.12
Diastolic BP - start 66 (60-72) 67 (61-70) 0.61
Diastolic BP - end 63 (58-74) 70 (60-72) 0.92
Pulse - start 77 (69-89) 71 (61-79) 0.01
Pulse - end 63 (60-72) 61 (59-66) 0.24
Serum creatinine – start (µmol/l) 73 (62-78) 73 (68-81) 0.13
Urine osmol baseline (mOsm/kg) 368 (153-651) 188 (87-651) 0.75
Lowest urine osmol (mOsm/kg) 70 (56-82) 63 (59-78) 0.66
Sodium excretion (mmol in 300 minutes) 43 (36-49) 35 (31-49) 0.21
Potassium excretion (mmol in 300 minutes) 23 (17-27) 17 (16-23) 0.24
Urea excretion (mmol in 300 minutes) 91 (79-102) 75 (66-97) 0.12
Median values with IQR
Figure 3 Effect of metformin on urine osmolality after a water loading test in healthy subjects
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Table 3 Test characteristics in the simvastatin group
Without 
simvastatin
With 
simvastatin
P value
Body weight (kg) - start 67 (59-75) 68 (59-74) 0.94
Body weight (kg) - end 67 (58-76) 67 (58-73) 0.50
Systolic BP - start 122 (113-132) 121 (114-133) 0.62
Systolic BP - end 118 (111-124) 120 (115-124) 0.70
Diastolic BP - start 70 (66-74) 71 (65-79) 0.97
Diastolic BP - end 66 (61-74) 69 (61-76) 0.81
Pulse - start 78 (75-90) 81 (62-90) 0.27
Pulse - end 61 (55-77) 61 (53-77) 0.67
Serum creatinine – start (µmol/l) 79 (68-92) 71 (61-87) 0.02
Urine osmol baseline (mOsm/kg) 760 (353-937) 388 (187-388) 0.02
Lowest urine osmol (mOsm/kg) 70 (61-89) 85 (65-96) 0.05
Sodium excretion (mmol in 300 minutes) 44 (36-51) 54 (43-61) 0.11
Potassium excretion (mmol in 300 minutes) 20 (12-32) 26 (13-35) 0.45
Urea excretion (mmol in 300 minutes) 90 (74-100) 101 (77-110) 0.33
Median values with IQR
Test results of the subjects on simvastatin are shown in Table 3 and Figure 4. Three out of 
twelve subjects were male. Median age was 23 years (IQR 20-26). Urine osmolality at start 
of the water loading test was significantly lower on the test day after simvastatin compared 
to the test day without simvastatin. Despite this, lowest urine osmolality was significantly 
higher after the use of simvastatin (+15 mOsm/kg, +21%, p=0.05). One subject experienced 
abdominal pain and one subject experienced headache during treatment with simvastatin.
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Figure 4 Effect of simvastatin on urine osmolality after a water loading test in healthy subjects
Figure 5 Correlation of baseline urine osmolality and lowest urine osmolality during the water 
loading test
As the urine osmolality at start of the water loading tests differed between “baseline” and 
after the week on study drugs in a significant number of subjects, we further studied the 
relation between urine osmolality at start and lowest urine osmolality. Overall, no correlation 
was seen between urine osmolality at start and at the end of the water loading tests (Figure 
5, Spearman’s rho=0.02 p=0.86).
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DISCUSSION
In this study we tested whether sildenafil, simvastatin or metformin stimulated ADH-
independent urine concentration in healthy volunteers. Based on the pathophysiological 
mechanisms and studies in animal models it was expected that these drugs could increase 
ADH-independent water reabsorption. 
We observed a significant, although limited, increase in lowest urine osmolality after 
simvastatin. No significant differences were observed with sildenafil or metformin. To 
appreciate the clinical relevance of the 21% higher urine osmolality with simvastatin, the 
effects should be compared with that of standard diuretic therapy. Hydrochlorothiazide 
reduces water requirement by 24-47% [2,3]. Although relatively limited in extent, the use 
of simvastatin could be beneficial to patients with NDI by reducing urine production by 
approximately 20%. Obviously, our data need to be confirmed and validated in patients with 
NDI. 
The lack of an effect of sildenafil and metformin seems in contrast to earlier reports. Of note, 
the effects of the three drugs have been mainly tested and demonstrated in animal models. 
Effects of metformin on urine concentration were only studied in rodent models. Treatment 
with 800 mg/kg/day metformin for 4 days increased collecting duct expression of AQP2, 
increased urine osmolality by 80% in tolvaptan treated rats and increased urinary osmolality 
by 31% in healthy rats (although this increase was not significant with a p-value of 0.08) [9]. 
Already a single dose of 600 mg/kg metformin increased urine osmolality by 180-200% in V2R 
knock-out mice [9,10]. 
A three week treatment with sildenafil did not affect urine osmolality in healthy rats [7]. In 
contrast, a single dose of 4 mg/kg sildenafil increased kidney tubular AQP2 expression 
in Brattleboro rats, a model of central diabetes insipidus [6]. In support of its efficacy, 200 
mg sildenafil per kg food administered for three weeks to rats with lithium-induced NDI, 
increased urine osmolality by 37% [7]. 
Brattleboro rats were also used to evaluate the effects of simvastatin on kidney water 
handling. A single dose of simvastatin increased urine osmolality by ~70% [11]. A single 
injection of fluvastatin resulted in a modest decrease in urine production in V2R mutant mice 
[13]. If these same mice were pre-treated with secretin, which activates AQP2 gene transcription 
and thereby increases intracellular AQP2 stores, fluvastatin resulted in a ~90% reduction in 
urine output [13]. 
Overall, the number of studies in animal models is limited, and only one study evaluated 
the effect of prolonged treatment. Another important observation is that the vast majority 
of studies were performed in animal models for diabetes insipidus whereas the studies 
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in healthy animals did not show a significant effect. Differences in drug dosing could also 
be relevant. Although we cannot exclude that higher dosages of the drugs could be more 
effective, for metformin and sildenafil the use of a higher dose does not seem feasible in view 
of the many known side effects, as also reported by our volunteers. Obviously, it is difficult 
to compare these studies in animal models with our water loading test in healthy humans. 
The potential role of sildenafil and simvastatin in the treatment of NDI was supported by few 
studies in humans and, thus, the evidence base is very limited. Sildenafil in a dose of 2 mg/
kg/day for 10 days was used in a child with NDI due to a mutation in the V2R [8]. Conventional 
therapy with hydrochlorothiazide, amiloride and indomethacin were continued. Treatment 
with sildenafil was associated with an increased urine osmolality (from 104 to 215 mosmol/
kg) and a parallel reduction in urine output (from 1764 ml to 950 ml). Data on prolonged 
treatment and follow up are lacking. There is evidence that simvastatin could positively 
affect urine concentration capacity in humans. Procino et al started simvastatin 20 mg/day 
in patients with hypercholesterolemia [12]. Within one week urine AQP2 and urine osmolality 
increased by 36%, an effect that was maintained for 12 weeks. Urine production concomitantly 
decreased, although to a much lesser degree. Although the authors suggest that their data 
provide evidence that simvastatin has pleiotropic effects and influences water reabsorption, 
the data can be interpreted differently. No information is given on food and water intake, both 
important parameters of urine output. Reduced water intake will simultaneously increase 
urine osmolality and urine AQP2 excretion. The authors do not provide serum sodium levels, 
which would allow to differentiate between ADH-dependent or independent increased 
water reabsorption. Moreover, as a control group the authors included patients who had 
been treated with simvastatin for one year. Diuresis in these patients was not different than 
diuresis of treatment-naive patients. 
Despite the overall lack of an effect with metformin and sildenafil in our study, we suggest 
that testing a combination of drugs such as simvastatin and sildenafil could be considered. As 
statins mainly promote AQP2 trafficking to the membrane and sildenafil or metformin induce 
phosphorylation of AQP2, using a combination of both a statin with sildenafil or metformin 
could theoretically have a synergistic effect. Procino supports this hypothesis by showing 
that fluvastatin alone does not result in a clinically significant decrease of urine output in V2R 
mutant mice but when it was combined with secretin, which increases intracellular stores of 
AQP2, it induced a significant decrease in urine output [13].
The most important limitations of our study are the trial design which is open, not blinded, 
and the inclusion of healthy subjects as opposed to NDI patients. The lack of an effect in 
healthy volunteers does not rule out a potential effect in patients with NDI as acute water 
loading in healthy subject can possibly result in different ADH related changes than in 
patients with NDI who have a chronically down-regulated ADH system. Another limitation 
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is that we did not control dietary intake of our subjects. Large differences in osmolar intake 
can affect minimal urine osmolality [14]. Although we observed slight differences in sodium 
and urea excretion between the two tests within individual subjects, these differences were 
not statistically significant. More importantly, if we take these differences into account, the 
effects of sildenafil and simvastatin on urine osmolality would be even less evident. This 
supports our conclusion that the drugs are not effective in affecting urine osmolality in 
healthy subjects.
CONCLUSION
In conclusion, although insight in the pathophysiological mechanisms provides arguments 
that metformin, sildenafil, and simvastatin could increase ADH-independent water 
reabsorption, experimental evidence is very limited. Our data suggest that simvastatin might 
have an effect in healthy volunteers. Validation studies are needed and, most importantly, 
these drugs should be tested alone and in combination in patients with NDI. 
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SUMMARY AND DISCUSSION
Renal tubular disorders are rare and knowledge about diagnostic tools and optimal treatment 
options is sparse. This thesis comprises studies that investigated different aspects of the 
diagnosis and treatment of patients with rare tubular disorders, with the aim to improve 
clinical care.
Diagnosis of renal tubular disorders
Diagnosis of renal hypophosphatemia 
The optimal diagnostic work-up of patients with isolated renal hypophosphatemia is 
unknown. Common causes of acquired isolated renal hypophosphatemia are the use 
of drugs, hyperparathyroidism or the presence of a tumor that produces a phosphaturic 
factor like fibroblast growth factor 23 (FGF23). These FGF23 producing tumors frequently 
express somatostatin receptors, and therefore stain positive on scans with somatostatin 
analogs. In chapter 2, the diagnostic yield of extensive evaluation of 17 patients with 
unexplained renal hypophosphatemia is reported. A major finding was that estrogen-
induced hypophosphatemia is an often overlooked cause of renal hypophosphatemia. Renal 
hypophosphatemia could be attributed to the use of oral contraceptives in five out of 17 
patients. The other 12 patients did not show signs of general tubulopathy and two patients 
had FGF23 levels above the upper limit of normal (>125 RU/ml), measured by a c-terminal 
FGF23 (cFGF23) assay. The two patients with elevated cFGF23 levels and six additional 
patients underwent a scan with a radiolabeled somatostatin analog. Only one of these 
patients was diagnosed with an FGF23 producing tumor. This patient had a cFGF23 level that 
was with 110 RU/ml below the upper limit of normal. The cause of renal hypophosphatemia 
remained unexplained in the other 11 patients despite extensive evaluation. These findings 
raise many new questions.
The first question is whether our patients with unexplained renal hypophosphatemia had an 
FGF23-dependent disease which we have missed. This could be the result of a low sensitivity 
of scans with somatostatin analogs for the detection of FGF23 producing tumors. The reason 
for using scans with somatostatin analogs is that FGF23 producing tumors are mostly of 
mesenchymal origin and express somatostatin receptors (SSTR). The exact percentage of 
SSTR positive tumors however is not known, neither is the exact sensitivity of the different 
scanning techniques which are available. We therefore could have missed FGF23-producing 
tumors in patients who underwent a scan. Besides that, the exact cut-off level of cFGF23 for 
excluding an FGF23-dependent hypophosphatemia is not known. As our single patient with 
an FGF23 producing tumor had a serum cFGF23 level within the reference range, we question 
whether the standard reference values can be used in patients with a hypophosphatemia. It 
is reasonable that the normal body response to hypophosphatemia is suppression of FGF23. 
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This would implicate that a normal (c)FGF23 level in a patient with hypophosphatemia 
points to FGF23-dependent hypophosphatemia, justifying a scan with somatostatin analogs. 
To test this hypothesis, we set out to investigate the FGF23 response to hypophosphatemia. 
We therefore measured cFGF23 levels in five healthy volunteers who were given a phosphate 
depleted diet in combination with the phosphate binder lanthanum carbonate. Against 
expectations, serum phosphate levels did not significantly drop in these healthy volunteers 
(Figure 1).
Figure 1 Serum phosphate levels in healthy volunteers on a phosphate restricted diet and 
concomitant use of lanthanum carbonate (N=5)
Serum PTH levels were stable (data not shown) and serum FGF23 levels were not suppressed 
(Figure 2).
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Figure 2 Serum FGF23 levels in healthy volunteers on a phosphate restricted diet and concomitant 
use of lanthanum carbonate (N=5)
Figure 3 Urinary phosphate excretion in healthy volunteers on a phosphate restricted diet and 
concomitant use of lanthanum carbonate (N=5)
However, the efficacy of the experimental procedure reducing phosphate absorption was 
confirmed by the significant decrease of urinary phosphate excretion (Figure 3). Interestingly, 
these healthy volunteers did develop complaints suggestive of hypophosphatemia (general 
body weakness, exercise intolerance, muscle complaints).
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The findings of this pilot study resulted in new questions: why was cFGF23 stable; which other 
factor contributed to renal phosphate retention; is serum phosphate a good representative 
marker for body and/or intracellular phosphate content? 
Serum phosphate and complaints do not seem to correlate well. On the one hand we 
have healthy volunteers on a phosphate depleted diet with preserved serum phosphate 
levels who developed complaints suggestive of phosphate depletion. On the other hand 
we encounter patients in daily clinical practice with low serum phosphate levels in the 
absence of complaints. These discrepancies between serum phosphate and complaints 
seem reasonable, as total body phosphate is mainly stored intracellularly while serum 
phosphate represents less than 1% of total body phosphate. Future research should focus 
on developing and validating methods to measure intracellular phosphate levels. Potential 
examples of alternative measures are direct intracellular measurements in erythrocytes 
or mononuclear cells and the use of phosphorus-31 nuclear magnetic resonance imaging 
(31p-NMR) to measure intracellular phosphate levels in muscle. These intracellular measures 
should be assessed in relation to complaints and compared with serum phosphate levels. 
The other question that arose from the findings in healthy volunteers on a phosphate 
depleted diet, is which factor caused phosphate retention in these subjects. The main 
phosphaturic factors PTH and FGF23 were not significantly decreased, although phosphate 
retention did occur in these individuals. A possible explanation for the phosphate retention 
is a decrease of another (unknown) phosphaturic factor. An interesting factor in this respect 
is nicotinamide. Nicotinamide is converted into nicotinamide adenine dinucleotide (NAD) 
via the enzyme Nampt whereby NAD inhibits phosphate transport through NaPi2a [1-3]. A 
few findings have suggested a role of nicotinamide in renal phosphate handling. Patients 
with unexplained renal hypophosphatemia after hepatectomy showed increased Nampt 
levels [4,5] and nicotinamide supplementation resulted in phosphaturia and lowering of 
serum phosphate in rats and dialysis patients [2,6,7,8]. An inhibitor of Nampt, FK866, lowered 
urine phosphate excretion and increased serum phosphate in rodents [4]. I hypothesise that 
nicotinamide (metabolism) might be involved in some of our patients with unexplained 
FGF23 independent renal hypophosphatemia (Figure 4). Nicotinamide parameters should 
therefore be evaluated in these patients.
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Figure 4 Nicotinamide metabolism and phosphate
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Another explanation for the lack of a decrease in cFGF23 in our healthy volunteers, could be 
due to the FGF23 assay that was used. Only one commercial FGF23 assay is available, which 
measures both intact biologically active FGF23 (iFGF23) and inactive C-terminal fragments 
(cFGF23). This assay could have masked suppression of FGF23 due to an increase in C-terminal 
fragments. The cFGF23 assay was used in our hypophosphatemic patients and healthy 
volunteers. It was assumed that the ratio between iFGF23 and cFGF23, representing the 
balance between FGF23 production and cleavage, is stable. Recent findings however showed 
that this is not always the case. Inflammation for instance clearly affects FGF23 metabolism. 
In acute inflammation, FGF23 production is increased. However, FGF23 degradation is even 
more increased, leading to stable iFGF23 but increased cFGF23 levels (Figure 5) [9]. In chronic 
inflammation, iFGF23 levels are higher.
Figure 5 FGF23 levels in inflammation (adapted from David, 2017)
In theory, iFGF23 could have indeed been lower in our healthy volunteers in combination 
with an increase of cleaved fragments, resulting in unaltered measurements using the cFGF23 
assay. Further research should therefore focus on measuring both iFGF23 and cFGF23 in a 
large group of patients with diverse causes of renal phosphate loss. This should ultimately 
lead to a practice guideline with advice on measurement and interpretation of FGF23 levels, 
and the need of performing a scan with radiolabeled somatostatin analogs. A proposal for 
such an algorithm is shown in Figure 6.
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Figure 6 Algorithm for the diagnostic work-up of patients with unexplained hypophosphatemia
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Diagnosis of renal hypomagnesemia 
Renal hypomagnesemia can be due to many causes, all interfering with normal renal 
magnesium handling. Normally, 95% of filtered magnesium is reabsorbed in consecutive 
segments in the nephron. The bulk of magnesium reabsorption takes place paracellularly 
through claudins in the proximal tubule and thick ascending limb of Henle’s loop. This 
transport is driven by a favourable concentration gradient of magnesium and/or a lumen-
positive electrochemical gradient, which is dependent on sodium reabsorption in the 
proximal tubule and thick ascending limb of Henle’s loop [10]. 
Approximately 5-10% of the filtered load is reabsorbed by the distal convoluted tubule 
(DCT) through an active transcellular reabsorption process. While not all key players in this 
active transcellular process have been identified, the Transient Receptor Potential channel 
Melastatin 6 (TRPM6), the Transient Receptor Potential channel Melastatin 7 (TRMP7), 
epidermal growth factor (EGF), sodium-chloride cotransporter (NCC), ClC-Kb, hepatocyte 
nuclear factor 1β (HNF1β), the γ subunit of Na-K-ATPase and the potassium channels Kv1.1 
and Kir4.1 appear to play a pivotal role (Figure 7).
Renal magnesium wasting occurs if there is a defect of one of these tubular transporters, ion 
channels or transcription factors governing their expression, either due to genetic mutations 
or acquired causes. An example of such a disorder is Gitelman syndrome (GS). GS is clinically 
characterized by hypokalemia, metabolic alkalosis, hypomagnesemia and hypocalciuria. GS 
is caused by impaired sodium chloride reabsorption in the distal convoluted tubule due to 
defective sodium-chloride cotransport through NCC. Hypokalemia and metabolic alkalosis 
are also features of Bartter syndrome (BS). Most patients with BS demonstrate hypercalciuria 
with normal serum magnesium levels. BS is caused by a dysfunctional sodium-potassium-
chloride cotransporter (NKCC) in the loop of Henle.
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Figure 7 Renal magnesium handling in the distal convoluted tubule (adapted from de Baaij, 2015)
Because thiazide diuretics exert their effects by blocking NCC in the distal tubule, a challenge 
with thiazide diuretics (so called thiazide test) historically has been used to investigate the 
functional presence of NCC in patients with suspected GS. Previous studies reported that 
the thiazide test can be used to differentiate between patients with GS and patients with 
BS. It was not known however whether the thiazide test can also differentiate between 
other causes of renal hypomagnesemia. In chapter 3 we show that a blunted response to 
thiazide diuretics is not pathognomonic for GS. Blunted responses were also seen in other 
renal magnesium wasting disorders, such as patients with mutations in FXYD2 or HNF1B. 
These results suggested that NCC function is also affected in these patients. This hypothesis 
was supported by a later study in HNF1β knockout mice that indeed displayed reduced 
transcription of NCC [12]. A shortcoming of our study was that patients with HNF1B mutations 
suffered from various degrees of renal insufficiency, while reference values for thiazide testing 
and other tubular function tests were based on small studies in young healthy volunteers. We 
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therefore evaluated four tubular function tests in individuals with different ages and renal 
function (chapter 4). The response to furosemide-fludrocortisone was similar to young 
healthy individuals in nearly all older individuals and patients with compromised renal 
function. The responses to furosemide, hydrochlorothiazide and DDAVP however differed 
between young healthy individuals, older individuals and patients with compromised renal 
function (Table 1).
Table 1 Test results of tubular function tests in individuals with different ages and renal function
Furosemide test Thiazide test DDAVP test
Maximal ∆FeCl Maximal ∆FeCl Maximal urine osmolality
Young healthy individuals 16.4 (14.9-19.9) 2.9 (2.6-3.9) 1002 (869-1074)
Older healthy individuals 11.0 (8.3-15.1) 2.3 (2.0-2.8) 820 (799-934)
Compromised renal function 14.0 (11.6-16.8) 2.1 (0.9-2.6) 624 (477-814)
P value 0.03 0.01 <0.01
Median values with interquartile ranges
FeCl: fractional chloride excretion (%)
∆FeCl: maximal change in FeCl compared to baseline FeCl
If one would apply the often quoted reference values for the furosemide and thiazide test 
to elderly or patients with compromised renal function, about 50% of subjects would be 
considered to have an abnormal test result. Reference values for most tubular function tests 
obtained in young healthy adults thus cannot be readily extrapolated to older subjects or 
patients with compromised renal function. Larger validation studies are needed to define true 
reference values in these patient categories and thiazide tests results described in chapter 3 
should be reconsidered. In doing so, we can appreciate that the patient with a mutation 
in FXYD2 was 46 years old and had a response that was lower than the lowest value in our 
cohort of older subjects. This suggests that in this patient the thiazide test is truly disturbed. 
One patient with a deletion of HNF1B showed a nearly absent response to thiazides which is 
unlikely to be explained solely by age and reduced kidney function. The other patient with a 
deletion of HNF1B  and a blunted response to thiazide diuretics was 37 years old, had an eGFR 
of 46 ml/min/1.73m2 and had a ∆FeCl of 1.41%. This response to thiazides is in line with the 
response in many healthy individuals with compromised kidney function in our pilot study. At 
this moment, we cannot conclude that this patient had a disturbed thiazide test.
Diagnosis of renal tubular acidosis
Urine acidification is the net effect of excretion of titratable acid and ammonium and the 
re-absorption of HCO3-. In distal renal tubular acidosis (dRTA) there is defective H+ excretion 
in the collecting duct secondary to defects in H+-ATPase, cytosolic carbonic anhydrase 
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Table 2 Comparison of urinary acidification after NH4Cl and FF tests
NH4Cl test
urine pH>5.3
NH4Cl test
urine pH≤5.3
Total
FF test; urine pH > 5.3 38 56 94
FF test; urine pH ≤ 5.3 9 166 175
Total 47 222 269
Combined results from Viljoen 2007, Both 2015, Shavit 2016 and Dhayat 2017 [13-16]
FF test: furosemide fludrocortisone test
NH4Cl test: ammonium chloride test
II (CAII) or anion exchanger 1 (AE1). These defects can be hereditary or acquired due to 
autoimmune diseases or drugs. Due to the defective H+ excretion, patients with dRTA are 
unable to adequately acidify the urine in case of an acid load such as ammonium chloride 
(NH4Cl), which therefore is used as a diagnostic test. The oral NH4Cl test, however, often 
leads to nausea and vomiting, resulting in early termination and inconclusive test results. 
Therefore, the furosemide fludrocortisone test (FF test) was developed. The FF test is based 
on the assumption that furosemide increases distal tubular sodium delivery and that 
fludrocortisone, by further stimulating sodium reabsorption through the epithelial sodium 
channel ENaC and thus increasing lumen negative charge, induces H+ excretion in the 
collecting duct. Recent reports showed considerable discrepancies between the NH4Cl test 
and the FF test (Table 2).
These differences could be explained by inadequate gastro-intestinal absorption of NH4Cl, 
differences in renal ammonia production, incomplete proximal HCO3- reabsorption, 
inadequate distal sodium delivery and/or the presence of an alternative pathway of urine 
acidification independent of ENaC. Such an ENaC-independent pathway of urine acidification 
has recently been demonstrated in animals through NHE3 in the thick ascending limb. 
We therefore performed both the FF test and NH4Cl test with ENaC blocked by its blocker 
amiloride. In chapter 5, we showed that if we perform FF tests under amiloride, no increase 
in H+ excretion was seen (Figure 8). In chapter 6, we performed NH4Cl tests under amiloride. 
It was seen that in the presence of amiloride, NH4Cl did not induce a decrease of urine pH 
nor increase in H+ excretion (Figure 9). Thus, furosemide and NH4Cl do not cause ENaC-
independent urine H+ excretion in man.
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Figure 9 Median urine H+ excretion after administration of NH4Cl without (●) and with amiloride (○)
Figure 8 Median urine H+ excretion after administration of furosemide and fludrocortisone without 
(●) and with amiloride (○)
Summary and Discussion  |  159
9
Amiloride theoretically could have blocked NHE3 and thereby disguise the ENaC-
independent pathway through NHE3. Amiloride, however, is far less potent in blocking NHE3 
than in blocking ENaC. A single dose of 20 mg amiloride leads to a urine concentration at the 
distal tubule of 3-20 µM whereas the IC50 value for blocking NHE3 is >50 µM in contrast to an 
IC50 of 0.1 µM for blocking ENaC [17-19]. Another argument against an alternative pathway of 
urine acidification in humans through NHE3 is that NHE3 has never been detected in human 
thick ascending limb. The human protein atlas only shows NHE3 staining in the proximal 
tubule. In conclusion, both NH4Cl and FF seem to acidify the urine fully dependent on ENaC 
in human. Inadequate gastro-intestinal absorption of NH4Cl is the most likely cause for a 
disturbed NH4Cl test result in patients with a normal response to FF. A possible explanation 
for a disturbed FF test in patients with a normal NH4Cl test is less obvious. The most likely 
cause is inadequate distal sodium delivery in response to furosemide, if for example the dose 
or tubular secretion of furosemide is inadequate. This reduced distal sodium delivery would 
then not be capable to induce significant sodium re-absorption through ENaC with secondary 
H+ secretion. Another possible explanation for a false positive FF test in the absence of dRTA 
could be incomplete proximal HCO3- absorption during the FF test. This might be the result 
of furosemide induced volume contraction and inhibition of carbonic anhydrase. Further 
research is needed to test these hypotheses. Ideally, patients with (genetically proven) dRTA 
with discrepant test results should be analysed in detail to test the previous hypotheses. Up 
to then we advise to initially perform a FF test. If this FF test shows a disturbed response (i.e. 
inadequate urine acidification), we advise to perform a confirmatory NH4Cl test. 
Treatment of renal tubular disorders
Treatment of hypophosphatemia
Treatment of patients with renal hypophosphatemia is challenging. The cornerstone 
of treatment is oral phosphate supplementation but it is frequently reported not to be 
effective. To further study the effect of supplementation therapy on both symptoms and 
serum phosphate levels, we suggest to perform N-of-1 trials with doubled-blind, placebo 
controlled phosphate replacement therapy and patient reported outcome measures as 
primary outcome measure (PROMs, see the paragraph on magnesium therapy below). 
Potential other treatment strategies should also be explored such as the use of dipyridamole. 
Previous studies showed a significant decrease in renal phosphate excretion in patients with 
renal hypophosphatemia and kidney transplant patients treated with dipyridamole [20-22]. 
However, these studies lacked a control group and did not take complaints and/or PROMs 
into account. We should perform a blinded, randomized, placebo-controlled trial with both 
laboratory parameters and patient reported outcome measures as outcome parameters.    
Treatment of hypomagnesemia
The   optimal  treatment strategy for patients with rare disorders causing renal hypomagnesemia 
is difficult as there is lack of randomized controlled trials, high doses of supplements are 
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needed due to ongoing renal losses and most treatment options are accompanied by serious 
side effects. Most patients however require lifelong treatment with drugs or supplements. An 
interesting personalized method to find out the best treatment strategy for these individual 
patients, is the use of N-of-1 trials. An N-of-1 trial is a prospectively planned trial conducted 
within an individual patient to evaluate the comparative effectiveness of two or more 
treatments [23]. The N-of-1 trial mostly consists of multiple randomized crossover periods and 
is often blinded and placebo controlled (Figure 10).
Figure 10 Example of an N-of-1 trial design
Due to its multiple cross-over design, N-of-1 trials are particularly appropriate for stable, 
chronic conditions with treatment modalities that have quick effects in both onset and 
termination. In chapter 7 we describe the results of N-of-1 trials in four patients. In these 
N-of-1 trials we compared three different oral magnesium salts in patients with renal 
hypomagnesemia. The main outcome parameters were patient reported outcome 
measures. Results were analysed by traditional and Bayesian statistical methods. The N-of-1 
trial method was able to successfully identify an optimum magnesium salt in an evidence-
based fashion in three out of four patients. The effects of magnesium salts differed within 
and between patients. Besides, serum magnesium levels did not correlate well with patient 
reported outcome measures. This might not be surprising as the majority of magnesium is 
stored intracellularly and only <1% of total body magnesium is present in the serum, similar 
to phosphate metabolism. Serum magnesium is probably not a good representative of total 
body magnesium content, although this is the measure we rely on in daily clinical practice. 
Future research should focus on developing methods to measure intracellular magnesium, 
which will be instrumental to titrate treatment in patients with hypomagnesemia. 
Intracellular magnesium can be measured in for example erythrocytes and mononuclear 
cells, but this method has not been validated yet. Another way of estimating intracellular 
magnesium is the use of 31ᵖ-NMR to measure intracellular magnesium levels in muscle [24]. 
These aforementioned methods of measuring intracellular magnesium should be tested in 
patients with hypomagnesemia and related to patient reported outcome measures.
Another area of research should focus on alternatives for oral magnesium supplementation, 
as the chief limit to its efficacy is the development of gastrointestinal complaints An 
alternative for oral magnesium supplementation, without diarrhoea as side effect, is 
intravenous magnesium replacement. Since most disorders are chronic in nature however, 
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this is not a long term solution. Chronic subcutaneous administration has been described 
[25], but this treatment modality is difficult, time consuming and has a high complication rate 
including infections and local irritation. Even chronic peritoneal administration through 
an indwelling catheter in a patient with preserved renal function has been reported [26]. As 
magnesium is absorbed in the gut either by passive absorption in the small intestine or by 
active transcellular reabsorption in the colon, administration of magnesium directly to the 
colon in the form of an enema could also be an effective alternative treatment option. Little 
is known about the exact kinetics of magnesium reabsorption after magnesium-containing 
enemas. The next step that is needed is a dose-response study with magnesium enemas in 
healthy volunteers, where after it can be tested in patients.
Treatment of nephrogenic diabetes insipidus
Nephrogenic diabetes insipidus (NDI) is a rare disorder characterised by resistance of the 
kidney to the action of anti-diuretic hormone (ADH, also known as vasopressin), resulting in 
a decrease in the capacity of the renal tubule to concentrate the urine. Water reabsorption in 
the collecting duct is initiated by ADH that binds to its receptor (type 2 vasopressin receptor, 
V2R) in collecting duct principal cells. This activates an intracellular signalling cascade via 
adenylyl cyclase and cyclic adenosine monophosphate (cAMP), that causes phosphorylation 
and insertion of aquaporin-2 water channels (AQP2) into the apical membrane through 
which water can enter the cell (Figure 11). 
Figure 11 Overview of intracellular mechanisms involved in transcellular water reabsorption in 
the collecting duct
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Current treatment options are limited to attempts to lower urine output by a low-solute 
diet and the use of diuretics or anti-inflammatory drugs. These measures are only partially 
effective. Increased knowledge about the pathophysiology of renal water handling has led 
to potential new treatment options for NDI that affect aquaporin metabolism via different 
pathways, such as sildenafil, metformin and simvastatin. Sildenafil increases cyclic 
guanosine monophosphate (cGMP) which induces phosphorylation of AQP2. Metformin 
activates adenosine monophosphate kinase (AMPK), which increases phosphorylation 
and accumulation of AQP2. Simvastatin is thought to enhance expression of AQP2 through 
down regulation of Rho GTPase and inhibition of AQP endocytosis leading to retention of 
more AQP2 water channels at the cell membrane. Recent reports in mainly animals indeed 
suggest a possible effect of these drugs on urine concentration [27-31]. Based on the underlying 
mechanisms of action, a combination of these drugs could have a synergistic effect as 
statins promote AQP2 trafficking to the membrane, and sildenafil or metformin induce 
phosphorylation of AQP2. In chapter 8, we tested the effect of sildenafil, metformin and 
simvastatin on ADH-independent urine concentration in healthy volunteers. We observed 
a significant, although limited, increase in minimal urine osmolality after simvastatin in 
our healthy volunteers. No significant increase in minimal urine osmolality was observed 
with sildenafil or metformin. The differences with earlier reports could be explained by the 
fact that previous studies were mainly performed in animals and/or animal (models of) 
nephrogenic diabetes insipidus. Validation studies in humans are needed, and these drugs 
should be tested in patients with nephrogenic diabetes insipidus as these patients might 
respond differently because they have a chronically suppressed ADH. We suggest to perform 
N-of-1 trials in NDI patients in which these three drugs and combinations are tested.
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SAMENVATTING
Tubulaire stoornissen zijn zeldzaam en kennis over de optimale diagnostiek en behandeling 
is beperkt. Dit proefschrift omvat studies die verschillende aspecten van zowel de diagnostiek 
als behandeling van patiënten met een zeldzame tubulaire stoornis onderzoeken, met als 
doel verbetering van klinische zorg. 
Diagnostiek van tubulaire stoornissen
In het eerste deel van dit proefschrift hebben we ons gericht op de diagnostiek van tubulaire 
stoornissen, een gebied dat nog veel beperkingen kent. Zo is het niet duidelijk wat de 
optimale diagnostische aanpak is voor patiënten met een geïsoleerde renale hypofosfatemie. 
Veel voorkomende oorzaken van een verworven geïsoleerde renale hypofosfatemie zijn 
het gebruik van medicatie, hyperparathyreoïdie of de aanwezigheid van een tumor die de 
fosfaturische factor fibroblast growth factor 23 (FGF23) produceert. Deze FGF23 producerende 
tumoren brengen vaak somatostatine receptoren tot expressie, waardoor ze aankleuren op 
scans met somatostatine analogen. In hoofdstuk 2 hebben we de resultaten beschreven 
van uitgebreide aanvullende diagnostiek van 17 patiënten die werden verwezen in verband 
met een onverklaarde geïsoleerde renale hypofosfatemie. Renale hypofosfatemie kon in 
deze groep worden toegeschreven aan het gebruik van orale anticonceptiva in 5 van de 17 
patiënten. Van de overige 12 patiënten hadden er twee patiënten een serum FGF23 waarde 
boven de normaalwaarde van 125 RU/ml (gemeten middels een assay die zowel intact FGF23 
meet als c-terminale FGF23 fragmenten). In totaal werd bij zes patiënten, waaronder de 
twee patiënten met een verhoogd FGF23, een scan met somatostatine analogen verricht. 
Een van deze zes scans toonde verhoogde opname, welke bleek te berusten op een FGF23-
producerende tumor. Deze patiënt had een FGF23 waarde van 110 RU/ml. De oorzaak van de 
geiosoleerde renale hypofosfatemie bleef onverklaard in de overige 11 patiënten ondanks 
uitgebreide aanvullende diagnostiek. De vraag die resteert is wat we missen; hebben deze 
patiënten een onbekende aandoening of hebben we FGF23 producerende tumoren gemist? 
De sensitiviteit van scans met somatostatine analogen voor het aantonen van een FGF23 
producerende tumor is onbekend. Bovendien weten we niet welke afkapwaarde voor FGF23 
gebruikt dient te worden ten tijde van een hypofosfatemie en of een assay die alleen intact 
FGF23 meet een beter onderscheidend vermogen heeft. Er is meer onderzoek nodig om deze 
vragen te kunnen beantwoorden, met als uiteindelijk doel het opstellen van een praktische 
richtlijn voor de diagnostiek van patiënten met een renale hypofosfatemie.
Hierna hebben we ons gericht op tubulaire functietesten. Tubulaire functietesten kunnen 
gebruikt worden om te bepalen waar precies in de tubulus het defect gelegen is dat leidt 
tot gestoord transport van electrolyten of water. Deze informatie kan gebruikt worden 
voor de fenotypering van patiënten en voor het in vivo bestuderen van pathofysiologische 
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mechanismen bij de mens. De thiazide test wordt bijvoorbeeld gebruikt voor het beoordelen 
van de functionele aanwezigheid van de natrium-chloride-cotransporter (NCC) in de distale 
tubulus. Deze test wordt in de klinische praktijk gebruikt voor het stellen van de diagnose 
Gitelman syndroom, een aandoening waarbij er sprake is van een verminderde of afwezige 
functie van NCC. Patiënten met Gitelman syndroom hebben vaak een hypokaliëmie, metabole 
alkalose, hypocalciurie en hypomagnesiëmie. In hoofdstuk 3 hebben we echter laten 
zien dat een gestoorde thiazide test niet pathognomonisch is voor de diagnose Gitelman 
syndroom. We zagen namelijk ook een verminderde respons op hydrochloorthiazide 
bij patiënten met een hypomagnesiëmie op basis van een mutatie in FXYD2 of HNF1B. 
Deze resultaten suggereren dat bij deze patiënten de NCC functie ook aangedaan is. Deze 
hypothese wordt ondersteund door een recente studie die laat zien dat bij HNF1β knock-out 
muizen de transcriptie van NCC verminderd is. Een belangrijke beperking van onze studie 
is echter de gestoorde nierfunctie die enkele patiënten hadden, terwijl referentiewaarden 
van tubulaire functietesten gebaseerd zijn op studies in een klein aantal gezonde jonge 
vrijwilligers met een normale nierfunctie. In hoofdstuk 4 hebben we daarom vier 
verschillende tubulaire functietesten geëvalueerd in individuen met een uiteenlopende 
leeftijd en nierfunctie. De respons op furosemide-fludrocortison was in ouderen en 
personen met een gestoorde nierfunctie nagenoeg gelijk aan de respons in jonge, gezonde 
vrijwilligers. De respons op furosemide, hydrochloorthiazide en desmopressine was echter 
afwijkend bij ouderen en personen met een gestoorde nierfunctie. Wanneer men de frequent 
geciteerde referentiewaarden voor de furosemide test en thiazide test zou toepassen op 
ouderen of personen met een gestoorde nierfunctie, zou ongeveer 50% van deze personen 
een afwijkende testuitslag hebben. Referentie waarden voor tubulaire functietesten die 
verkregen zijn in jonge gezonde vrijwilligers kunnen dus niet zomaar geëxtrapoleerd worden 
naar ouderen of mensen met een gestoorde nierfunctie. Grotere validatie studies zijn nodig 
voor het definiëren van referentiewaarden in deze patiëntencategorieën.   
Hierna hebben we het gebruik van tubulaire functietesten bij patiënten met een distale renale 
tubulaire acidose (dRTA) nader bekeken. Patiënten met een dRTA zijn niet in staat de urine 
adequaat aan te zuren in reactie op een zuurbelasting met bijvoorbeeld ammoniumchloride 
(NH4Cl). De NH4Cl test wordt derhalve gebruikt als diagnostische test voor het aantonen 
van een dRTA. Aangezien deze test vaak tot misselijkheid en braken leidt, is de furosemide 
fludrocortison (FF) test ontwikkeld. De FF test is gebaseerd op de aanname dat furosemide 
leidt tot een verhoogd distaal natrium aanbod dat gereabsorbeerd wordt via het epitheliale 
natrium kanaal ENaC, extra gestimuleerd door fludrocortison, wat vervolgens leidt tot 
toename van H+ secretie in de verzamelbuis. Recente studies laten echter zien dat er een 
aanzienlijke discrepantie is tussen de uitkomsten van de NH4Cl test en de FF test. Een groot 
aantal patiënten laat een adequate verlaging van de urine pH zien na NH4Cl maar niet na FF. 
Ook zijn er een aantal patiënten die juist een verlaging van de urine pH laten zien na FF maar 
niet na NH4Cl. Deze verschillen zouden verklaard kunnen worden door onvolledige gastro-
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intestinale opname van NH4Cl, een inadequate natriuretische reactie op furosemide en/of het 
bestaan van andere mechanismes van urine acidificatie onafhankelijk van ENaC. Een recente 
publicatie toonde aan dat een dergelijke ENaC-onafhankelijke route van urine acidificatie in 
dieren aanwezig is en afhankelijk is van NHE3 in de lis van Henle. Om te onderzoeken of deze 
alternatieve (ENaC onafhankelijke) route voor urine acidificatie ook bij mensen aanwezig en/
of relevant is, hebben we zowel de FF test als de NH4Cl test uitgevoerd onder behandeling 
met amiloride (waardoor ENaC geblokkeerd wordt). In hoofdstuk 5 en 6 hebben we laten 
zien dat bij gelijktijdig gebruik van amiloride, noch toediening van NH4Cl, noch gebruik 
van FF leiden tot een toename van de H+ excretie. Concluderend lijkt het aanzuren van de 
urine in reactie op NH4Cl en FF bij mensen volledig afhankelijk te zijn van ENaC. Onvolledige 
gastro-intestinale opname is daarom de meest waarschijnlijke verklaring van een afwijkende 
NH4Cl test bij een normale FF test. De oorzaak voor een gestoorde FF test bij een normale 
NH4Cl test is minder voor de hand liggend. Mogelijk is er in dergelijke gevallen sprake van 
onvoldoende distaal natrium aanbod geïnduceerd door furosemide. Nader onderzoek van 
urine bij patiënten met dergelijke discrepante testuitslagen is nodig om een goede verklaring 
te vinden.
Behandeling van tubulaire stoornissen
In het tweede deel van dit proefschrift hebben we ons gericht op de behandeling van 
patiënten met zeldzame tubulaire stoornissen. Door een gebrek aan (grote) gerandomiseerde 
studies bij deze zeldzame ziektebeelden is de optimale behandelstrategie vaak niet bekend. 
De meeste patiënten hebben levenslange behandeling met medicijnen of supplementen 
nodig. Een interessante alternatieve methode om de beste behandelstrategie voor een 
individuele patiënt te onderzoeken is een zogenaamde N=1 trial. Een N=1 trial is een 
prospectief geplande trial welke bestaat uit multipele gerandomiseerde cross-over perioden 
binnen één patiënt. In hoofdstuk 7 hebben we de resultaten beschreven van N=1 trials 
uitgevoerd bij vier patiënten met een renale hypomagnesiëmie. In deze N=1 trials hebben we 
drie verschillende magnesium preparaten vergeleken. De belangrijkste uitkomstparameters 
waren door de patiënt zelf gerapporteerde klachten. De N=1 trial methode was in staat om 
het optimale magnesium preparaat te identificeren in drie van de vier patiënten. De effecten 
van de verschillende magnesium preparaten verschilden tussen de patiënten. Bovendien 
correleerden serum magnesium waarden slecht met de door de patiënt gerapporteerde 
uitkomstmaten. Serum magnesium is waarschijnlijk geen goede representatieve maat 
voor de totale hoeveelheid magnesium in het lichaam en/of voor het intracellulair 
magnesiumgehalte. Dit is niet verrassend, aangezien slechts <1% van het totale magnesium 
in het lichaam zich in het serum bevindt. Het serum magnesium is wel de parameter die in 
de dagelijkse klinische praktijk gebruikt wordt om de behandeling op te titreren. Aanvullend 
onderzoek is nodig om betere diagnostische methoden vast te stellen voor het meten van 
intracellulair magnesium. 
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In hoofdstuk 8 hebben we potentiële nieuwe behandelmogelijkheden onderzocht voor 
patiënten met nefrogene diabetes insipidus. Nefrogene diabetes insipidus is een zeldzame 
aandoening waarbij de nier niet voldoende reageert op de werking van het anti-diuretisch 
hormoon (ADH). Hierdoor is het concentrerend vermogen van de nier verminderd. Klinisch 
kenmerken deze patiënten zich door de productie van grote hoeveelheden urine. Huidige 
behandelopties zijn slechts beperkt effectief. Recente dierstudies tonen een positief effect 
van sildenafil, metformine en simvastatine op het urine concentrerend vermogen van de nier. 
Deze middelen zouden daarom een additionele behandeling kunnen vormen voor patiënten 
met nefrogene diabetes insipidus. We hebben het effect van deze middelen op de urine 
osmolaliteit onderzocht bij gezonde vrijwilligers die een waterbelastingstest ondergingen, ter 
onderdrukking van ADH. We zagen een significante, maar beperkte, stijging van de (minimale) 
urine osmolaliteit na behandeling met simvastatine. Er werd geen significante stijging gezien 
van de (minimale) urine osmolaliteit na behandeling met sildenafil of metformine. De 
verschillen met eerdere studies kunnen verklaard worden door het feit dat eerdere studies 
voornamelijk zijn verricht bij dieren en/of diermodellen van nefrogene diabetes insipidus. 
Validatie studies zijn derhalve nodig en deze middelen dienen getest te worden in patiënten 
met nefrogene diabetes insipidus.   
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